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Abstract

DISCOVERY AND CHARACTERIZATION OF BILE ACID AND STEROID METABOLISM
PATHWAYS IN GUT-ASSOCIATED MICROBES
Spencer Harris, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017
Major Director: Phillip Hylemon, Ph.D.
Professor, Department of Microbiology and Immunology

The human gut microbiome is a complex microbial ecosystem residing in the lumen of our
gastrointestinal tract. The type and amounts of microbes present in this ecosystem varies based
on numerous factors, including host genetics, diet, and environmental factors. The human gut
microbiome plays an important role in normal host physiological functions, including providing
energy to colonocytes in the form of short-chain fatty acids. However, gut microbial metabolites
have also been associated with numerous disease states. Current tools for analyzing the gut
microbiome, such as high-throughput sequencing techniques, are limited in their predictive
ability. Additionally, “-omic” approaches of studying the complex array of molecules, such as
transcriptomics (RNA), proteomics (proteins), and metabolomics (previously identified
physiologically active molecules), give important insight as to the levels of these molecules but
do not provide adequate explanations for their production in a complex environment. With a

xviii

better physiological understanding of why specific metabolites are produced by the gut
microbiome, more directed therapies could be developed to target their production. Therefore, it
is immensely important to study the specific bacteria that reside within the gut microbiome to
gain a better understanding of how their metabolic actions might impact the host. Within this
framework, this study aimed to better understand the production of secondary bile acid
metabolites by bacterial in the gut microbiome. High levels of secondary bile acids are
associated with numerous pathophysiological disorders including colon cancer, liver cancer, and
cholesterol gallstone disease. In the current study, three bile acid metabolizing strains of bacteria
that are known members of the gut microbiome were studied. A novel strain of Eggerthella
lenta was identified and characterized, along with the type strain, for its ability to modulate bile
acid and steroid metabolism based on the atmospheric gas composition. Additionally, it was
shown that the oxidation of hydroxyl groups on primary bile acids by E. lenta C592 inhibited
subsequent 7α-dehydroxylation by Clostridium scindens. The gene involved in the production of
a Δ4,6-reductase enzyme, responsible for catalyzing two of the final reductive steps in the 7αdehydroxylation pathway, was putatively identified and characterized in Clostridium scindens
ATCC 35704. Lastly, the transcriptomic profile of Clostridium scindens VPI 12708 in the
presence of numerous bile acids and steroid molecules was studied. These studies contribute
significantly to the understanding of why specific bile acid metabolites are made by members of
the gut microbiome and suggest ways of modulating their production.

xix

Chapter 1: Introduction

Introduction to the human gut microbiome

The human body can be thought of as a vehicle used by trillions of microscopic passengers. In
fact, the number of prokayotic cells associated with our bodies outnumbers our own eukaryotic
cells by an order of magnitude (1). The overall conglomeration of microbes making up the
“human microbiome” varies based on numerous factors including: diet, environment, and host
genetics, among others (2). There has been significant effort by scientists to better understand
this complex microbial community. Next generation nucleic acid sequencing, along with
advances in both computational and bioinformatic analysis, allows for whole-genomic
sequencing from both isolated strains in culture and those isolated via single-cell sorting (3) as
well as reconstruction of these individual genomes in more complex microbial communities (4)
and even modeling bacterial metabolic potentials (5). In tandem with these high-throughput
analyses, the assignment of bacterial strains into operational taxonomic units (OTUs) is
accomplished via comparison against 16S sequencing data. The utilization of OTU classification
has important implications, as it is used to predict metabolic potential of complex microbial
ecosystems. It is on the basis of OTU assignment that the observation was made that in spite of
vast variation of microbial constituents, there is maintenance of metabolic potential across
different individuals (2).

Within this association between humans and microbes, a large amount of attention has been paid
to the lumen of the large intestine. The anaerobic environment here harbors the highest
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concentration of microbes in the human body, as well as a vast host mucosal layer allowing for
direct interaction with the microbes. With over 1013 prokaryotic cells (6), the number of
microbial genes eclipses our own by over 100-fold. The “human gut microbiome” refers to this
incredibly diverse microbial ecosystem and under normal physiological conditions it establishes
a symbiotic relationship with us. The gut microbiome has important, established roles in
producing energy sources for gut epithelial cells (7), modulating host immunity (8, 9), and
preventing colonization by harmful pathogens (9). This, however, is only the beginning of our
understanding of the complex interplay between gut-associated microbes and their hosts.

Microbial fermentation of complex carbohydrates in the large intestine

As with many niches in symbiotic ecosystems, there is usually an evolutionary “opening” that
allows for abundant but otherwise unused byproducts and nutrients to be exploited for energy
production, respiration, or used for other cellular processes. The most quantitatively important
example of this phenomenon in the large intestine is the plant-derived complex carbohydrates
that escape absorption and metabolism in the small intestine. Resistant starches undergo
anaerobic fermentation by bacteria, forming short chain fatty acids (SCFAs) (10). The three
major SCFAs produced in human large intestine include acetate, propionate, and butyrate (11).
Figure 1.1 depicts the structure of these three major SCFAs. SCFAs are present at a
concentration of 13-130mM in the lumen of the gut (12), and are rapidly absorbed by the
surrounding epithelial cells. Buryrate is favored by the colonic epithelial cells as an energy
source (12), but all SCFAs are an important source of energy for intestinal epithelial cells,
contributing to an estimated 3-9% of our calorie intake per day (7).

2

Figure 1.1: Chemical structure of major short chain fatty acids produced by gut-associated
microbes

3

4

Both propionate and acetate are detected in portal circulation (12, 13), but propionate is mostly
metabolized by the liver, leaving acetate as the major SCFA reaching systemic circulation (13).
It is important to note that SCFA production varies widely and is impacted by bacterial species
present, gut transit time, pH, hydrogen partial pressure, and the availability of complex
carbohydrate substrates (14-16).

Landmark studies have been performed comparing the contributions of genetics, environmental,
and dietary factors towards predisposition to colorectal cancer (CRC). Native Africans eating a
diet rich in complex carbohydrates and low in animal protein had a significantly lower rate of
CRC compared to African Americans eating a “Western diet” low in complex carbohydrates but
high in fats and animal protein (17, 18). The mechanism by which increased complex
carbohydrates play into prevention of CRC has been a topic that has received a lot of attention.

Both butyrate and propionate have been shown to have beneficial effects on colonocytes and gutassociated immune cells, and also impact colorectal tumor growth. On normal colonic epithelial
cells, SCFAs aid in the maintenance of normal physiological functions by sustaining the integrity
of the mucosal barrier (19, 20), regulating inflammatory responses (9, 21), and cell
growth/differentiation (22, 23). Butyrate and propionate are inhibitors of histone deacetylases
(HDACs), leading to induction of apoptosis in CRC cell lines (24, 25). SCFAs also impact
peripheral regulatory T cells (Treg) through the same HDAC inhibition, leading to an
upregulation of forkhead box P3 (FOXP3) and enhancement of the Treg population and antiinflammatory function, under normal conditions (26). Because of the dual functionality of
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preventing CRC cell proliferation and maintaining homeostatic conditions, the production of
SCFAs in the colon has been suggested as a means of reducing the occurrence of CRC.

Microbial production of hydrogen gas in the large intestine

SCFAs are not the only end products of the fermentative actions of gut microbes on
carbohydrates in the colon. Both carbon dioxide (CO2) and hydrogen gas (H2), found in
abundance in the colon, are byproducts of anaerobic bacterial fermentation (27). The majority of
CO2 produced by gut-associated microbes is either absorbed into circulation through the
enterocytes or is immediately utilized by other microbes in the vicinity (28). On the other hand,
approximately 60-70% of H2 produced remains after utilization by other microbes to be excreted
via breath or flatus (28). Upwards of 13L per day of H2 can be produced in the human colon
(29), while germ-free animal studies show negligible hydrogen gas production until introduced
to fecal slurries containing gut microbes (30). The amount of H2 found in the lumen of the large
intestine varies based on numerous factors, but is mainly impacted by the rate of production
versus the rate of utilization of H2 by various members of the gut microbiota (14, 28, 29).

H2 producers are relatively abundant in the gut microbiota. Hydrogen production is common
within the Firmicutes and Bacteroidetes phylum, the two major constituents colonizing the colon.
In vitro studies have shown that members of the genera Roseburia (31), Ruminococcus (32),
Eubacterium (33-35) generate H2. Another means of microbial H2 production is through the
oxidation of ferredoxin, pyridine nucleotides, and formate by microbial hydrogenases. Through
this process, anaerobic bacteria are able to rid their cells of reducing equivalents and maintain

6

intracellular redox balance. Genes encoding various hydrogenases are widespread throughout
bacteria known to inhabit the colon, especially in the Bacteroidetes phylum (36).

Hydrogen gas utilization by microbes in the large intestine

Because H2 is a major byproduct produced by many gut bacteria, microbes able to utilize it as a
substrate would have an evolutionary advantage in the gut microbiota. One such group of H2
utilizers is methanogens, a group of archaea that are able to reduce CO2, methanol, or acetate to
methane gas (CH4), using H2 as an electron donor (37). CH4 is an entirely microbial-derived
product, as it is neither made nor utilized by our own cells (38). The reduction of CO2 to CH4 is
carried out by a series of dehydrogenases and reductases, forming an electron transport chain
(38). CO2 is first reduced and attached to methanofuran as a formyl group, then affixed to
tetrahydromethanopterin, undergoes a dehydration followed by two reductive steps, is transferred
to its next carrier sulfhydryl-coenzyme M along with the generation of a Na+ gradient, and
undergoes a final reduction resulting in CH4 (39, 40) (Figure 1.2).

This process is energetically favorable, the resulting change in free energy (ΔGº’) = -131 kJ/mol
and leads to approximately one mol ATP generated for each mol CH4 formed (41).
Methanobrevibacter smithii is the most numerically prominent methanogen found in the gut
microbiome and can be present in up to 1010 CFU/g in stool (42). Presence of methanogens in
the gut microbiome is impacted by diet (17, 38), host genetics (43), and environmental factors
(17). Early studies on methanogens in humans used breath assays to determine presence of CH4
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Figure 1.2: Biochemistry of the methanogenesis pathway in archaea from CO2
Conversion of CO2 and H2 to methane via methanogenesis in Methanobrevibacter species starts
by the fixation of CO2 with H2 to methanofuran. The resulting formyl group is then transferred
to tetrahydromethanopterin. After a dehydration step, the resulting molecule undergoes two
successive reductive steps (requiring additional H2). The resulting methyl group is then
transferred to reduced coenzyme M. The last step requires reduced coenzyme B and the nickelcontaining porphinoid F430, and results in the production of methane.
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producers (45). Detection of CH4 in a breath assay is indicative of relative activity of methane
producers, although the lack of CH4 detection was not necessarily indicative of their absence
(46). More modern molecular techniques have been developed to screen for a highly conserved
methanogenic gene, i.e. coenzyme M reductase (mcrA) (47, 48). Studies have shown that
methanogens are found in colonic samples at rates ranging from less than 103 to over 109 CFU/g
stool (49).

Methanogens have been implicated to have various effects on human health. For instance,
patients with terminal ileal disease, Crohn’s disease, and ulcerative colitis (UC) have been shown
to have significantly lower amounts of CH4 excretion compared to healthy controls (50-54).
Moreover, gene copy number of mcrA is significantly reduced in patients with UC (47).
Whether the lack of methanogens contributes to or is merely a symptom of these disorders
remains to be elucidated, although the reduced gut microbial diversity found in these disorders
may contribute to the reduction in methanogenesis. There is less definitive data surrounding the
effects methanogens may play on CRC, and the data that exists is mixed. Older reports indicate
increased amounts of CH4 in patients with CRC versus control patients (55, 56), while newer
ones show no difference or less methanogens in patients with CRC versus control patients (57,
58).

In the colon, methanogens are not the only group of microbes that are able to utilize H2.
Sulfate reducing bacteria, are able to reduce sulfate (SO42-) as their terminal electron acceptor,
forming hydrogen sulfide gas (H2S or HS-). This reaction is able to utilize reducing equivalents
from numerous electon donors, including lactate, pyruvate, ethanol, formate, SCFAs, and amino

10

acids (59, 60), although H2 appears to be the preferred electron donor for the most prevalent
sulfate reducing bacteria found in the gut microbiome (61). Similar to methanogenesis,
reduction of sulfate to hydrogen sulfide gas is carried out through an electron transport chain
(62) (Figure 1.3). Sulfate and ATP are first linked via an ATP-sulfurylase to form adenosine-5’phosphosulfate, which then undergoes reduction via APS-reductase leading AMP and sulfite
(SO3--) (62). Sulfite then undergoes three successive reductive steps leading to H2S (63). This
process is even more energetically favorable under physiological conditions than
methanogenesis, resulting in ΔGº’ = -152.2 kJ/mol, although the overall ATP generation is
estimated to still be 1 mol ATP per mol H2S formed (41).

Sulfate reducing bacteria with the highest activity and affinity for H2 are found within the genus
Desulfovibrio (59) and are known members of the gut microbiome at a level of 104 to 1011 CFU/g
wet weight (46, 64). Newer molecular techniques screening for genes conserved in sulfate
reduction have confirmed sulfate-reducing bacteria are relatively ubiquitous in the human gut
microbiome (65, 66). In addition to using numerous electron donors, sulfate can come from
numerous sources both endogenous and exogenous, including secreted mucin, non-absorbed
proteins, sulphur-containing amino acids, and taurine (a source of sulfite) (63, 64, 67). Since
both sulfate-reducing bacteria and methanogens in the gut microbiota compete for the same pool
of H2, the deciding factor is the availability of sulfate for hydrogen sulfide production.
Energetically, hydrogen sulfide generation is a more favorable reaction than methanogenesis.
While presence of one strain is not mutually exclusive of the other, screening tests of human
fecal samples have shown that patients usually harbor either methanogens or sulfate-reducing
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Figure 1.3: Biochemistry of sulfidogenesis in gut microbes from sulfate and taurine
In the process of hydrogen sulfidogenesis from sulfate, adenosine triphosphate is first linked to
sulfate via ATP sulfurylase. This molecule is then reduced, forming AMP and sulfite. Sulfite
can also be liberated from bile acid conjugate taurine via bacteria such as B. wadsworthia (68).
Sulfite then undergoes three successive reductions (via dissimilatory sulfite reductases) to
ultimately produce hydrogen sulfide.
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bacteria (46), although in situations of abundant H2 there are reports of both being present and
active (59, 60, 69). In vivo studies comparing methanogenesis and H2S production in mouse
models confirm that when both methanogens and H2S producers are present and available sulfate
is abundant, H2S production dominates and methanogenesis along with viable methanogens are
below the limits of detection (70, 71). By reducing the amount of sulfate available,
methanogenesis has been shown to recover (71), suggesting a direct inverse link between H2S
production and methanogenesis and confirming that sulfate-reducing bacteria out-compete
methanogens for utilization of H2.

High levels of H2S have been reported to have deleterious effects on human health. Several
studies have suggested a link between ulcerative colitis and gut microbial H2S production (72,
73) while others have refuted this claim (74). There is a demonstrated link between UC and a
western diet high in protein and sulfur-containing amino acids (75, 76). Similarly, removal of
such foods from the diet of UC patients results in an improved outcome (76). Another source of
sulfite, taurine from conjugated bile salts, has been shown to be increased in the lumen of the
large intestine in individuals eating a western diet (77, 78). Studies have also suggested a link
between bacteria able to liberate sulfate from conjugated bile acids and the development of
colitis in mice (68). In addition to ulcerative colitis, H2S production has been associated with
CRC. In a mouse model of colonic dysplasia, mice given a source of sulfate had significantly
more colonic dysplasia than those treated with a source of sulfate plus metronidazole, suggesting
both H2S is formed by gut microbes and that it is associated with dysplasia (79). Stool H2S
levels in CRC cancer patients have been shown to be increased (80). However, a concurrent

14

increase in H2S producing bacteria was not significant, suggesting that H2S producing activity
instead of presence of H2S producing bacteria is more predictive for CRC (81, 82).

One suggested link between H2S and CRC is the H2S-mediated inhibition of acyl-CoA
dehydrogenase in colonocytes, the enzyme responsible for butyrate oxidation (83, 84).
Inhibition of butyrate oxidation leads to increased epithelial permeability, decreased absorption
of ions, as well as membrane lipid and mucus formation (85). Even at physiological
concentrations, H2S has been shown to be cause DNA damage in colonocytes, at least partially
via stimulation of reactive oxygen species (ROS) (86, 87). In addition to direct DNA damage,
H2S can induce inflammatory and DNA damage repair pathways in human intestinal cells (88).
Levels of the enzyme thiosulphate sulphotransferase, responsible for detoxifying H2S, are
significantly reduced in patients with CRC (89). Taken as a whole, H2S is a likely culprit for
creating and maintaining an environment that can, over time, lead to the formation of CRC in
individuals that have sufficient substrates promoting H2S formation in the colon.

A third mechanism of utilizing H2 produced by gut microbial fermentation is through
acetogenesis. Acetogenesis is the process by which bacteria fix CO2 and molecular H2 to form
acetate. The study of acetogenesis takes its roots in the study of gas metabolism by anaerobic
soil bacterium, as one of the first reports of this “new type of glucose fermentation” was found in
a strain of Clostridium thermoaceticum isolated from manure (90). Subsequent studies by
Harland Wood and Lars Ljungdahl elucidated enzymatic pathway responsible for autotrophic
synthesis of acetate from CO2 known as the Wood-Ljungdahl pathway (WLP) (91). The WLP is
a multi-step enzymatic pathway that utilizes eight reducing equivalents and two CO2 to form
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acetate (Figure 1.4). The overall reaction yields even less energy than methanogenesis or
sulfidogenesis, with a

Gº’ = -95kJ/mol (41). ATP is generated from ADP during the final

substrate-level phosphorylation of acetyl-CoA to acetate (92). However, more recently it has
been suggested that instead of acetogenesis being a pathway of energy production, it is a means
of regenerating oxidized pyridine nucleotides and ferredoxin to maintain intracellular redox
equilibrium (93). As many of these bacteria are found in anaerobic environments and electron
acceptors are at a premium, the ability of acetogens to use CO2 as an electron acceptor via the
WLP gives them an evolutionary advantage. In addition, the majority of acetogens are able to
use a multitude of different electron acceptors and electron donors, making them good at
adapting to the energy and redox requirements of their environment (94).

In addition to harboring the genes for the WLP, most acetogens additionally have membrane
bound hydrogenases that are able to interconvert their reducing equivalents in an electron
transport chain. One of the best-characterized examples of this is the Rhodocbacter nitrogen
fixation (RNF) complex originally characterized in an electron transporter associated with
nitrogenases (95-97). The RNF complex, found in numerous strains of acetogens, couples the
oxidation of ferredoxin (Fd) to the reduction of pyridine nucleotides and the generation of either
a Na+ or H+ membrane gradient (98) (Figure 1.5). This process is reversible and can help cycle
reducing equivalents between various electron carriers (99, 100). The gradient produced by the
RNF complex can then be utilized to generate additional ATP, coupling acetogenesis to an ATPgenerating process in the cell in addition to regenerating oxidized electron carriers (93, 98). Not
all acetogens harbor RNF complexes, although those that do not usually encode some
membrane-bound energy conserving hydrogenase system capable of interconverting reducing
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Figure 1.4: Diagram of acetate formation via the Wood-Ljungdahl Pathway
The multistep process of CO2 fixation to acetate starts with the fixation of carbon dioxide by
formade dehydrogenase. Formate is then linked to tetrahydrofolate (requiring ATP) via formyltetrahydrofolate synthetase. Formyl-tetrahydrofolate is then recognized by a cyclohydrolase,
forming methenyl-THF. This molecule undergoes two successive reductive steps by methyleneTHF dehydrogenase and methylene-THF reductase, respectively. The resulting methyl-group is
transferred to a corrinoid/iron sulfur protein via a methyltransferase. Then, along with CoA and
carbon monoxide (from reduction of CO2 by a carbon monoxide dehydrogenase), the methyl
group is used to generate acetyl CoA via acetyl-CoA synthase. This acetyl-CoA then undergoes
substrate-level phosphorylation, ultimately leading in the production of acetate and the
generation of ATP. This process is energy-neutral (1 mol ATP used/1 mol ATP generated per
mol acetate), but requires a significant amount of reducing equivalents (four reducing
equivalents/mol acetate) (101).
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Figure 1.5: Schematic of RNF Complex and ATP Synthase in Acetogens
RNF complex is a multi-subunit NADH/ferredoxin oxidoreductase capable of reversibly
oxidizing reduced ferredoxin forming reduced NADH and generating a proton or Na+ gradient.
Other transmembrane machinery can utilize this gradient for transport or for energy generation,
such as an ATP synthase.
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equivalents whilst generating an ion gradient (98, 102, 103). More recently, acetogenesis has
begun to garner interest as an alternative pathway of H2 elimination in the lumen of the large
intestine. Due to the contributions of CH4 production of livestock to global warming (104),
acetogens have been suggested as a potential alternative probiotic in the rumen of cattle (105).
The largest group of characterized acetogens present in mammalian gut microbiomes is from the
Firmicutes phylum (106). However, unlike the methanogenesis and sulfidogenesis, the
acetogenesis phenotype has also been identified in other phyla, making acetogens a more diverse
group of H2 utilizers (107). Studies have shown that in humans, acetogenesis during glucose
fermentation by gut microbes contributes to up to a third of the total amount of acetate produced
(11). Much less is known about contributions acetogens may have on human health. Since
acetogens, in contrast with methanogens and sulfidogens, are a more heterogenous group of
organisms, traditional means of molecular screening testing are less effective, though some
studies that have screened genes from the acetogenic pathways in stool samples have found them
at rates of 103 – 107 genes/g stool (49). Based on the energetics, acetogenesis is the least
energetically favorable reaction behind methanogenesis and sulfidogenesis. However, in vivo
data suggests acetogens are the most quantitative potential H2 utilizers present in the gut
microbiome (11, 106). Taken together, this suggests that acetogenic utilization of H2 in the colon
may be the prevalent method in humans that harbor neither active methanogens nor active H2S
producers. Ultimately, acetogenesis in the human colon can be influenced by numerous factors
that impact microbial fermentation, the levels of available CO2 and H2, the presence of
methanogens or sulfidogens, and presence of sulfate or sulfite for reduction.
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Bile acid formation and enterohepatic circulation

Under normal physiological conditions, microbial fermentation of complex carbohydrates and
amino acids in the colon is quantitatively the most prevalent reaction occurring. However, other
exogenous and endogenous molecules also enter the lumen of the large intestine where they
become substrates for microbial conversion. One such group of molecules is bile acids, sterol
molecules synthesized by hepatocytes from cholesterol. The two major bile acids produced in
humans are cholic acid (3α, 7α, 12α-trihydroxy-5β-cholan-24-oic acid; CA) and
chenodeoxycholic acid (3α, 7α-dihydroxy-5β-cholen-24-oic acid, CDCA) (Figure 1.6). Bile
acids are conjugated to either taurine or glycine forming bile salts, resulting in their characteristic
amphipathic nature. Bile salts are actively secreted across the canalicular membrane of
hepatocytes via the bile salt export pump (BSEP) (108), and subsequently stored and
concentrated in the gallbladder during the interdigestive phase. Upon the arrival of fatty acids
and/or amino acids reaching the duodenum, enteroendocrine cells in the mucosal lining of the
duodenum secrete cholecystokinin (CCK). CCK stimulates release of pancreatic enzymes,
inhibits gastric emptying, and induces the gallbladder to constrict (109). This constriction causes
the stored bile salts through the cystic duct, common bile duct, ampulla of Vater, and finally
through the relaxed sphincter of Oddi into the lumen of the duodenum (110). Once in the lumen
of the small intestine, bile salts serve to aid in the sequestration and absorption of lipids and lipid
soluble vitamins (A,D,E,K) via the formation of micelles (111). Bile salts activate pancreatic
lipase, producing monoglycerides and free fatty acids, which become key components of the
mixed micelles (112). Due to their high concentration and detergent-like actions, bile salts also
help to prevent overgrowth of bacteria in the small
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Figure 1.6: Chemical structure of primary bile acids and their conjugates
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intestine (113). Once the bile salts reach the terminal ileum they are actively transported across
the apical membrane of ileal enterocytes via the apical sodium-codependent bile acid transporter
(ASBT) (108). They are then transported across the apical membrane of enterocytes via the
OSTα/OSTβ transporter (114) and enter portal circulation. When they reach the liver, bile salts
are highly efficiently taken up through active transport across the sinusoidal membrane of
hepatocytes via Na+ taurocholate cotransporting polypeptide (NTCP) and returned to the pool of
bile salts (115), thus completing a process known as enterohepatic circulation. Enterohepatic
circulation of bile salts is only approximately 95% effective, allowing 400-800mg/day of bile
salts to escape into the large intestine where they become substrates for numerous microbial
biotransformations (113).

Bile acid metabolism by gut microbes

Beginning in the ileum and occurring in earnest once in the large intestine, the first reaction bile
salts undergo is deconjugation of bile acids from their taurine or glycine conjugate via bile salt
hydrolases (BSH) (116). Typically the ratio of glycine:taurine conjugation in humans is 3:1,
however this is impacted by diet. It has been shown that individuals on a “Western diet” have
predominantly taurine conjugation, while individuals on a vegetarian diet shift towards glycine
conjugation (77, 78). BSH activity is widely present in the microbes populating both the large
and small intestines. Gram-positive commensal bacteria with BSH activity include Clostridium
(117, 118)), Enterococcus (119), Bifidobacterium (120, 121), and Lactobacillus (122, 123).
BSH activity is less widespread in commensal Gram-negative bacteria, but include members of
Bacteroides genus (124). Gut-associated archaea Methanobrevibacter smithii and
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Methanosphera stadmanae have also been found to have BSH activity (116). BSH enzymes
specifically hydrolyze the N-acyl bond on the 24th carbon that is responsible for linking the
amino acid conjugate to the bile acid (Figure 1.7) (125). Studies that have characterized BSH
activity from purified enzymes show that their pH sensitivities tend to be between 5-6, are
located intracellularly, and have higher activity on glycine-conjugated bile salts (121, 126-128).

Once bile acids are liberated from their conjugate, they become substrates for numerous
microbial biotransformations. 7α-dehydroxylation is a process by which a small group of
bacteria within the Clostridia genus are able to remove the hydroxyl group from the seventh
carbon of both CA and CDCA forming secondary bile acids deoxycholic acid (3α, 12αdihydroxy-5β-cholen-24-oic acid; DCA) and lithocholic acid (3α-monohydroxy-5β-cholen-24oic acid; LCA), respectively (113) (Figure 1.7). This process is unique to gut microbes, as
hepatocytes do not produce secondary bile acids nor are they found in fecal samples of germ free
animals (129, 130). Studies measuring fecal bile acid composition show that secondary bile acids
form the major constituency (113), suggesting that even though only approximately 0.0001% of
gut microbes harbor the 7α-dehydroxylation pathway (131), it is the most quantitatively
significant biotransformation of primary bile acids by gut microbes after BSH. In metagenomic
analyses, C. scindens, a well-characterized 7α-dehydroxylating species, has been shown to be a
member of the “core gut microbiome” in humans, due to its high rate of prevalence in human
fecal samples (132). DCA, and to a smaller degree LCA, both passively diffuse across the
epithelial barrier and enter portal circulation, where they are reabsorbed by the liver and
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Figure 1.7: Diagram of bile salt biotransformations by gut bacteria
Endogenous bile salts are produced by the liver and then undergo biotransformation by gut
microbes. Bile acids are liberated from their conjugates by microbial bile salt hydrolases.
Primary bile acids then undergo numerous further reactions, such as oxidation and epimerization
(bottom) or 7α-dehydroxylation (right).
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accumulate in the bile acid pool, since human hepatocytes cannot perform 7α-hydroxylation
(133).

While bile acids had seen usage as “liver tonics and laxatives” earlier, contemporary scientific
interest in both primary bile acids and secondary bile acids began after determination of their
chemical structure in 1932 (134). In 1946, an effective method for developing cortisone from
DCA was developed (135). Three years later the use of cortisone in patients was shown to cause
significant improvement in patients dealing with rheumatoid arthritis (136). However, since at
the time the only source for DCA was from bile isolates from livestock, pharmaceuticals began
to worry there would not be enough supply to cover the demand for cortisone (134), and as a
result plant sterols became used as a more widespread and effective precursor to cortisone (137).
As such, interest in bile acids dwindled but for a few dedicated laboratories. However, work on
bile acids continued in a Swedish laboratory run by Sune Bergström where means of tracking H3
and 14C incorporation into bile acids (138), as well as GC and MS techniques for measurements
of bile acids were developed (139). Bergstrom and colleagues were the first to distinguish
primary bile acids, made by the host, and secondary bile acids, made by commensal intestinal
microbes (140, 141). In this earliest work of determining the pathway for microbial conversion
of primary bile acids to secondary bile acids, it was proposed that the mechanism was a two-step
process with a single intermediate, cholen-6-oic acid (142). However, subsequent work by
Hylemon et al. of CA-induced conversion of [24-14C]-CA by Clostridium scindens showed the
formation of numerous bile acid metabolites (143). MS identification of the metabolites and
chemical synthesis and introduction to CA-induced Clostridium scindens showed DCA was the
major end product, suggesting these were intermediates in the formation of DCA (143). Taken
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together, it was suggested that the formation of secondary bile acids by 7α-dehydroxylating
bacteria was an inducible, multi-enzymatic process.

Although 7α-dehydroxylation of primary bile acids leads to the most abundant end products,
there are several other biotransformations that bile acids can undergo in the large intestine.
Members of the intestinal microbiota have genes that encode a variety of pyridine nucleotidedependent hydroxysteroid dehydrogenases (HSDH). HSDHs are widely distributed throughout
various members of the gut microbiota (113). Gut microbes are known to be capable of
oxidation and reduction of the hydroxyl groups on the 3-, 7-, and 12- carbons of bile acids
(Figure 1.7). The epimerization of bile acid hydroxyl groups (α ↔ β) requires two positionspecific bile acid α- and β- HSDHs, which generate a stable oxo-bile acid intermediate i.e., 7αhydroxy ↔ 7-oxo ↔ 7β-hydroxy. Bacterial bile acid HSDHs differ in their pH optima, pyridine
nucleotide specificity (NAD(H), NADP(H), or both), subunit molecular weight, and gene
regulation (113). Amino acid sequence analysis suggests that most bacterial HSDHs in the gut
microbiota belong to the short-chain alcohol/polyol dehydrogenase family (113). Bile acid
HSDHs have been found and characterized in numerous genera inhabiting the lumen of the
colon, including Bacteroides (144, 145), Clostridium (146-148), Escherichia (149), Eggerthella
(150), Eubacterium (151-154)), Peptostreptococcus (155), and Ruminococcus (156, 157).

Bile acids with oxidized hydroxyl groups (oxo-bile acids) have been shown to be present in fecal
bile acids (158-160), portal circulation (161, 162), and human serum (163). Interestingly, the
hydroxyl groups on dihydroxy-bile acids (DCA, CDCA) have been shown to be more sensitive
to microbial oxidoreduction than trihydroxy-bile acids (CA) (164). Also, cholecystectomised
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patients have been shown to have increased levels of oxo-bile acid derivatives in enterohepatic
circulation (165). This observation is likely that due to the increased levels of bile acids being
seen by the gut microbes in cholecystectomised patients leading to increased microbial
biotransformation. The extent of epimerization and the accumulation of oxo-bile acids appears
to be influenced by the oxidation/reduction potential of the local cellular environment. For
example, the formation of oxo-bile acids may be more favorable in bacteria associated closer to
the mucosal edges, where there is a higher redox potential than further inside the lumen of the
intestines (125).

Consequences of bile acid metabolism on microbial and host physiology

To understand the effects of microbial biotransformations of bile acids on host and microbial
physiology, it is important to first discuss the effects that bile acids have on normal host
physiology. Near the turn of the millennium, it was discovered that endogenous bile acids were
ligands for the orphan nuclear receptor farsenoid X receptor (FXR) (166, 167). Under normal
physiological conditions, primary bile acids CA and CDCA activate FXR in enterocytes, leading
to expression of fibroblast growth factor 15/19 (FGF15/19) (168). FGF15/19 then acts on the
hepatic FGFR4 receptor in hepatocytes and, among other effects, leads to a down-regulation of
CYP7A1, the rate-limiting enzyme of bile acid synthesis (169). Through this pathway, bile acids
are able to effectively inhibit their own synthesis.

Soon after the discovery of FXR activation by bile acids, it was shown that transmembrane Gcoupled protein receptor 5 (TGR-5), a widely distributed receptor throughout human cells, is
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activated by bile acids (170, 171). TGR-5 is a Gαs receptor that leads to an increase in
intracellular c-AMP (172). It has been reported that activation of TGR-5 can lead to the release
of glucagon-like peptide 1 (GLP-1), which has roles in glucose homeostasis as well as appetite
suppression (173). Subsequent work also showed bile acids as ligands for pregnane-activated
receptor (PXR) (174), vitamin D receptor (VDR) (175), sphingosine-1 phosphate receptor 2
(S1PR2) (176), and some muscarinic receptors (M2,3) (177).

While primary bile acids have been shown to be agonists for many different receptors, the
potency of their activation differs based on their substituents. In addition, secondary bile acids
produced by gut microbes have differing and sometimes more potent agonist properties than
primary bile acids. In the case of FXR, primary bile acid CDCA appears to be the most potent
activator, but both secondary bile acids LCA and DCA are more potent than CA (167).
Similarly, PXR appears to be most potently activated by LCA (174), VDR by 3-oxo-LCA (175),
and TGR-5 by DCA and LCA (170). Taken together, this suggests that not only can bile acids
modulate the structure of the gut microbiome, but the microbes can also modulate host
physiology by the creation of secondary bile acid “hormones” (178).

In addition to modulating normal host physiology, bacterial bile acid metabolites such as DCA
and LCA also have roles in pathophysiological disorders. There is a body of evidence
suggesting a link between secondary bile acids (DCA and LCA) and numerous gastrointestinal
diseases, including colon cancer (67), liver cancer (179), and cholesterol gallstone disease (131).
Both LCA and DCA levels are increased in fecal samples of CRC patients compared to control
(180). In African Americans, when compared to rural, native Africans, a high-fat diet is
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correlated with increased levels of DCA/LCA as well as an increased rate of CRC (18). DCA
and LCA have been shown to be effective enhancers of mutagenesis (181, 182), and in rats
endogenous levels of secondary bile acids led to increased CRC tumor numbers and invasiveness
(183). In addition, rats supplemented with DCA show decreased production of protective
SCFAs when compared to control, along with significant changes to the makeup of the gut
microbiota away from SCFA-producing bacterial species (184).

The mechanism by which DCA and LCA may contribute to the formation of CRC is an area of
significant study. Based on their hydrophobicity, DCA and LCA can cause membrane
pertubations in colonocytes (185). Chronic exposure to secondary bile acids has been shown to
lead to resistance to apoptosis and enhanced cell proliferation in many epithelial cell lines (186,
187). Secondary bile acids have been shown to generate reactive oxygen and reactive nitrogen
species, can cause DNA double-stranded breaks, and inhibit DNA repair mechanisms (188, 189).
They also cause NF-κB activation in intestinal epithelial cells, which can promote CRC
development (126, 188, 190-192). It has been suggested that DCA may directly stimulate CRC
progression through activation of protein kinase C, which effects growth regulation,
differentiation, and apoptosis (193). DCA has also been shown to cause hypomethelation of
DNA, leading to increased transcription of proto-oncogenes (194). In CRC cells, DCA has been
shown to phosphorylate β-catenin, causing increased invasiveness (195). DCA can also prevent
apoptosis in CRC cells via activation of EGFR, NF-κB, and Akt (188, 196, 197). While
secondary bile acids themselves have not been shown to be carcinogenic (67), they produce an
environment both in the microbiota (decreased production of protective SCFAs) and in the
enterocytes themselves that promotes progression of CRC. These effects on colonocytes also
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seem to be dose-dependent, as low concentrations of bile acids and secondary bile acids appear
to be protective, while higher concentrations have deleterious effects.

Even oxidized or epimerized bile acids have differing effects on host physiology. 3-oxo-LCA
has been shown to be the most potent agonist for the VDR (175). Epimerization of the 7αhydroxyl group on CDCA yields a much more hydrophilic and therefore less toxic metabolite
ursodeoxycholic acid, which has been shown to be protective against CRC-inducing effects of
DCA (157). Recent studies reported that 7-oxo-lithocholic acid acts as a competitive inhibitor of
human hepatic 11β-HSDH-1 (198). 11β-HSDH-1 is responsible for converting 7-oxo-LCA back
to CDCA, however it also catalyzes the activation of cortisol from cortisone (199). When 7-oxoLCA is in high enough concentrations, it acts as a competitive inhibitor preventing production of
active cortisol. 7-oxo-LCA and ursodeoxycholic acid are both less potent agonists of FXR than
the endogenous bile acid they are formed from, CDCA (167). Since the expression of the
antimicrobial peptide cathelicidin is controlled by FXR in enterocytes, it follows that by
lessening the affinity of bile acids for FXR, an otherwise susceptible microbe could increase its
fitness in the lumen of the large intestine. The full extent to which alteration in bile acid
hydroxyl oxidation or epimerization effects host metabolism is a field that requires more
significant study.

The effects of bile salt biotransformations is not restricted to host-microbe interactions, as there
are many microbe-microbe interactions that occur as a result of bile salt metabolism. Taurine
can be found conjugated to primary bile acids and is more prevalent in the bile acid pool of those
eating a Western diet (78). When liberated from bile acids through BSH activity by microbes in
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the intestinal tract, taurine becomes a substrate for further bacterial metabolism. Microbes are
able to utilize taurine as an energy source via Stickland fermentation (200). In addition, the
formation of H2S through metabolism of taurine by Bacteroides has been shown to enhance 7αdehydroxylation by Clostridium sp. in germ-free mice colonized with both bacterial strains
(201). Addition of taurocholic acid to a low-fat diet in IL-10 deficient mice led to a bloom of
sulfate-reducing bacteria and induced colitis (68). These effects seem to be specific for taurine
conjugation, as glycine liberated from bile salts has not been shown to be a source of sulfate for
H2S production nor does it induce 7α-dehydroxylation.

Bile acid 7α-dehydroxylation has recently been shown to have consequences for Clostridium
difficile colonization and growth in the gastrointestinal tract. C. difficile infection, the causative
agent of antibiotic-associated diarrhea and colitis, is a significant health concern for patients
taking broad-spectrum antibiotics (202). An estimated 29,000 deaths are attributed to C. difficile
infection (CDI) in the US every year (203), and the numbers are expected to increase as the
aging population becomes more colonized. Although rates of C. difficile colonization vary
significantly, it has been reported that up to 90% of healthy neonates and infants, 15% of healthy
adults, and 51% of elderly patients are asymptomatic C. difficile carriers (204). Treatment of
patients with broad-spectrum antibiotics, especially in hospital settings, leads to a decreased level
of protective gut microbes which allows for the over proliferation of C. difficile which tend to be
resistant in their spore form (205). Once induced to germinate in the GI tract, increased C.
difficile proliferation leads to overproduction of vegetative cells that produce toxin A and B
causing diarrhea and severe colitis in some patients (206). In patients with relapsing C. difficile
infection, approximately 17% of patients do not respond to metronidazole or vancomycin
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treatment (207). However, fecal transplants of gut microbiota from healthy donors have been
shown to be a successful treatment, with 81% having resolution of CDI after the first fecal
infusion and 94% having resolution after a second fecal infusion (208). Initial reports indicated
an increased fecal bacterial diversity in fecal-infused CDI patients, as well as an increase in
Bacteroidetes and Clostridium sp. as well as a decrease in Proteobacteria species (208). A more
directed attempt to ascertain the gut microbes that were responsible for resistance to CDI
suggested that Clostridium scindens, the group of bacteria responsible for production of
secondary bile acids, was strongly associated with inhibition of Clostridium difficile colonization
and antibiotic-induced CDI in animal models and human patients (209). Earlier work on C.
difficile linked bile salts and bile acids to germination of spores, showing that when CA, TCA, or
DCA were added germination of C. difficile spores occurred (210, 211). Later work by Sorg et
al showed C. difficile specificity for specific bile acids, as taurocholate, cholate, and
deoxycholate induced germination in vitro but chenodeoxycholate did not (212). It was later
shown by the same group that chenodeoxycholate competitively inhibits taurocholate
germination of C. difficile spores (213). More recent work found a germinant receptor (CspC) in
C. difficile was recognized specifically by 12α-hydroxylated bile acids (214). Binding to this
receptor led to the release of Ca2+ dipicolinic acid from the inside of the spore and subsequent
influx of water, ultimately leading to growth into a vegetative cell (214). Some recent studies
have shown that secondary bile acids inhibit C. difficile growth in vitro (215) and that
ursodeoxycholic acid inhibits C. difficile growth and sporulation (216). Since C. scindens are the
major producers of secondary bile acids, it would follow that these secondary bile acids are the
mechanism by which C. scindens is associated with protection against CDI. However,
experimental proof of C. difficile growth inhibition by physiological concentrations of secondary
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bile acids in vitro or in vivo is lacking. Furthermore, a molecular mechanism by which DCA
inhibits growth (as opposed to germination) is also absent. More work to determine the interplay
between these bacteria in the colon is necessary, but the potential for a probiotic to prevent
against CDI is an exciting prospect.

Research Objectives:

The research described in this thesis is aimed at better understanding numerous mechanisms by
which gut-associated bacteria metabolize bile acid and steroid molecules and how this
metabolism is linked to overall microbial physiology in the anaerobic environment of the colon.
Within this framework, three objectives were pursued. The first objective was the
characterization of a novel strain of Eggerthella lenta, screening and comparing its ability to
metabolize various primary and secondary bile acids and steroid molecules, and linking its
unique pattern of bile acid metabolites with specific gene clusters linked to acetogenesis. The
second objective was the discovery of a gene in Clostridium scindens ATCC 35704 responsible
for the production of a Δ4,6-reductase that catalyzes two of the three reductive steps of the 7αdehydroxylation pathway. The third objective was the utilization RNA-seq analysis to determine
the transcriptomic changes in Clostridium scindens VPI 12708 treated with various steroid and
bile acids, with the ultimate goal of locating the gene encoding a 17α-hydroxysteroid
dehydrogenase responsible for production of epitestosterone from androstenedione. The work in
this thesis gives better insight into the 7α-dehydroxylation pathway in Clostridium scindens. In
addition, a unique interplay between atmospheric gases, bile acid oxidation, and 7α-
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dehydroxylation was discovered and evidence put forth to characterize Eggerthella lenta as an
acetogen.
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Chapter 2: Materials and Methods

Bacterial strains and materials

Clostridium scindens ATCC 35704 obtained from ATCC, Clostridium scindens VPI 12708
obtained from Virginia Polytechnic Institute, Clostridium absonum ATCC 27555 obtained from
ATCC, and human fecal isolates C592, I10, SA14, 19BHI, KS11, SO46, SO77 from
collaborators at Ryukyus University in Okinawa, Japan are maintained as -80°C glycerol stocks
in our laboratory. Eggerthella lenta ATCC 25559 was acquired commercially (ATCC). Before
further analysis, strains were propagated on brain heart infusion (BHI) agar plates and grown
under anaerobic conditions in Brewer jar with AnaeroPack (Mitsubishi) for 48 hours at 37°C,
and colonies were picked and grown individually. Unless otherwise noted, bacterial strains were
grown in liquid BHI broth (Becton, Dickinson) in round bottom flasks anaerobically under 100%
N2 gas atmosphere (Airgas), supplemented with 5g/L yeast extract (Becton, Dickinson), 1g/L
cysteine HCl (Sigma) and 40mL/L of a salt solution containing 0.2g CaCl2, 0.2g MgSO4, 1g
K2HPO4, 1g KH2PO4, 10g NaHCO3 per liter. When arginine (Sigma) was used, it was added
separately to the media to a final concentration of 5g/L (0.5% wt/volume) or 10g/L (1%
wt/volume). Chenodeoxycholic acid (3α-, 7α- dihydroxy-5β-cholan-24-oic acid; CDCA), cholic
acid (3α-, 7α-, 12α-trihydroxy-5β-cholan-24-oic acid; CA), and deoxycholic acid (3α-, 12αdihydroxy-5β-cholan-24-oic acid, DCA) were obtained from Sigma. Allocholic acid (3α-, 7α-,
12α-trihydroxy-5α-cholan-24-oic acid; ACA), androst-4-ene-3,17-dione (androstenedione),
androst-4-en-17β-ol-3-one (testosterone), and androst-4-en-17α -ol-3-one (epitestosterone) were
obtained from Steraloids. [24-14C]-labeled CDCA and CA were obtained from American
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Radiochemicals. [24-14C] DCA and lithocholic acid (3α-monohydroxy-5β-cholen-24-oic acid;
LCA) were produced biologically. Before addition to culture, bile acids were suspended in
methanol to a concentration of 10mM before being diluted to their final concentration in culture
media.

Production of radiolabeled secondary bile acids and bile acid metabolism screening

For numerous experiments, [24C-14C]-bile acid biotransformation to secondary metabolites was
screened. Unless otherwise noted, bile acid biotransformation profiles were investigated in
whole cell cultures grown at 37ºC overnight in anaerobic BHI medium under 100% N2
atmospheric gas. For primary bile acid biotransformation screens, cultures were grown in the
presence of 25µM bile acids and 1µCi labeled bile acids. For secondary bile acid metabolism
screens, cultures were grown in the presence of 25µM secondary bile acids with varying amounts
of analogous [24-14C]-labeled bile acids. Culture growth was monitored using UV
spectrophotometry (BioMate 3), monitoring at 600nm. Once adequate growth was observed,
cultures were acidified to pH = 3.0 by adding 1N HCl (Sigma) and confirmed via pH meter.
Cultures were then extracted with 2x volume ethyl acetate (Fischer Scientific). The organic
layer was isolated and concentrated under a stream of N2 gas. Organic extracts were then
suspended in methanol, spotted, and run on silica gel TLC plates (J.T. Baker) with a 75:20:2
benzene:dioxane:acetic acid (Sigma) mobile phase. Plates were exposed to MS autoradiographic
film (Kodak) overnight and bands corresponding to bile acid metabolites were scraped off and
quantified using liquid scintillation spectrophotometry (RPI Budget-Solve; Tri-Carb 2100TR).
These biotransformation of [24-14C]-labeled bile acids experiments were run alongside unlabeled
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bile acid biotransformation experiments, separated on the same TLC plates as described above,
and the corresponding unlabeled bands were scraped and isolated for future MS analysis.

Bile acid metabolite characterization

For future MS analysis, 100mL C592 cultures were grown to stationary phase as stated above in
the presence of 25µM CDCA or DCA with and without [24-14C] radiolabel. Bile acid
metabolites were extracted, separated, and isolated as stated above and then underwent LC-MS
analysis. LC-MS analysis was run on a Shimadzu UPLC coupled with a Shimadzu LCMS-ITTOF System (Shimadzu Corporation, Kyoto, Japan). The LC operating conditions were as
follows: LC column, C-18 analytical column (Capcell Pak C18, Shiseido, Japan), 250 mm × 2
mm i.d., particle size - 3µm (C18 (RP18, ODS, Octadecyl); mobile phase, H2O containing 0.1%
formic acid (A), and acetonitrile containing 0.1% formic acid (B); total flow rate of mobile
phase, 0.2 ml/min; total run time including equilibration, 41 minutes. The initial mobile phase
composition was 70% mobile phase A and 30% mobile phase B. The percentage of mobile phase
B was changed linearly over the next 5 minutes until 35%. Over the next 25 minutes, the
percentage was increased to 98% linearly. After that the percentage was maintained for 5
minutes, the mobile phase composition was allowed to return to the initial conditions and
allowed to equilibrate for 5 minutes. The injection volume was 10 µL. The mass spectrometer
(LCMS-IT-TOF) was operated with an electrospray ionization (ESI) source in both positive and
negative ion mode with multiple reaction monitoring (MRM). The nebulizer gas pressure was
set at 150kPa with the source temperature of 200°C and the gas flow at 1.5L/min. The detector
voltage was 1.65kV. High-purity nitrogen gas was used as collision cell gas. The raw
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chromatograph and mass spectrogram data were processed with the LC solution Workstation
software (Shimadzu). For further characterization of C592 CDCA metabolites, as well as the
production of 3-dehydro-DCA for putative Δ4,6-reductase screening, radiolabeled CDCA, DCA,
putative 7-oxo-CDCA, and putative 7-oxo-isoCDCA were treated with 0.25 unit/mL purified 3αhydroxysteroid dehydrogenase (Sigma) for one hour in the presence of 150µM NAD+ (Sigma) in
0.1M Tris-HCl buffer (pH 8.0). Enzymatic reaction was quenched with ethyl acetate and
separated on TLC as described above.

Steroid metabolism screening

Similar to bile acid metabolism screening, steroid metabolism screening was performed in whole
cell cultures grown at 37ºC overnight in anaerobic BHI media under 100% N2 gas. For whole
cell biotransformation screening of androstenedione, testosterone, and epitestosterone
metabolism, cultures were grown in the presence of 25µM of the steroid molecule. Once
adequate growth was observed, growth was quenched with the addition of 2x volume ethyl
acetate. The organic layer was then isolated, the solvent evaporated, and the extract suspended
in 500µL methanol. One hundred microliters were injected and run on high-pressure liquid
chromatography (Agilent) using a C-18 reverse phase column (Agilent Eclipse XDB-C18), 50:50
methanol:water mobile phase at a flow rate of 1mL/min, as adapted from previous work in (217).
Absorbance of steroid metabolites was monitored at 240nm by UV-Vis spectroscopy. The C.
scindens VPI 12708 androstenedione metabolite was fractionally collected and sent for NMR
analysis, which was performed as previously described (217). For TLC separation of 11βOHAD and hydrocortisol cell culture biotransformation screens, organic extracts were run
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similarly to described above except for the use of a different mobile phase: 5:25:0.2 isooctane;
ethyl acetate; glacial acetic acid.

Primer design, polymerase chain reaction, and plasmid construction

Genomic DNA from C. scindens ATCC 35704, C. scindens VPI 12708, and C592 were isolated
as described previously (218). Genomic DNA was then used as template for further PCR and
genomic sequencing. A streptavidin tag engineered into the reverse primer (for EDS08212.1 and
various putative 17α-HSDH candidates) or the forward primer (various putative 17α-HSDH
candidates) and genes to test for activity were PCR amplified, restriction digested, and ligated
into expression vectors. Generic 16S primers (16s357F, 16s1392R) and ExTaq polymerase kit
(Takar) were used for initial 16S screening of Eggerthella lenta strain C592.

Methods for PCR amplification and plasmid construction are based on previously published
methods (217). The gene encoding the putative Δ4,6 reductase, EDS08212.1, was PCR
amplified using the TITANIUM TAQ PCR Kit (Clontech) using primers designed to include the
E. coli ribosome binding site and KpnI restriction site on the forward primer and a streptavidinaffinity peptide encoding sequence and BamHI restriction site on the reverse primer. The PCR
product was purified through gel electrophoresis, underwent restriction endonuclease treatment
(Kpn1 and BamHI), and was ligated into the pSport1 expression vector. Recombinant plasmid
was transformed into chemically competent E. coli DH5α cells via heat stock method, plated,
and grown for 16 hours at 37 °C on lysogeny broth (LB) agar plates supplemented with
ampicillin (100 µg/mL). A single colony from each transformation was inoculated into LB
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medium (5 mL) containing ampicillin (100 µg/mL) and cultivated overnight at 37°C with
agitation. The cells were subsequently centrifuged (3220 x g, 15 min, 4 °C) and plasmids were
extracted from the resulting cell pellet using the QIAprep Spin Miniprep kit (Qiagen, Valencia,
CA). The foreign DNA inserts in the recombinant plasmids were sequenced to confirm the
correctness of the gene sequence (Virginia Commonwealth University Nucleic Acid Sequencing
Core Facility, Eurofins Genomics). Similar methods were used for putative 17α-HSDH genes of
interest. In some cases, troubleshooting changes were made via altering the streptavidin tag
presence and location (C-terminal tag, N-terminal tag, or No strep tag), varying restriction
endonuclease sequences, and utilization alternative expression vectors (pASK-IBA15plus and
pASK-IBA43plus).

C592 genomic sequencing

Genomic DNA (1.5µg) was sheared in a gTube (Covaris, Woburn, MA) for 1 minute at 6,000
rpm in an Eppendorf MiniSpin plus microcentrifuge (Eppendorf, Hauppauge, NY). The sheared
DNA was converted into a Nanopore library with the Nanopore Sequencing kit SQK-NSK007
(Oxford Nanopore, UK). The library was sequenced on a SpotON Flowcell MK I (R9) flowcell
for 48 hours, using a MinION MK 1B sequencer. Basecalling was performed in real time with
the software Metrichor version 2.40.17. Poretools v-0.5.1 software (219) was used to extract
sequences from Oxford Nanopore MinION output file folder, and then converted to fastq format.
FastQC v-0.11.2 software was also used to further access quality scores and other attributes of
the data set. A Perl script was then used to trim adaptors from the raw nanopore reads. The
adapter trimmed reads were used to blast against NCBI Ecoli_strK12_MG1655 genome. Reads
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with greater than 95% alignment to this genome were removed. 2,113,230 reads from the
Illumina paired end MiSeq run and 14,023 reads from Oxford Nanopore sequencing platform
were used for de novo hybrid assembly with SPAdes-v3.9.0 (220). The assembly produced 245
contigs, five of which were 500 base pairs and longer. The top five contigs were selected to blast
NCBI NT database. Nucleotide level comparisons between Eggerthella lenta DSM 2243
genome and the longest contig from the assembly were done with the dnadiff program from
MUMmer v-3.23 (221). Annotation comparisons between Eggerthella lenta DSM 2243 genome
and the longest contig were made with Prokka v-1.11 (222). Annotated CDS file for the longest
C592 contig were then imported into Geneious v9.1.3 for Mauve alignment and further analysis,
as well as utilized to form KEGG maps via BlastKOALA (223).

C. scindens VPI 12708 RNA purification and Illumina sequencing

After -80ºC stock of C. scindens VPI 12708 was grown overnight at 37ºC in BHI broth, a 1%
inoculum was transferred to 100mL BHI containing 25µM of either: cholic acid, allocholic acid,
androstenedione, cortisol, or only BHI (for uninduced control) along with relevant [24-14C]-bile
acid. Cells were allowed to grow to early-log phase, an additional 25µM of the inducing
molecules were added, and then at mid-log phase cells were pelleted by centrifugation. Pelleted
cells were immediately suspended in RNALater (Ambion) and placed in -80ºC freezer.
Supernatant was extracted and the metabolism of all four molecules in culture was confirmed via
TLC and HPLC analysis, as outlined above.
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Isolation of mRNA from C. scindens VPI 12708 follows a similar procedure to previously
published work (Ridlon 2013). Cell pellets were suspended in 500µL lysis buffer (200mM NaCl,
20mM EDTA, in diethylpyrocarbonate-treated water) and then transferred to 2mL bead beating
tubes (Sarstedt). To each tube, 1mL 5:1 acid phenol (Ambion), 200mL 20% SDS (Ambion), and
200µL zirconium beads was added. Cells were then disrupted on max RPM on a MiniBeadBeater (Biospec Products) for one-minute increments twice and placed on ice in between.
Samples were then centrifuged to separate the aqueous and phenol phases. The aqueous phase
was isolated and subsequently washed with an additional 1mL of 5:1 acid phenol, and then
separated again via centrifugation. The nucleic acids in the purified aqueous phase were
precipitated by addition of 2x volume of 2-propanol (Sigma), 100µL ammonium acetate
(Ambion), and 1µL glycoblue (Ambion). Samples were incubated at -80ºC overnight,
centrifuged for 30 minutes, and the pellet isolated. RNA was isolated from the nucleic acid
samples using the Ambion “Megaclear” kit, according to the manufacturers instructions.
Purified RNA samples were treated 2x with DNAse (Takara), following manufacturers
instruction. Resulting RNA was checked for purity via a 1.6% denaturing gel electrophoresis (for
16S and 23S bands) as well as via RT-PCR to check for contaminating genomic DNA following
the Clontech manufacturer instructions.

Purified total RNA then underwent mRNA enrichment protocol, following a similar procedure to
previously published work from our lab (217). Custom biotinylated TEG-spaced
oligonucleotides were designed against C. scindens VPI 12708 16S and 23S rRNA sequences.
Dynabeads M-280 Streptavidin (Invitrogen) were made RNAse free and then bound to
oligonucleotides by resuspending beads in 500uL DEPC 0.5x SSC containing 360 pmol of each
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oligonucleotide. Beads were captured using Promega magnetic stand (Promega). After
oligonucleotide beads were isolated, the rRNA capture-hybridization protocol was run using a
Biorad C1000 thermocycler (Biorad). Total RNA (1µg) was suspended in 35uL 6x SSC, heated
to 70ºC for 5 minutes, cooled to 0ºC for 3 minutes, and then 150uL of oligonucleotide-bound
beads were added. The mixture was then incubated at 68ºC for 30 minutes. Beads were
magnetically captured using the Promega stand, and the supernatant containing the enriched
mRNA was isolated and precipitated as described above. Total RNA and enriched mRNA were
compared using Bioanalyzer to see a distinct drop in the bands corresponding to rRNA subunits
before RNAseq analysis.

mRNA-enriched C. scindens VPI 12708 samples were then used to create libraries for Illumina
whole transcriptome sequencing using the NEBNext Ultra RNA Library Prep Kit for Illumina,
following manufacturer’s instructions (NEBNext). Samples were then run using MiSeq
instrumentation using a 2 x 300 bp recipe. Resulting reads were then were aligned to a
previously annotated C. scindens VPI 12708 genome using the BowTie2 algorithm.

Protein overexpression and purification

For the putative Δ4,6-reductase gene expression, pSport-EDS08212 plasmid was transformed
into E. coli BL-21 CodonPlus (DE3) RIPL chemically competent cells by the heat shock method
and grown overnight at 37 °C on LB agar plates supplemented with ampicillin (100 µg/mL).
After 16 hours, five isolated colonies were used to inoculate 10 mL of fresh LB medium
supplemented with antibiotics and grown at 37 °C for 6 hours with vigorous aeration. The pre-
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cultures were then added to fresh LB medium (1L), supplemented with the same antibiotic at the
same concentrations, and grown with vigorous aeration at 37 °C. At OD600 of ~0.3, isopropyl βD-1-thiogalactopyranoside (IPTG) inducer was added to each culture at a final concentration of
0.1mM and the temperature was decreased to 16 °C. Following 16 hours of culturing, cells were
pelleted by centrifugation (4,000 x g, 30 min, 4 °C). Cells were then suspended in buffer (20mM
sodium phosphoate buffer pH 7.0, 0.1M NaCl, 15% glycerol, 10mM 2-mercaptoethanol) and
treated with lysozyme (5ug/mL) on ice for 1 hour. Cell suspension was then run through a
French press at 1,500 psi and following cell extract was centrifuged (30min, 16,000g, 4ºC).
Recombinant EDS08212.1 gene product was then purified using Strep-Tactin® resin (IBA) as
per manufacturing protocol. The recombinant protein was eluted using an elution buffer
composed of 20mM Tris-HCl, 150mM NaCl, 20% glycerol, 10mM 2-mercaptoethanol pH 7.9
and 2.5mM desthiobiotin. Protein purity was assessed using both sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting using the Strep Tag II
antibody (IBA). The purified protein concentration was determined via the Bradford Assay
(BioRad). The same methods were used for the overexpression and purification of putative 17αHSDH enzymes from C. scindens VPI 12708 with minor adjustments. Constructs lacking a
streptavidin tag were not purified on a Strep-resin column nor were visualized via Western blot
hybridization.

Δ4,6-reductase and 17α-HSDH purified enzyme reactions

To test the oxidation of 3-dehydro-DCA by EDS08212.1, we used a standard buffer composed of
20mM sodium phosphate (pH 7.0), 100mM NaCl, 20% glycerol, and 10mM 2-mercaptoethanol.
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When utilized, pyridine nucleotides (NAD+, NADP+, NADH, NADPH) were added at 150µM
final concentration. 3-dehydro-DCA was added at 30µM final concentration. The reaction was
initiated by addition of 0.5µg purified rEDS08212 to 1ml reaction buffer and was terminated
after 6 hrs at 37°C by addition of 75µl 1N HCl, and was extracted and chromatographed as
described above.

Similar methods were used for testing purified putative 17α-HSDH enzymes. Buffers used
included 20mM sodium phosphate (pH 7.0) or 100mM sodium acetate buffer (pH 5.5) with
either 10mM 2-mercaptoethanol or 1mM dithiothreitol (Sigma). When utilized, pyridine
nucleotides (NAD+, NADP+, NADH, NADPH) were added at 150µM final concentration. 1µg
purified recombinant putative 17α-HSDH enzymes were added to each 1mL reaction volume. In
the case of whole cell extract assays, up to 100ug of whole cell protein extract was added per
1mL reaction volume. Aerobic metabolism of androstenedione and epitestosterone was tested by
monitoring changes in pyridine nucleotide oxidation states spectrophotometrically by absorption
at 340nm over time. Alternatively, aerobic metabolism of the steroid molecules was screened by
extraction of reaction mixtures and separation on HPLC as described above. Anaerobic
metabolism used the same reaction buffers that had been made anaerobic under N2 stream. The
metabolism of substrates was tracked via HPLC separation, as described above. Additionally, E.
coli BL-21 CodonPlus (DE3) RIPL transformed with putative 17α-HSDH gene plasmid
constructs were grown aerobically and anaerobically, induced with IPTG at early log phase, and
inoculated with 25µM androstenedione or epitestosterone. Whole cell conversion of these
steroids was then screened via extraction and HPLC separation, as described above.
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Bioinformatics analysis and statistics

Phylogenetic analysis of EDS08212.1 by maximum-likelihood was performed using RAxML
8.2.0 (224), with gamma-distributed heterogeneity rates, automatically selected empirical
substitution model, and 100 bootstrap pseudoreplicates. Selection and alignment of sequences
from the NCBI nr database were performed as previously described (217). The resulting tree was
drawn in Dendroscope (225) and cosmetic adjustments were performed in Inkscape.

For C. scindens VPI 12708 RNAseq analysis, significance was assessed using a false discovery
rate corrected p-values of 0.05, which were calculated and assessed using this cut-off. RNAseq
was utilized to make a heatmap using a distance metric of 1-(abs(pearson correlation)), and the
“ggplot” and “heatmap.2” R packages.
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Table 2.1: Bacterial strains used in the present study
Strain
Clostridium scindens VPI 12708
Clostridium scindens ATCC 35704
Clostridium absonum ATCC 27555
Eggerthella lenta ATCC 25559
Eggerthella lenta strain C592
I10
SA14
19BHI
KS11
SO46
SO77
E. coli BL21 (DE3)
E. coli Top10

Source
VPI
ATCC
ATCC
ATCC
Collaborators at Ryukyus University
Collaborators at Ryukyus University
Collaborators at Ryukyus University
Collaborators at Ryukyus University
Collaborators at Ryukyus University
Collaborators at Ryukyus University
Collaborators at Ryukyus University
New England Biolabs
Thermo Fischer
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Table 2.2: Primers used in the present study
Primer

Use

Sequence (5’ – 3’)

16s357F

Fwd: C592 16S

CTCCTACGGGGAGGCAGCAA

amplification
16s1392R

Rev: C592 16S

ACGGGCGGTGTGTRC

amplification
16s35704cap1

C. scindens VPI

GCGTTACTGACTCCCATGGTGTGACGG/3BioTEG/

12708 rRNA
depletion
16s35704cap2

C. scindens VPI

CTTGCGAACGTACTCCCCAGGTGGACTA/3BioTEG/

12708 rRNA
depletion
16s35704cap3

C. scindens VPI

GCTTCGGTCTTATGCGGTATTAGCAGCC/3BioTEG/

12708 rRNA
depletion
23s35704cap1

C. scindens VPI

CCAGGGTAGCTTTTATCCGTTGAGCGA/3BioTEG/

12708 rRNA
depletion
23s35704cap2

C. scindens VPI

GACAGTGCCCAAATCATTACGCCTTTCG/3BioTEG/

12708 rRNA
depletion
23s35704cap3

C. scindens VPI

AACCTGTTGTCCATCGGCTACGGC/3BioTEG/

12708 rRNA
depletion
23s35704cap4

C. scindens VPI

GGACATGGATAGATCACCCGGTTTCG/3BioTEG/

12708 rRNA
depletion
23s35704cap5

C. scindens VPI

GACACCTCCGGATCAAAGGGTATTTGCC/3BioTEG/

12708 rRNA
depletion
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Primer

Use

Sequence (5’ – 3’)

pSport112708_

Rev: Cs12708_

GTCGACTTATTCCTCAGCCTGCTC

00455NTERM

00005_00084

Rnew

w/ N-terminal
Strep tag

pSport112708_

Fwd: Cs12708_

00455NTERMF 00005_00084

CTGCAGATTAGAGAGGTGGATAACATGTGG-AGCCACCCGCAGTTCGAAAAAAATTTATTT

w/ N-terminal
Strep tag
CLONE12708_

Fwd: Cs12708_ CACTGCTCATGGTGACCTATTTCTA

00455F

00005_00084
no tag

CLONE12708_

Rev: Cs12708_

00455R

00005_00084

GCTATCATCTTCACCTCTCATCATT

no tag
pSport_00455_

Fwd: Cs12708_

CF

00005_00084

TAATCTGCAGATTAGAGAGGTGGATAAC

w/ C-terminal
Strep tag
pSport_00455_

Rev: Cs12708_

ATATGTCGACTTATTTTTCGAACTGCGGGT-

CR

00005_00084

-GGCTCCATTCCTCAGCCTGCTC

w/ C-terminal
Strep tag
pASK_64_18

Fwd: Cs12708_

Forward

00064_00018

GGATCCAATTCATATACAGTA

in pASK p43
and p15 vectors
p43_68_18_R

Rev: Cs12708_

CCATGGCCTATTCGCTCG

00064_00018
in pASK p43
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Primer

Use

Sequence (5’ – 3’)

p15_64_18_R

Rev: Cs12708_

ATGCATCCATGGCTCCTTATATTCGCTCG

00064_00018
in pASK p15
Cs12708_64_

Fwd: Cs12708_ GTCGACGGATCCCGGAGAATGAAT-

18F

00064_00008

-TCATATACAGTA

in pSport1 with
N-terminal
Strep tag
Cs12708_64_

Rev: Cs12708_

AAGCTTCTATTTTTCGAACTGCGGGTG-

18R

00064_00008

-GCTCCATATTCGCTCGACTTTCTG

in pSport1 with
N-terminal
Strep tag
Cs12708_114

Fwd: Cs12708_ CTGCAGAAAAGGAAGGGGATGATAGG

_9_NF

00114_00009
in pSport1 with
N-terminal
Strep tag

Cs12708_114

Rev: Cs12708_

GGATCCTTATTTTTCGAACTGCGGGTGG-

_9_NR

00114_00009

-CTCCAAACAAGCGTCCAGCC

in pSport1 with
N-terminal
Strep tag
Cs12708_114

Fwd: Cs12708_ GTCGACCTGCAGGATAGGATGAAGAA-

_9_NoTagF

00114_00009 in -TTTATTTGAT
pSport1 no tag

Cs12708_114

Rev: Cs12708_

ATGCATGGATCCAATTGTCTAAACAAG-

_9_NoTagR

00114_00009 in -CGTCAA
pSport1 no tag
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Primer

Use

Sequence (5’ – 3’)

Cs12708_124

Fwd: Cs12708_ CTGCAGAAAGGAGAACAAAAAGGA

_9_NF

00124_00009
in pSport1 with
N-terminal
Strep tag

Cs12708_124

Rev: Cs12708_

GGATCCTTATTTTTCGAACTGCGGGTGGCT-

_9_NF

00124_00009

-CCATATCAACGGTTCATA

in pSport1 with
N-terminal
Strep tag
Fwd – Forward; Rev – Reverse; 3BioTEG – 3’ Biotin with triethyleneglycol (TEG) spacer
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Table 2.3: Plasmids used in the present study
Plasmid

Description

Source

pCRTMBlunt II-TOPO®

Kanamycin resistance,

Thermo Fischer

designed for blunt-end ligation
pSPORT-1

Ampicillin resistance, contains Thermo Fischer
lac-promotor for expression in
E. coli cells

pASK-IBA43plus

Ampicillin resistance, contains IBA
C-terminal Strep-tag, tetpromotor expression vector

pASK-IBA15plus

Ampicillin resistance, contains IBA
N-terminal Strep-tag, tetpromotor expression vector
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Chapter 3: Characterization of novel Eggerthella lenta strain C592

Introduction:

Significant effort is underway studying the human gut microbiome and how it impacts human
health. The first step in this process is to obtain a basic understanding of the makeup of this
microbial community. The advent of next generation sequencing, along with advances in
computational power have provided the ability to assign functional characterization organisms
based on clusters of orthologous groups (COG) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) databases, allows scientists to gain insight into the effects microbes may have on each
other and the host (226). However, the reference genomes that guide predictive annotations of
novel microbial strains only account for a third of the entire metagenomic data received from
high-throughput shotgun sequencing of fecal samples (227). A complementary approach is to
attempt to assign strains to OTUs based on 16S DNA sequence (2). However, in doing so it is
very easy to miss significant differences that may exist among species within a specific OTU.
These significant differences are evident when studying the gut “sterolbiome”, the genes
involved in bile acid and steroid metabolism. For example, within the same species,
Clostridium scindens strains have been shown to have varying ability to metabolize steroids. C.
scindens ATCC 35704 encodes a steroid 17,20-desmolase which is absent from its sister strain
C. scindens VPI 12708 (217). Additionally, C. scindens VPI 12708 has been shown to have
unique 17α−HSDH activity that is not found in C. scindens ATCC 35704 (228). Understanding
and characterizing the sterolbiome’s potential to biotransform these molecules in humans is
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important because even small modifications to the base structure of bile acids and steroids can
have significant physiological effects, even at nanomolar concentrations (167, 229, 230).

One bacterial strain that has garnered significant attention in the study of the human gut
sterolbiome is Eggerthella lenta. Within the classs Actinobacteria and the family
Coriobacteriaceae, E. lenta is a non-motile, non-sporulating, gram-positive short rod-shaped
bacterium usually found in pairs or chains (231). The first isolation of what would later be
named Eggerthella lenta was from normal adult fecal samples by Arnold H. Eggerth in 1935,
and classified under the Bacteroides genus, although no type strain was obtained (232). Soon
after, the first reported type strain for Eggerthella lenta was isolated from a rectal tumor and
added to the Prevot collection under the Eubacterium genus classification (231). It was later
transferred to the Eggerthella genus after further characterization and phylogenetic analysis (233,
234).

E. lenta has been proposed as an important gut microbial strain to characterize and potentially
inhibit in patients undergoing treatment for cardiovascular disease. Cardiac glycosides, derived
from Digitalis purpurea, have been used for centuries to treat both heart failure and atrial
fibrillation (235). Approximately 10% of those treated with cardiac glycosides harbor an
intestinal microbiota capable of reducing the α,β-unsaturated butyrolactone ring, thereby
inactivating the drug (Figure 3.1) (236). It has been shown that some strains of E. lenta,
including the type strain, have the ability to reductively inactivate digitoxin (237). Within these
active E. lenta strains, a two-gene locus termed the “cardiac glycoside reductase operon”
(cgrAB) was found that encodes proteins resembling bacterial cytochromes that are associated
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Figure 3.1: Diagram of reductive digoxin inactivation by Eggerthella lenta
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Adapted from (236)
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with the formation of reduced digoxin products from digoxin (238), although it has yet to be
proven that this “cgr locus” encodes a digoxin reductase. These reduced digoxin products have
reduced cardiac reactivity, likely due to a decreased affinity to the Na+/K+ ATPase in
cardiomyocytes (239). The role of E. lenta in the formation of inactivated digoxin products on
the availability of digoxin is important because of the narrow range at which digoxin is
therapeutically effective before it becomes toxic (240).

In addition to the metabolism of cardiac glycosides, E. lenta has been shown to metabolize
endogenous steroid molecules. Because of their metabolism of endogenous corticosteroids, E.
lenta has been identified as a candidate to be linked to essential hypertension, although more
work is necessary to delineate the extent of its involvement. The initial work of linking the gut
microbiota to hypertension began in rats, where the development of hypertension could be
attenuated by treatment with neomycin and vancomycin (241, 242). However, attempts to
delineate the specific microbes responsible for this modulation at the time were unsuccessful and
not pursued further (243). In the study of adults with 17-hydroxylase insufficiency, a genetic
defect causing hypertension due to an increased level of deoxycorticosterone leading to renal
sodium retention (244), it was found in urinary steroid analysis that 21-deoxycorticosterone was
a major metabolite of corticosterone (245). Radiolabeled assays showed that 21deoxycorticosterone was a direct metabolite of corticosterone, and that its production did not
occur in germ free rats (245, 246). Around the same time it was discovered that Eggerthella
lenta produced a 21-dehydroxylase capable of converting cortisone to 11β-hydroxy-progesterone
(247, 248). A major regulator of systemic blood pressure is aldosterone, which imparts its action
by binding to the mineralocorticoid receptor in renal epithelial cells (249). This leads to the
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expression of sodium reabsorption mechanisms, ultimately increasing extracellular volume
(249). However, cortisol is a much more potent agonist for the mineralocorticoid receptor in
renal epithelial cells and is in much higher concentrations in serum. The reason that aldosterone
is the major systemic modulator of blood pressure is that renal cells also contain 11βhydroxysteroid dehydrogenase-2 (11β-HSD2), which can inactivate cortisol once inside the cell,
forming inactive cortisone (250). Therefore, 11β-HSD2 acts as a modulator of cortisol activity.
It has been shown that 11β-hydroxy-progesterone is a competitive inhibitor for the 11β-HSD2
enzyme (251). E. lenta is the only gut microbe reported to contain 21-dehydroxylase activity
capable of converting cortisol to 11β-hydroxy-progesterone, although not all strains harbor
activity (248). In a model of hypertension caused by obstructive sleep apnea in rats, it was found
that the gut microbiome of those with hypertension showed an increase in Coriobacteriaceae,
which includes E. lenta (252).

Additionally, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) found in the liver and
responsible for converting cortisone to activated cortisol (the reverse of 11β-HSD2), has been
shown to be competitively inhibited by oxo-bile acid derivatives of microbial bile acid
metabolism, such as 7-oxo-lithocholic acid (198, 199), although more oxo-bile acid derivatives
need to be screened. E. lenta has been reported to harbor 3α-HSDH, 7α-HSDH, and 12α-HSDH
activity, varying on the strain, which are involved in the formation of oxo-bile acids (151, 153).

Metabolism of corticosterone and bile acids by E. lenta may also have implications on CRC
formation. 11β-HSD2 is also found in colonocytes, the disruption of which has been shown to
rescue APC knockout mice from tumor formation through a Cox-2 dependent mechanism (253).

62

Therefore, the inhibition of 11β-HSD2 activity by E. lenta-derived corticosterone derivatives
may alter prostaglandin synthesis and reduce colonic inflammation, both factors important to
CRC development.

In addition, the metabolism of bile acids by E. lenta may lead to the formation of less toxic bile
acid metabolites and affect CRC progression as well. As reviewed earlier, secondary bile acids
DCA and to a lesser degree LCA, formed from primary bile acids CA and CDCA, have been
associated with the formation of CRC. However, other secondary bile acids produced by gut
microbes are less toxic. Ursodeoxycholic acid (UDCA) is formed by the oxidation and
subsequent epimerization of the 7α hydroxyl group of CDCA via microbial 7α-HSDH and 7βHSDH enzymes (125). UDCA has been shown to be less toxic to both microbial and host cells,
and additionally have seen some use as therapeutic agents in liver and biliary disease. The βconfiguration of the 7-hydroxyl group leads to a more hydrophilic molecule, leading to its
reduced toxicity (254, 255). In addition to epimerization of the C7-hydroxyl group on CA,
CDCA, and UDCA, the C3-hydroxyl group is also subject to isomerization by bacterial enzymes
in the gut, including some produced by E. lenta. E. lenta has been found to encode both a 3αHSDH and 3β-HSDH necessary to convert DCA to iso-DCA (150). The same work showed that
iso-DCA was less toxic to other gut microbes than DCA, indicating it may be a detoxification
mechanism (150). The effects of isomerized secondary bile acids on colonocytes remains
unstudied, but it can be hypothesized that due to their increased hydrophilicity, iso-secondary
bile acids would be less toxic than secondary bile acids. What was not established in this
previous study was whether E. lenta could convert primary bile acids to 3β-epimers. Removal of
the C7-hydroxyl group on primary bile acids requires the formation of a 3-oxo-Δ4-intermediate
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and to date no 7α-dehydroxylating bacteria has been shown to encode a 3β-HSDH. Therefore,
we predict that isomerization of primary bile acids would lead to formation of alternate bile acid
metabolites and prevent 7α-dehydroxylation.

Studies identifying the makeup of the inhabitants of the gut microbiome have shown the two
major represented phyla being Bacteroidetes and Firmicutes, making up on average 85% of the
total phylotypes (256, 257). The next most represented phylum is Actinobacteria, of which E.
lenta is a member. Even though it is found in lower relative abundance in the gut, E. lenta still
has significant implications to both gut microbiome and host physiology. Studies of both germfree mice and hamsters have indicated that OTUs identified as or closely related to E. lenta are
associated with increased hepatic triglycerides, increased synthesis of primary bile acids via the
alternative pathway, and increased liver cytochrome activity (258, 259). Interestingly, E. lenta
and Clostridium scindens, both numerically minor constituents of the gut microbiome, which are
nevertheless responsible for substantial metabolism of bile acids and steroid molecules, were
shown to be associated with increased hepatic triglyceride synthesis in conventionalized ex-germ
free mice (258). The bile acid composition (a switch to primary bile acids produced via the
alternative pathway) as well as increased hepatic FXR and PXR signaling, suggesting a
significant role of E. lenta in gut microbiome-modulated energy homeostasis via bile acid
signaling pathways (258). A mechanism by which E. lenta may be exerting these effects is
through activation of TGR5, leading to glucagon-like peptide-1 (GLP-1) release from
neuroendrocrine cells, leading to increased insulin release from the pancreas, which stimulates
production of triglycerides by hepatocytes. However, it has been shown that secondary bile acids
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DCA and LCA are the most potent activators of TGR-5 (170, 171) and E. lenta has not been
shown to create these molecules.

Human studies have shown that diet substantially alters the structure and metabolic activity of
the gut microbiome (226, 256). One such quantitative study of changes to gut microbial
diversity based on varying diets showed E. lenta levels can vary in the same individual based
purely on diet. A significant increase in E. lenta was observed in human subjects given a diet
high in non-starch polysaccharides relative to other dietary polysaccharides, including resistant
starch and a “weight loss” diet high in protein (260). Similarly, fecal concentrations of SCFAs
acetate, propionate, butyrate, as well as succinate, were all significantly higher in in the same
patients eating a diet high in non-starch polysaccharides when compared to other diets (260).
These results suggest that E. lenta thrives in an environment where anaerobic bacterial
fermentation is occurring.

Based on the previous literature, it is apparent that E. lenta impacts both gut microbial and host
physiology. However, a better understanding of the types of bile acid and steroid products it
recognizes and the metabolites it creates is necessary. Furthermore, understanding how bile
acids and steroids play into the overall metabolism of E. lenta may give insight into why bile
acids and steroids are utilized in the more complex gut microbial environment. We set out to
better understand E. lenta bile acid and steroid metabolism through characterization of a novel
strain; C592, a human fecal isolate from a Japanese octogenarian. Comparison of steroid
metabolism and genome sequence between the type strain E. lenta ATCC 25559 reveals
important strain-dependent differences in the sterolbiome among E. lenta isolates. I discovered
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that both these bacteria make unique patterns of oxidized bile acid and steroid metabolites,
including a novel ability to metabolize testosterone. I show that the pattern of metabolites made
can be altered based on the atmospheric gases present during their growth. Based on these
observations, the full genome sequencing/annotation of C592, and preliminary fermentative end
product analysis, I hypothesize that Eggerthella lenta is an acetogen able to link the metabolism
of bile acids to the formation of acetate in order to maintain intracellular redox equilibrium. In
addition, I show that the bile acid metabolites made by E. lenta ATCC 25559 and C592 inhibit
subsequent 7α-dehydroxylation by Clostridium scindens.
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Results:

Initial screening of C592 primary bile acid metabolism

Strain C592 is a gram-positive, obligate anaerobe isolated from a human fecal sample from Dr.
Fusae Takamine (University of Ryukyus) in Okinawa, Japan during a screen for fecal bile acid
7α-dehydroxylating bacteria. However, the bile acid metabolites derived from whole-cell cholic
acid-induced 14C-cholic acid metabolism by the C592 strain had unique retardation factor (RF)
values as compared to known metabolites synthesized by 7α-dehydroxylating bacteria (Figure
3.2). In comparison to both high-activity and low-activity 7α-dehydroxylating strains, C592 CA
metabolites do not comigrate with CA, DCA, or allodeoxycholic acid (ADCA), a 5α-epimer of
DCA (Figure 3.2). In addition, numerous secondary metabolites were generated from CA,
whereas the major product from other 7α-dehydroxylating strains comigrates with the DCA
standard (Figure 3.2).

These results suggested C592 is producing unique bile acid metabolites

from CA. C592 CA metabolism screening was repeated, inducing with either CA or allocholic
acid (ACA), a 5α epimer of CA. Results showed that both CA and ACA-induced C592 cultures
metabolized [14C]-CA to secondary products unique from known 7α-dehydroxylated metabolites
DCA and ADCA (Figure 3.3). There was no difference in the migration of 14C-CA metabolites
between CA and ACA-induced C592 metabolism by TLC analysis. C592 was also screened for
its ability to metabolize CDCA, the other primary bile acid produced by human hepatocytes.
C592 CDCA-induced metabolism of [14C]-CDCA showed formation of three secondary products
(Figure 3.4). Experiments looking at C592 uninduced whole cell metabolism of [14C]-CA and
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Figure 3.2: TLC of whole cell extracts from various fecal bacterial strains induced by
cholic acid to metabolize [24-14C]-cholic acid

First section of TLC plate includes cholic acid, deoxycholic acid, and allodeoxycholic acid TLC
standards. The second section contains organic extracts from whole-cell cholic acid-induced
[24-14C]-cholic acid metabolism. I10, SA19, C592, 19BHI, KS11, SO96, SO77 are all human
fecal isolates previously screened for bile acid metabolizing potential. Cultures were grown
overnight with 25µM cholic acid and 1µCi labeled cholic acid and separated on TLC as
described in Materials and Methods. The major CA metabolite for I10, SA19, 19BHI, KS11,
SO96, and SO77 comigrates with the DCA standard. However, the C592 metabolites appear to
migrate separately with one migrating similarly to ADCA.

68

69

Figure 3.3: Conversion of [24-14C]-cholic acid by allocholic acid- and cholic acid-induced
C592

First section of TLC plate includes cholic acid, deoxycholic acid, and allodeoxycholic acid TLC
standards. The second section contains organic extracts from C592 whole-cell bile acid-induced
[24-14C]-cholic acid metabolism. C592 was grown in the presence of either 25µM cholic acid or
25µM allocholic acid, along with 1µCi cholic acid. Cultures were extracted and run on TLC as
described in the Materials and Methods. C592 metabolizes [24-14C]-cholic acid to five
secondary metabolites, with no apparent difference in the spectrum of metabolites when induced
with either cholic or allocholic acid. No C592 CA metabolites comigrate with DCA or ADCA,
suggesting they are not 7α-dehydroxylated.
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Figure 3.4: Conversion of [24-14C]-CDCA by CDCA-induced C592

First spot on the TLC plate is the chenodeoxycholic acid TLC standard. The second spot
contains the organic extracts from a C592 whole-cell chenodeoxycholic acid-induced [24-14C]chenodeoxycholic acid metabolism. C592 was grown in the presence of 25µM
chenodeoxycholic acid along with 1µCi chenodeoxycholic acid. Cultures were extracted and run
on TLC as described in the Materials and Methods. C592 metabolizes [24-14C]chenodeoxycholic acid to three secondary metabolites.
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[14C]-CDCA as well as C592 whole cell protein extract metabolism of [14C]-CA and [14C]CDCA showed no significant difference from the induced samples, indicating this was not an
inducible phenomenon (data not shown).

Next C592 was compared against known bile acid 7α-dehydroxylating and epimerizing bacterial
whole-cell cultures. Clostridium scindens VPI 12708 is a known high-activity 7αdehydroxylating bacterium known to harbor a bile acid-inducible operon (bai-operon). The
products created from CA-induced [14C]-CA metabolism in whole cell cultures are known,
including 3-oxo-deoxycholic acid, DCA, and 7-oxo-cholic acid (Figure 3.5). Additionally, when
induced with ACA, C. scindens VPI 12708 shifts its metabolic profile to create 3-oxoallodeoxycholic acid and allodeoxycholic acid, in addition to some trace DCA (143) (Figure 3.5).
Both whole cell extracts of 12708 [14C]-CA metabolism were used as comparisons to help
determine possible C592 CA metabolites, although only 7-oxo-cholic acid appeared to
comigrate, indicating C592 CA metabolites are not 7α-dehydroxylated (Figure 3.5). In addition,
C592 CDCA-induced [14C]-CDCA metabolism was compared against two other bacteria known
to metabolize CDCA. C. scindens VPI 12708 is known to convert CDCA into several
metabolites, including LCA, 3-oxo-lithocholic acid, 3-oxo-chenodeoxycholic acid, and 7-oxolithocholic acid (7-oxo-LCA) (Figure 3.6). Clostridium absonum was also screened, as it has
been previously shown to harbor both a 7α-HSDH and 7β-HSDH, allowing it to epimerize
CDCA at the 7-hydroxyl group forming ursodeoxycholic acid (146). C. absonum whole cell
CDCA metabolism generated 7-oxo-lithocholic acid as well as ursodeoxycholic acid (Figure
3.6). When these known CDCA metabolites were compared to the three C592 CDCA
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Figure 3.5: TLC separation of organic extracts from C. scindens VPI 12708 and C592 bile
acid-induced whole cell conversions of [24-14C]-CA

The first spot on the TLC plate is a cholic acid TLC standard. The next three spots are organic
extracts from whole-cell bile acid-induced [24-14C]-cholic acid metabolism screens in C.
scindens VPI 12708 or C592. Based on previous literature, C. scindens VPI 12708 is known to
differentially produce deoxycholic acid or allodeoxycholic acid from cholic acid when induced
with either cholic acid or allocholic acid, respectively (143). In addition, C. scindens VPI 12708
bile acid induced cultures usually generate some 7-oxo-cholic acid and 3-oxo-deoxycholic acid
(when induced with cholic acid) or 3-oxo-allodeoxycholic acid (when induced with allocholic
acid), based on Rf (143). One C592 cholic acid metabolite appears to comigrate with
allodeoxycholic acid and another with 7-oxo-cholic acid, but the rest have unique migration
patterns.
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Figure 3.6: TLC separation of organic extracts from C. scindens VPI 12708, C. absonum,
and C592 CDCA-induced whole cell conversions of [24-14C]-CDCA

The first spot on the TLC plate is a chenodeoxycholic acid TLC standard. The next three spots
are organic extracts from whole-cell chenodeoxycholic acid-induced [24-14C]-chenodeoxycholic
acid metabolism screens in C. scindens VPI 12708, Clostridium absonum, or C592. Previous
literature has determined LCA as a major product of C. scindens VPI 12708 CDCA metabolism
(261). Additionally, C. absonum is known to epimerize chenodeoxycholic acid to
ursodeoxycholic acid via 7α-HSDH and 7β-HSDH reactions (146, 262). When whole cell
conversion of CDCA of these two known CDCA metabolizers is compared to C592, one
metabolite (7-oxo-lithocholic acid) comigrates while the two others do not.
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metabolites, the only metabolites that shared a similar Rf was 7-oxo-LCA, indicating the other
two compounds were unique CDCA metabolites.

Determination of C592 phylogeny based on 16S sequencing

C592 was confirmed to be pure through anaerobic BHI agar plate growth, colony isolation, and
subsequent bile acid metabolism screening. There was no growth under aerobic BHI agar
plating. Purified C592 was grown anaerobically in BHI broth overnight at 37ºC for genomic
DNA isolation and purification. Purified C592 genomic DNA was used as template for 16S
sequence amplification using generic primers (Table 2.2). The ~1kb PCR product was run on a
1% agarose gel, isolated, purified, and sequenced. The resulting C592 16S DNA fragment had
>99% sequence similarity to the Eggerthella lenta type strain.

Comparison of phenotypic similarities between C592 and E. lenta ATCC 25559

E. lenta ATCC 25559 (25559) was acquired from the American Type Culture Collection, plated
anaerobically, and colonies picked for further analysis. Purified 25559 was grown anaerobically
in BHI media and compared with C592 growth. Growth of C592 and 25559 was similar
between both strains both with and without arginine, which has been shown to be stimulatory for
E. lenta growth in vitro (Table 3.1). Both showed similar Gram-positive bacillus morphology
(data not shown).

Comparison of C592 and 25559 metabolism of primary and secondary bile acids
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Table 3.1: Overnight growth comparison between C592 and E. lenta ATCC 25559
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Since E. lenta is known to epimerize primary and secondary bile acids, we screened the ability of
C592 and 25559 to metabolize numerous bile acids. Grown overnight in BHI broth under inert
N2 gas, C592 and 25559 both metabolize 25µM CDCA into three metabolites; CDCA-A,
CDCA-B, and CDCA-C (Figure 3.7). CDCA-A has a similar Rf to 7-oxo-LCA, however,
CDCA-B and CDCA-C do not share Rf values with previously described CDCA metabolites
generated by bile acid 7α-dehydroxylating bacteria. Both strains metabolize CDCA to
completion, leaving no remaining CDCA after 24 hours. In a time course experiment, CDCA
metabolism begins in early-log phase, with no detectable CDCA remaining by mid-log phase
(data not shown). In addition, both C592 and 25559 can grow in higher concentrations of CDCA
(50µM and 500µM) as well as completely metabolizing the increased CDCA concentrations to
the same three secondary metabolites (data not shown). C592 and 25559 also completely
metabolize CA to six metabolites (Figure 3.8). One CA metabolite has a similar Rf value to 7oxo-CA, however the rest do not match known CA metabolites based on Rf values.

E. lenta has been previously shown to isomerize secondary bile acids, so the ability for C592 to
metabolize DCA and LCA was tested. In order to test secondary bile acid metabolism, 14Csecondary bile acids were synthesized biologically. C. scindens VPI 12708 was grown with CA
and 14C-CA or CDCA and 14C-CDCA overnight and the resulting bile acid metabolites were
separated on TLC, isolated, and quantified via liquid scintillation spectrometry. The resulting
[14C]-secondary bile acids were used for whole cell metabolism assays. Both C592 and 25559
fully metabolize 25µM DCA to secondary metabolites, DCA-A and DCA-B (Figure 3.9). C592
also recognizes LCA, fully metabolizing it to a single secondary metabolite (data not shown).
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Figure 3.7: TLC separation of CDCA-induced C592 and Eggerthella lenta ATCC 25559
whole cell metabolism of [24-14C]-CDCA

The first frame is a chenodeoxycholic acid TLC standard. The next two frames are organic
extracts from whole-cell chenodeoxycholic acid-induced [24-14C]-chenodeoxycholic acid
metabolism screens in C592 and E. lenta ATCC 25559. Both C592 and E. lenta ATCC 25559
metabolize CDCA to three metabolites; CDCA-A which comigrates with 7-oxo-lithocholic acid,
CDCA-B and CDCA-C, which do not comigrate with known CDCA metabolites. CDCA
metabolites CDCA-A, CDCA-B, and CDCA-C were isolated from TLC plates and used for
further characterization
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Figure 3.8: TLC separation of CA-induced C592 and Eggerthella lenta ATCC 25559 whole
cell metabolism of [24-14C]-CA

The first frame is a cholic acid TLC standard. The next two frames are organic extracts from
whole-cell cholic acid-induced [24-14C]-cholic acid metabolism screens in C592 and E. lenta
ATCC 25559. Both C592 and E. lenta ATCC 25559 metabolize CA to a similar pattern of
metabolites.
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Figure 3.9: TLC separation of DCA-induced C592 and Eggerthella lenta ATCC 25559
whole cell metabolism of [24-14C]-DCA

The first frame is a deoxycholic acid TLC standard. The next two frames are organic extracts
from whole-cell deoxycholic acid-induced [24-14C]-deoxycholic acid metabolism screens in
C592 and E. lenta ATCC 25559. Deoxycholic acid was made biologically via metabolism of
CA by C. scindens VPI 12708, as described in the Materials and Methods. Both C592 and E.
lenta ATCC 25559 metabolize DCA to in a similar pattern to two distinct metabolites, DCA-A
and DCA-B. These two metabolites were isolated from the TLC plate and used for further
analysis.
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C592 and 25559 metabolism of CDCA was also tested in the presence of varying molecules
which were hypothesized to alter the pattern of bile acid metabolism. Arginine, at a
concentration of 0.5% wt/vol, did not inhibit formation of CDCA metabolites (data not shown).
Neither pyruvate nor glutamate (100µM final concentration) altered C592 metabolism of CDCA
(data not shown).

Mass spectrometry characterization of C592 CDCA and DCA metabolites

C592 metabolism of CDCA and DCA was repeated in a larger volume in order to obtain enough
of each metabolite to perform MS analysis. 100mL C592 BHI cultures were grown anaerobically
overnight under inert N2 gas in the presence of 25µM CDCA. The metabolites were separated
on TLC alongside C592 14C-CDCA whole cell metabolism extracts and the corresponding bands
for unlabeled CDCA-A, CDCA-B, and CDCA-C were isolated. MS analysis on the resulting
bands was performed. MS analysis of authentic CDCA was performed resulting in a
mass/charge of 392.57m/z. CDCA-A and CDCA-B metabolites saw a loss of two mass units
(390m/z) on MS analysis, indicating oxidation of a single hydroxyl-group (Figure 3.10). CDCAC was four mass units less than CDCA (388m/z), indicating probable oxidation of two hydroxyl
groups (Figure 3.10). CDCA is a dihydroxy bile acid (C3, C7) and a loss of 4 AMU is consistent
with CDCA-C being identified as 3,7-dioxo-5β-cholanoic acid. CDCA-A has a similar Rf to 7oxo-LCA and shows the expected mass on MS analysis. Additionally, when CDCA-A was
treated with purified 3α-HSDH from Pseudomonas testosteroni in the presence of NAD+, a
single product migrating with the same Rf value of 3,7-dioxo-5β-cholanoic acid is observed.
Taken together, these results suggest CDCA-A is 3α-hydroxy-7-oxo-5β-cholanoic acid.
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Figure 3.10: C592 CDCA metabolite separation and subsequent MS characterization

C592 CDCA metabolites were separated as previously described on TLC both with and without
[24-14C]-radiolabel. Isolated unlabeled substrates then underwent MS analysis as described in
the Materials and Methods. Both CDCA-A and CDCA-B exhibited mass/charge ratios of
390m/z, suggesting a loss of 2 AMU when compared to CDCA, consistent with the oxidation of
a single hydroxyl group. CDCA-C exhibited a loss of 4 AMU (388m/z) when compared to
CDCA, consistent with the oxidation of two hydroxyl groups. Correlating this data with TLC
and 3α-HSDH treatment data, the putative identities of these metabolites are: CDCA-A - 3αhydroxy-7-oxo-5β-cholanoic acid, CDCA-B - 3β-hydroxy-7-oxo-5β-cholanoic acid, CDCA-C 3,7-dioxo-5β-cholanoic acid.
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CDCA-B has the same mass as CDCA-A. However, the Rf matches neither 7-oxo-LCA nor 3oxo-CDCA. In addition, when treated with purified 3α-HSDH in the presence of NAD+, there is
no product formed. These results suggest that CDCA-B is 3β-hydroxy-7-oxo-5β-cholanoic acid.

The same procedure was used to perform MS analysis on the C592 DCA metabolites. MS
analysis for DCA has been performed previously with a resulting mass of 392.57m/z. When
compared to the mass of DCA, C592 DCA metabolite DCA-A shows a loss of two mass units
(390m/z), indicating the oxidation of a single hydroxyl group (Figure 3.11). DCA-B shows a
loss of four mass units (388m/z), indicating the oxidation of two hydroxyl groups (Figure 3.10).
Similarly to CDCA, DCA only contains two hydroxyl groups, one at the 3rd and 12th carbons.
Therefore, DCA-B can be identified as 3,12-dioxo-5β-cholanoic acid. DCA-A is likely either 3oxo-DCA or 12-oxo-DCA, the specific oxidized hydroxyl group was not determined.

Comparison of steroid metabolism by C592 and 25559

Since E. lenta type strain has previously been shown to metabolize neutral steroids such as
deoxycortisone, deoxycortisol, and dehydrocorticosterone (248), we determined substrate
specificity for C592 and 25559 metabolism of numerous compounds sharing the steroid
backbone. C592 and 25559 were grown overnight anaerobically in BHI broth in the presence of
25µM androstenedione and its 17α/β-reduced end products, epitestosterone and testosterone,
respectively. Cultures were extracted and the metabolites separated on reverse phase column
HPLC and monitored at 240nm. Neither androstenedione nor epitestosterone were metabolized
to a secondary metabolite (data not shown). However, both C592 and 25559 metabolized
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Figure 3.11: C592 DCA metabolite separation and subsequent MS characterization

C592 DCA metabolites were separated as previously described on TLC both with and without
[24-14C]-radiolabel. Isolated unlabeled substrates then underwent MS analysis as described in
the Materials and Methods. DCA-A exhibited mass/charge ratio of 390m/z, suggesting a loss of
2 AMU when compared to DCA, consistent with the oxidation of a single hydroxyl group.
DCA-B exhibited a loss of 4 AMU (388m/z) when compared to DCA, consistent with the
oxidation of two hydroxyl groups. DCA-A is hypothesized to be either- 3α-hydroxy-12-oxo-5βcholanoic acid or 12α-hydroxy-3-oxo-5β-cholanoic acid. DCA-B is predicted to be 3,12-dioxo5β-cholanoic acid.
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testosterone to a secondary metabolite that comigrated with androstenedione (Figure 3.12). The
data indicates that C592 and 25559 recognize the 17β-hydroxyl group on testosterone and
preferentially oxidize it. This is the first report of 17β-HSDH activity in E. lenta. C592 and
25559 were also tested for their ability to metabolize hydrocortisone and cholesterol, however no
products were detected under N2 gas (data not shown). Taken together, it appears that under
inert N2 anaerobic growth, both C592 and 25559 preferentially oxidize bile acid and steroid
hydroxyl groups (Figure 3.13).

Whole genomic sequencing of C592 and comparison to E. lenta type strain

In order to get a more comprehensive comparison of novel strain C592 and E. lenta 25559, the
genome C592 was sequenced. Genomic DNA was isolated from C592 was sheared and
converted to a Nanopore library. The library was then sequenced on SpotON Flowcell MK 1 for
48 hours using a MinION MK 1B sequencer. Poretools and FastQC was used to determine
quality scores of the data set and reads from E. coli were removed via a Perl script. SPAdesv3.9.0 was then used for de novo hybrid assembly of the reads. This resulted in five contigs
>500bp, the top five of which were blasted to the NCBI NT database (Table 3.2). NODE_1
indicates the C592 genomic DNA, while four smaller contigs were also picked up likely
indicating the presence of plasmids (Table 3.2). MUMmer v-3.23 was used to perform nucleotide
level comparisons between the C592 NODE_1 contig and the E. lenta type strain closed genome
(Table 3.3). This comparison showed that C592 and 25559 share approximately 88% base pair
identity, however over 400k base pairs (>10%) were unaligned (Table 3.3). Mauve alignment
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Figure 3.12: C592 metabolizes testosterone to androstenedione under inert N2 gas

C592 was grown the presence of 25mM testosterone and then extracted as described in the
Materials and Methods. The organic extract was run on HPLC, monitoring at 240nm for
absorption via UV-Vis. Based on both androstenedione and testosterone controls, C592
metabolizes testosterone to a product that comigrates with the androstenedione control yet
maintains the 4-ene-3-oxo moiety required for 240nm absorption. This suggests the 17βhydroxyl group on testosterone is being oxidized by C592. Similar experiments run with
epitestosterone did not show production of a secondary metabolite, suggesting this activity is
specific to the β-configuration of the C17-hydroxyl group.
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Figure 3.13: Summary of C592 and 25559 bile acid and neutral steroid metabolic potential

This diagram shows C592 bile acid and steroid metabolic potential. Based on the data presented
so far, C592 has shown the potential for numerous biotransformations of the three hydroxyl
groups found on primary and secondary bile acids, including 3α-, 3β-, 7α-, 12α-HSDH activity.
Additionally, C592 has been shown to exhibit 17β-HSDH activity.
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Table 3.2: De novo hybrid assembly of the five largest contigs from C592 genomic
sequencing

SPAdes-v3.9.0 Hybrid Assembly
Contig Name

Length

NODE_1

3,593,230

NODE_2

45,419

Coverage BLAST Top Hits (NT database)
71x Eggerthella lenta DSM 2243, complete genome
148x Gordonibacter pamelaeae 7-10-1-b draft genome
Uncultured prokaryote from Rat gut metagenome

NODE_3

3,947

864x

metamobilome, plasmid pRGRH0595
Uncultured prokaryote from Rat gut metagenome

NODE_4

2,749

1663x

metamobilome, plasmid pRGRH0074
Uncultured prokaryote from Rat gut metagenome

NODE_5
Total

2,231

1780.77

metamobilome, plasmid pRGRH0074

3,647,576
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Table 3.3: Nucleotide level comparisons between C592 NODE_1 contig and the E. lenta
type strain closed genome

Sequences
TotalSeqs
AlignedSeqs
TotalBases
AlignedBases
UnalignedBases
Alignments
1-to-1
TotalLength
AvgIdentity
[Feature Estimates]
Breakpoints
Relocations
Translocations
Inversions
InsertionSum
InsertionAvg
TandemIns
TandemInsSum
TandemInsAvg
[SNPs]
TotalSNPs
TotalGSNPs
TotalIndels
TotalGIndels

Eggerthella lenta DSM 2243
genome

C592 NODE_1

1
1(100.00%)
3,632,260
3,196,021(87.99%)
436,239(12.01%)

1
1(100.00%)
3,593,230
3,188,117(88.73%)
405,113(11.27%)

220
3,172,629
98.66

220
3,172,428
98.66

554
26
0
14
466,071
2,118.50
0
0
0.00

554
35
0
14
434,221
1,929.87
2
255
127.50

35,383
8,237
4,555
99

35,383
8,237
4,555
99
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of the C592 and 25559 genomes was performed, showing significant rearrangement but high
similarity between the two genomes (Figure 3.14). Comparison of annotations were performed
between C592 and the E. lenta type strain and showed that C592 encodes 3047 proteins, while
25559 encodes 3110 proteins (Table 3.4). Taken together, although C592 and 25559 appear to
have similar bile acid metabolic profiles and highly conserved genomic regions, their genomes
also harbor significant differences.

Searching the C592 genome for an explanation for the production of oxo-bile acid
derivatives under anaerobic conditions

The production of oxo-bile acids under anaerobic condition is unique, since most anaerobic
bacteria scavenge for electron accepters to regenerate their oxidized metabolic cofactors, such as
pyridine nucleotides and ferredoxin. Conversely, the oxidation of bile acids would generate
reduced pyridine nucleotides. Therefore, we sought to determine a reason C592 would be
carrying out such a reaction in an anaerobic environment. Using the genetic information gained
from C592 genomic sequencing, KEGG maps were populated with enzymes annotated to be
present in C592 based on KEGG gene ontology using BlastKOALA and pathway mapping tools.
Of the entirety of encoding sequences in C592, only 1340 (42%) matched KEGG annotations
(Figure 3.15). Sixty-one enzymes were annotated to be involved in carbon metabolism. C592
contains genes for the glycolysis pathway, an incomplete TCA cycle (missing succinyl-CoA
synthetase), and a pyruvate:ferredoxin oxidoreductase capable of creating acetyl-CoA from
pyruvate. Interestingly, annotation of the complete genome sequence of C592 and comparative
genomics against E. lenta ATCC 25559 suggests that both
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Figure 3.14: Mauve alignment of C592 and E. lenta type strain genomes

Mauve gene alignment was performed between the longest C592 contig from sequencing and the
E. lenta type strain closed genome and visualized using Circos as described in the Materials and
Methods. There are some gaps in this alignment both within the localized collinear blocks
(LCB) and in between LCBs.
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Table 3.4: CDS protein annotation comparison between C592 and Eggerthella lenta type
strain

contig
bases:
tmRNA:
tRNA:
rRNA:
Repeat region:
CDS:

Eggerthella_lenta_DSM_2243 New Assembly
contigs: 1
contigs: 1
3,632,260
3,593,230
1
1
54
54
6
6
1
1
3047
3110
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Figure 3.15: Overall C592 BlastKOALA results

Annotated sequences from the C592 genomic data in FASTA format were further analyzed using
the KEGG Orthology and Links Annotation (BlastKOALA) (223). C592 KEGG maps were
generated using KEGG mapping software. 42.1% of the total C592 annotated genes were
recognized by the BlastKOALA algorithm and populated to relevant KEGG maps. Overall
breakdown of the recognized C592 sequences shows that the two largest groups represented by
KEGG maps were environmental information processing and genetic information processing,
with numerous other groups represented as well.
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strains encode a near complete Wood-Ljungdahl pathway for generation of acetate from CO2
(Figure 3.16). Of the nine enzymes in this pathway, KEGG annotation located six of the genes
in C592. Further searching of C592 genomic data showed putative genes for two of the
remaining three genes in the pathway (Table 3.5). These results gave a possible explanation for
the requirement of reducing equivalents from bile acids, as the fixation of CO2 to acetate requires
multiple reducing equivalents.

In addition to carbon metabolism, C592 was shown to have numerous other metabolic pathways
of interest. Of note, it contains genes required for the metabolism of arginine, as the E. lenta
type strain is reported to have (263). C592 is annotated to have genes allowing it to convert
arginine to form ornithine, ammonia, and CO2 while generating ATP from ADP (Figure 3.16).
In addition, it has genes allowing it to interconvert arginine and fumarate, likely depending on its
energetic needs (Figure 3.17). This shows energy conservation gene pathways in E. lenta are
maintained in C592.

Identifying gene clusters of interest in C592 and 25559

Work on the characterization of genes in the E. lenta type strain encoding bile acid isomerization
enzymes has been done previously (150). Devlin et al. screened numerous E. lenta short-chain
dehydrogenase/reductase enzymes (SDR) for bile acid 3α-HSDH and 3β-HSDH activity,
focusing on their ability to isomerize DCA. However, of all ten genes tested, only three were
found to be active. Six of the seven tested were found in high homology in C592, including the
two confirmed 3β-HSDH and one 3α-HSDH (Table 3.6). Additional SDR, oxidoreductases,
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Figure 3.16: C592 encodes genes annotated to be involved in the Wood Ljungdahl pathway

C592 KEGG annotated data generated from BlastKOALA was used with the KEGG Mapper
Reconstruct Pathway tool, utilizing data from the KEGG Atlas (264). Green lines indicate genes
present in C592 that match the relevant annotation in the pathway. C592 has genes annotated to
be part of the Wood-Ljungdahl pathway. These include formate dehydrogenase, formyltetrahydrofolate synthetase, formyl-tetrahydrofolate cyclohydrolase, methylene-tetrahydrofolate
reductase, phosphotransacetylase, and acetate kinase. Three genes in this pathway were not
annotated via KEGG mapping, but two had similar candidates found through searching the C592
genome for similar enzymes. These include a methylene-tetrahydrofolate reductase, and the
carbon monoxide dehydrogenase. A methyltransferase/acetyl-CoA synthase was not located in
the C592 genome. All of these identified C592 genes are also highly conserved in the E. lenta
ATCC 25559 type strain. Table 3.6 contains the ascension numbers for the relevant WoodLjungdahl pathway genes in C592 and their corresponding genes in E. lenta ATCC 25559.
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Table 3.5: Wood Ljungdahl Pathway Homologous Genes in C592 and E. lenta ATCC 25559

Wood-Ljungdahl Pathway Homologous Genes
Formate-tetrahydrofolate synthetase
C592:

Type Strain:

Name

db_xref

Length

Formate--tetrahydrofolate ligase (EC 6.3.4.3) CDS

SEED:fig|6666666.209054.peg.396

1,668

Name
formate--tetrahydrofolate
ligase CDS

db_xref
GI:506241661

Length
1,668

Formyl-tetrahydrofolate cyclohydrolase / methylene-tetrahydrofolate dehydrogenase
C592:
Name
Methylenetetrahydrofolate dehydrogenase (NADP+)
(EC 1.5.1.5) / Methenyltetrahydrofolate
cyclohydrolase (EC 3.5.4.9) CDS

Type Strain:
db_xref

Length

SEED:fig|6666666.209054.peg.400

870

Name

db_xref

tetrahydrofolate
dehydrogenase CDS

GI:497294816

Length

870

Methylene-tetrahydrofolate reductase
C592:
Name
bifunctional homocysteine S-methyltransferase/5,10methylenetetrahydrofolate reductase protein CDS

Type Strain:
db_xref

Length

SEED:fig|6666666.209054.peg.677

903

Name

db_xref

methionine synthase CDS

GI:497295229

Length
903

Carbon monoxide dehydrogenase
C592:
Name
Xanthine dehydrogenase, molybdenum binding
subunit (EC 1.17.1.4) CDS

Type Strain:
db_xref

Length

SEED:fig|6666666.209054.peg.1780

2,298

(Did not show up in Mauve alignment)

Phosphate acetyltransferase and acetate kinase
C592:

Type Strain:

Name

db_xref

Length

Phosphate acetyltransferase (EC 2.3.1.8) CDS

SEED:fig|6666666.209054.peg.1464

999

Acetate kinase (EC 2.7.2.1) CDS

SEED:fig|6666666.209054.peg.1463

1,215

110

Name
phosphate acetyltransferase
CDS

db_xref

Length

GI:496664653

999

acetate kinase CDS

GI:496664654

1,215

Figure 3.17: KEGG map of C592 arginine metabolism genes and the link to Kreb’s cycle

C592 KEGG annotated data generated from BlastKOALA was used with the KEGG Mapper
Reconstruct Pathway tool, utilizing data from the KEGG Atlas (264). Green lines indicate genes
present in C592 that match the relevant annotation in the pathway. C592 encodes genes allowing
it to metabolize arginine to ammonia while generating ATP, CO2, and ornithine. This pathway
of ATP generation in the E. lenta type strain, outlined in the box, was first described by Sperry et
al and was described as necessary for optimal E. lenta growth (263). C592 additionally encodes
enzymes that allow it to generate fumarate from arginine, which can then be utilized as an
electron acceptor to form succinate. C592 encodes numerous redundant fumarate reductases
throughout its genome.
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Table 3.6: Annotated reductases in C592 and E. lenta ATCC 25559 genomes
Reductase genes tested in Devlin et. al 2015
C592:
Name
3-oxoacyl-[acyl-carrier protein] reductase
(EC 1.1.1.100) CDS
Sorbitol-6-phosphate 2-dehydrogenase (EC
1.1.1.140) CDS
Dehydrogenases with different specificities
(related to short-chain alcohol
dehydrogenases) CDS
3-oxoacyl-[acyl-carrier protein] reductase
(EC 1.1.1.100) CDS
3-oxoacyl-[acyl-carrier protein] reductase
(EC 1.1.1.100) CDS
Glucose 1-dehydrogenase (EC 1.1.1.47) CDS

E. lenta type strain:
db_xref
SEED:fig|6666666.
209054.peg.735
SEED:fig|6666666.
209054.peg.1846
SEED:fig|6666666.
209054.peg.1011
SEED:fig|6666666.
209054.peg.879
SEED:fig|6666666.
209054.peg.1230
SEED:fig|6666666.
209054.peg.3084

? Gap in Mauve Alignment

Confirmed
activity?

Name

db_xref

short-chain dehydrogenase CDS

GI:496664150

Elen_2515

3-ketoacyl-ACP reductase CDS

GI:506240750

Elen_1325

short-chain dehydrogenase CDS

GI:496663880

Elen_2188

short-chain dehydrogenase CDS

GI:496663981

Elen_0690

beta-ketoacyl-ACP reductase CDS

GI:496661655

Elen_1987

glucose-1-dehydrogenase CDS
short-chain
dehydrogenase/reductase SDR CDS

GI:506240102

Elen_0198

GI:506240693

Elen_1208

3β-HSDH

3α-HSDH

3β-HSDH

Other reductases in C592 and E. lenta type strain genome
C592:

E. lenta type strain:

Name

db_xref

Name

db_xref

2,4-dienoyl-CoA reductase [NADPH] (EC 1.3.1.34) CDS

SEED:fig|6666666.209054.peg.377

NADH:flavin oxidoreductase CDS

GI:497294813

putative Fe-S oxidoreductase CDS

SEED:fig|6666666.209054.peg.412

GI:506241657

oxidoreductase FAD/NAD(P)-binding CDS
3-oxoacyl-[acyl-carrier protein] reductase (EC 1.1.1.100)
CDS

SEED:fig|6666666.209054.peg.516

hypothetical protein CDS
ferredoxin-NADP+ reductase subunit
alpha CDS

SEED:fig|6666666.209054.peg.735

short-chain dehydrogenase CDS

GI:496664150

Short-chain dehydrogenase/reductase SDR CDS
oxidoreductase of aldo/keto reductase family, subgroup
1 CDS

SEED:fig|6666666.209054.peg.851
SEED:fig|6666666.209054.peg.149
2
SEED:fig|6666666.209054.peg.169
2

short-chain dehydrogenase CDS
2,5-diketo-D-gluconic acid reductase
CDS

GI:496664009

FAD-dependent oxidoreductase CDS

GI:497294359

FIG00624394: hypothetical protein CDS
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GI:506241633

GI:506240950

Periplasmic aromatic aldehyde oxidoreductase, FAD
binding subunit YagS CDS
Xanthine dehydrogenase, molybdenum binding subunit
(EC 1.17.1.4) CDS
Periplasmic aromatic aldehyde oxidoreductase, ironsulfur subunit YagT CDS
Fe-S oxidoreductase, related to NifB/MoaA family with
PDZ N-terminal domain CDS

SEED:fig|6666666.209054.peg.177
9
SEED:fig|6666666.209054.peg.178
0
SEED:fig|6666666.209054.peg.178
1
SEED:fig|6666666.209054.peg.183
5
SEED:fig|6666666.209054.peg.189
8
SEED:fig|6666666.209054.peg.191
4
SEED:fig|6666666.209054.peg.192
3
SEED:fig|6666666.209054.peg.194
4
SEED:fig|6666666.209054.peg.205
2
SEED:fig|6666666.209054.peg.212
2
SEED:fig|6666666.209054.peg.216
4
SEED:fig|6666666.209054.peg.242
4
SEED:fig|6666666.209054.peg.265
4
SEED:fig|6666666.209054.peg.282
3
SEED:fig|6666666.209054.peg.288
3
SEED:fig|6666666.209054.peg.305
7

Gap in Mauve Alignment
Gap in Mauve Alignment
Gap in Mauve Alignment
hypothetical protein CDS

GI:506240759

FMN reductase CDS
B12-binding domain-containing
radical SAM protein CDS

GI:496662103

oxidoreductase CDS

GI:496662126

FAD-dependent oxidoreductase CDS

GI:497294180

flavin reductase CDS

GI:496662252

Fe-S oxidoreductase CDS

GI:506240601

FAD-dependent oxidoreductase CDS

GI:506240573

YgiQ family radical SAM protein CDS

GI:506241324

radical SAM protein CDS

GI:497295255

NADH:flavin oxidoreductase CDS
NAD(P)H dehydrogenase (quinone)
CDS

GI:506240206

Fe-S oxidoreductase CDS

GI:497293772

Gap in Mauve Alignment

oxidoreductase CDS

GI:496664037

Gap in Mauve Alignment

FAD-dependent oxidoreductase CDS

GI:496661933

Gap in Mauve Alignment

NADH:flavin oxidoreductase CDS

GI:496661830

Gap in Mauve Alignment

short-chain dehydrogenase CDS

GI:506240690

predicted NADPH-dependent reductase CDS
FIG092679: Fe-S oxidoreductase CDS
Heterodisulfide reductase, cytochrome reductase subunit
CDS
Sarcosine oxidase alpha subunit (EC 1.5.3.1) CDS
Flavin reductase-like, FMN-binding:Rubredoxin-type
Fe(Cys)4 protein CDS
Aldo/keto reductase:4Fe-4S ferredoxin, iron-sulfur
binding CDS
NAD(FAD)-utilizing dehydrogenase, sll0175 homolog CDS
Fe-S OXIDOREDUCTASE (1.8.-.-) CDS
Fe-S oxidoreductase CDS
putative NADH-dependent flavin oxidoreductase CDS
FMN-dependent NADH-azoreductase CDS
Aldo/keto reductase:4Fe-4S ferredoxin, iron-sulfur
binding CDS
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GI:506240718

GI:496663491

and dehydrogenases were identified in both C592 and 25559, totaling 26, although not all are
identified in both genomes via the Mauve alignment (Table 3.6). Of interest, Devlin et al.
identified a “bai-like” operon in the E. lenta type strain containing numerous SDR enzymes
reductases in an operon (150). C592 contains the same operon in high homology, but is missing a
key enzyme in the pathway, directly downstream of the three SDR enzymes (Figure 3.18). It
has been hypothesized that this missing gene directly downstream of three SDR enzymes is the
gene for the 21-dehydroxylase enzyme, indicating that C592 may not 21-dehydroxylate
corticoids.

In the determination of cardiac glycoside reductase activity in the E. lenta type strain, a putative
gene cluster responsible for this activity was identified based on RNAseq results (238).
However, when searching the aligned genome of C592, this two-gene cluster is absent (Figure
3.19). This suggests that C592 should not exhibit digoxin reductase activity. Alternatively, if
digoxin reductase activity is measured, it is likely this two-gene cluster in the type strain is not
responsible for producing the enzymes responsible.

When searching the KEGG maps based on C592, it was found that many genes in the WoodLjungdahl acetogenesis pathway are present. These same genes are also present in the E. lenta
type strain genome. In addition, both genomes encode membrane-energization gene clusters
responsible for producing multi-subunit hydrogenases capable of functioning as an electron
transport chain while generating a proton or Na+ gradient. A Rhodocbacter nitrogen fixation
(RNF) complex, found in acetogens as a means of coupling ATP generation to the WoodLjungdahl pathway (95-97), is also found in both C592 and 25559 (Figure 3.20). Not all
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Figure 3.18: Gene cluster alignment of “bai-like” operon from C592 and 25559

A. Alignment of a gene cluster in C592 and 25559 that contains numerous reductases. Within
this series of reductases in the type strain is a gene annotated as a scytalone dehydratase. It
shares that annotation to the 7α-dehydratase from C. scindens (265). We hypothesize that this
gene encodes the enzyme responsible for the 21-dehydroxylase enzyme. B. E. lenta type strain
has been reported to have 21-dehydroxylase activity previously (247, 248). Interestingly, this
putative gene is missing from C592 while the two flanking genes remain with high homology.
C592 is currently being tested for its ability to 21-dehydroxylate deoxycortisone.
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Figure 3.19: Gene cluster alignment of the putative cardiac glycoside reductase operon
from C592 and 25559

Gene cluster identified by Haiser et al to encode the cardiac glycoside reductase in Eggerthella
lenta ATCC 25559 is missing from C592. Homologous genes are not found elsewhere in the
genome. C592 is currently being tested for cardiac glycoside reductase activity, although based
on the absence of the genes predicted to encode activity, it is hypothesized it will not exhibit the
phenotype.
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Figure 3.20: Gene cluster alignment of RNF complex operon from C592 and 25559

Gene clusters in C592 and 25559 annotated to encode an RNF complex are similar to those
found in acetogens (95-97). Green bar above the mauve alignment indicates level of homology.
Green indicates >90% homology, yellow indicates 30-90% homology, red indicates >30%
homology. The operon encoding the RNF complex is highly conserved between the two strains.
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acetogens harbor genes for an RNF complex, others instead encode “energy conserving
hydrogenase” (Ech) complexes that similarly generate a proton gradient while generating H2
from reduced ferredoxin (266). Both C592 and 25559 also harbor a putative Ech gene cluster
(Figure 3.21). In addition, both strains harbor ATP synthase transmembrane complexes, able to
utilize this proton gradient generated from RNF and Ech complexes to generate ATP from ADP
(Figure 3.22). Taken together, these results strongly suggest that both C592 and 25559 share
many genetic similarities to acetogens, especially with regard to redox balancing and ATP
generating processes.

One important molecule for acetogenesis is CO2, which can be quickly utilized in anaerobic
environments. Therefore, the ability to form CO2 independently would be evolutionarily
advantageous for an acetogen. C592 has genes to metabolize arginine and agmatine to form a
carbamoyl phosphate intermediate and carbamate kinases to ultimately generate ATP, CO2, and
ammonia (Table 3.7). In addition, C592 appears to harbor multiple amino acid decarboxylases.
A gene encoding a putative glutamate decarboxylase was located next to a glutamate/gammaaminobutyric acid (GABA) antiporter, indicating C592 could metabolize glutamate to GABA +
CO2 and then use CO2 as an electron acceptor (Table 3.8). In addition, C592 is annotated to
have a histidine decarboxylase, which would yield histamine and CO2 from histidine (Table 3.8).
Taken together, it is apparent that C592 has numerous avenues for generating its own CO2 via
intracellular processes, depending on substrate availability. Additionally, C592 appears to have
the ability to make biogenic amines, such as GABA and histamine, which could have significant
effects on host physiology.
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Figure 3.21: Gene cluster alignment of energy-conserving hydrogenase operon from C592
and 25559

Gene clusters in C592 and 25559 annotated to encode an Ech complex are similar to those found
in acetogens not harboring an RNF complex (98, 266). Green bar above the mauve alignment
indicates level of homology. Green indicates >90% homology, yellow indicates 30-90%
homology, red indicates >30% homology. The operon encoding the Ech complex is highly
conserved between the two strains.
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Consensus identity

Type

C592
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Figure 3.22: Gene cluster alignment of ATP synthase operon from E. lenta strains C592
and 25559

Gene clusters in C592 and 25559 annotated to encode an ATP synthase operon. This
transmembrane protein would be able to utilize a putative proton gradient generated from either
Ech- or RNF-complexes to generate ATP (93, 266).
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Table 3.7: Annotated arginine and agmatine metabolism genes in E. lenta strain C592
Name
Arginine deiminase (EC 3.5.3.6) CDS
Agmatine deiminase (EC 3.5.3.12) CDS
Arginine deiminase (EC 3.5.3.6) CDS
Agmatine deiminase (EC 3.5.3.12) CDS
Agmatine deiminase (EC 3.5.3.12) CDS
Ornithine carbamoyltransferase (EC 2.1.3.3) CDS
Aspartate carbamoyltransferase (EC 2.1.3.2) CDS
Ornithine carbamoyltransferase (EC 2.1.3.3) CDS
Putrescine carbamoyltransferase (EC 2.1.3.6) CDS
Putrescine carbamoyltransferase (EC 2.1.3.6) CDS
Ornithine carbamoyltransferase (EC 2.1.3.3) CDS
Carbamate kinase (EC 2.7.2.2) CDS
Carbamate kinase (EC 2.7.2.2) CDS
Carbamate kinase (EC 2.7.2.2) CDS
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db_xref
SEED:fig|6666666.209054.peg.3131
SEED:fig|6666666.209054.peg.2844
SEED:fig|6666666.209054.peg.1265
SEED:fig|6666666.209054.peg.866
SEED:fig|6666666.209054.peg.857
SEED:fig|6666666.209054.peg.2843
SEED:fig|6666666.209054.peg.1518
SEED:fig|6666666.209054.peg.1266
SEED:fig|6666666.209054.peg.864
SEED:fig|6666666.209054.peg.855
SEED:fig|6666666.209054.peg.593
SEED:fig|6666666.209054.peg.1267
SEED:fig|6666666.209054.peg.867
SEED:fig|6666666.209054.peg.858

Table 3.8: Annotated glutamate and histidine decarboxylationg genes in E. lenta strain
C592
Name
Probable glutamate/gamma-aminobutyrate
antiporter CDS
Glutamate decarboxylase (EC 4.1.1.15) CDS
histidine decarboxylase, pyruvoyl type(
EC:4.1.1.22 ) CDS
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db_xref
SEED:fig|6666666.209054.peg.3136
SEED:fig|6666666.209054.peg.3135
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Within the realm of carbon metabolism, C592 has genes encoding an incomplete TCA cycle
(Table 3.9). Of particular interest, C592 appears to encode duplicate genes for fumarate
reductase, a mechanism by which anaerobic bacteria are able to deposit reducing equivalents
onto fumarate to generate succinate. Additionally, the C592 genome encodes genes for
generating fumarate from arginine, including an arginosuccinate synthase and arginosuccinate
lyase (Table 3.10). Fumarate is widely utilized anaerobically as a potential electron acceptor,
leading to the formation of succinate (36). Previous work with the type strain of E. lenta as well
as preliminary fermentative end product analysis (data not shown) suggest that both C592 and
25559 generate succinate as well as acetate as their major fermentative end products. The
incomplete TCA cycle of C592 (ending at succinate), the multitude of fumarate reductases, and
the ability to shift arginine to fumarate, suggests fumarate is a major electron acceptor in E.
lenta. C592 also has genes that encode various other electron-accepting reactions, such as
dimethyl sulfoxide reduction and nitrogen reduction (data not shown). Acetogens are described
as being a heterogenous group of organisms, specifically with regard to their utilization of
various electron donors and electron acceptors (93). These results correlate with those findings
in other acetogenic bacteria, as both C592 and E. lenta appear to utilize numerous bile acids and
steroids as electron donors and various other molecules as electron acceptors.

Varying atmospheric gases changes C592 and 25559 bile acid and steroid metabolism

Since both 25559 and C592 appear to be acetogens based on genetic composition and previous
fermentative end product analysis, next we tested the effects altered atmospheric gases would
have on bile acid metabolism. It was hypothesized since hydroxyl groups on bile acids were
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Table 3.9: Annotated genes from the Kreb’s cycle in E. lenta strain C592
Gene Name
Citrate synthase (si) (EC 2.3.3.1) CDS
Aconitate hydratase (EC 4.2.1.3) CDS
Isocitrate dehydrogenase [NAD] (EC 1.1.1.41)
CDS
Isocitrate dehydrogenase [NADP] (EC 1.1.1.42)
CDS
2-oxoglutarate oxidoreductase, gamma subunit
(EC 1.2.7.3) CDS
2-oxoglutarate oxidoreductase, beta subunit
(EC 1.2.7.3) CDS
2-oxoglutarate oxidoreductase, alpha subunit
(EC 1.2.7.3) CDS
2-oxoglutarate oxidoreductase, delta subunit,
putative (EC 1.2.7.3) CDS
Malate dehydrogenase (EC 1.1.1.37) CDS
fumarate hydratase CDS
Fumarate hydratase class I, aerobic (EC
4.2.1.2); L(+)-tartrate dehydratase beta subunit
(EC 4.2.1.32) CDS
Succinate dehydrogenase flavoprotein subunit
(EC 1.3.99.1) CDS
Succinate dehydrogenase iron-sulfur protein
(EC 1.3.99.1) CDS
fumarate reductase/succinate dehydrogenase
flavoprotein domain protein CDS
Succinate dehydrogenase flavoprotein subunit
(EC 1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
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1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
putative fumarate reductase flavoprotein
subunit CDS
putative fumarate reductase flavoprotein
subunit CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
fumarate reductase/succinate dehydrogenase
flavoprotein domain protein CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
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putative fumarate reductase flavoprotein
subunit CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
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Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
putative fumarate reductase flavoprotein
subunit CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
Fumarate reductase flavoprotein subunit (EC
1.3.99.1) CDS
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Table 3.10: Annotated genes for arginine biosynthesis in E. lenta strain C592
Name
Argininosuccinate synthase (EC 6.3.4.5) CDS
Argininosuccinate lyase (EC 4.3.2.1) CDS
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being used as electron donors, if a more energetically favorable electron donor was present then
C592 and 25559 would shift to utilizing that electron donor and the oxidation of bile acids would
be inhibited. Both C592 and 25559 encode membrane-associated and cytoplasmic ferredoxin
hydrogenases (including and Ech complex described above) capable of utilizing hydrogen to
reduce oxidized ferredoxin. The RNF complex, as well as other electron-bifurcating enzymes
not yet identified in C592 or E. lenta, can then move electrons from reduced ferredoxin to
oxidized NAD+, thereby generating reduced NADH, which would ultimately inhibit bile acid
oxidation. C592 and 25559 metabolism of CDCA was tested under inert nitrogen, carbon
dioxide, and hydrogen gas to mimic gases that might be present to varying degrees in the human
intestinal tract to see if any changes in bile acid or steroid metabolism occurred. Under inert N2
gas, C592 and 25559 completely metabolize CDCA into mostly CDCA-A and CDCA-C,
although the relative amount is different between strains (Figure 3.23). When grown in the
presence of CO2 gas, CDCA was completely metabolized to the same three CDCA metabolites
found under N2 gas culture conditions, although CDCA-A is the major metabolite for both strains
(Figure 3.24). When grown in the presence of H2 gas, CDCA metabolism by both C592 and
25559 is significantly inhibited (Figure 3.25). While there was some production of 7-oxo-CDCA
and 3-oxo-CDCA, the majority of the CDCA remains unutilized in the cell cultures. These
experiments were repeated for both C592 and 25559 metabolism of testosterone. Under H2, both
C592 and 25559 have their metabolism of testosterone completely inhibited (data not shown).
These results show that C592 and 25559 are able to shift their electron donors, and ultimately
bile acid and steroid metabolism, based on substrate availability, preferring to use the most
energetically favorable substrate possible. Such an ability to be flexible with redox balancing is
beneficial for any microbe living in the competitive environment of the human intestinal tract.
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Figure 3.23: Quantitation of C592 and 25559 metabolites of CDCA when grown overnight
under inert N2 gas

C592 and E. lenta ATCC 25559 were grown overnight in the presence of 25µM CDCA and
1µCi [24-14C]-CDCA under inert N2, extracted, and run on TLC as previously described. Bands
corresponding to CDCA metabolites were scraped and the relative amounts of each were
determined through liquid scintillation spectrometry. Representative TLC on left. Top right
indicates relative amount of each of the metabolites with pie charts to show amounts relative to
total radioactivity detected from lane, experiment run in triplicate. The major product for 25559
under N2 is 7-oxo-3α-chenodeoxycholic acid, whereas for C592 it is 3,7-dioxochenodeoxycholic acid.
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Figure 3.24: Quantitation of C592 and 25559 metabolites of CDCA when grown overnight
under CO2 gas

C592 and E. lenta ATCC 25559 were grown overnight in the presence of 25µM CDCA and
1µCi [24-14C]-CDCA under CO2, extracted, and run on TLC as previously described. Bands
corresponding to CDCA metabolites were scraped and the relative amounts of each were
determined through liquid scintillation spectrometry. Representative TLC on left. Top right
indicates relative amount of each of the metabolites with pie charts to show amounts relative to
total radioactivity detected from lane, experiment run in triplicate. The major product for 25559
and C592 CDCA metabolism under CO2 is 7-oxo-3α-chenodeoxycholic acid.
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Figure 3.25: Quantitation of C592 and 25559 metabolites of CDCA when grown overnight
under H2 gas

C592 and E. lenta ATCC 25559 were grown overnight in the presence of 25µM CDCA and
1µCi [24-14C]-CDCA under CO2, extracted, and run on TLC as previously described. Bands
corresponding to CDCA metabolites were scraped and the relative amounts of each were
determined through liquid scintillation spectrometry. Representative TLC on left. Top right
indicates relative amount of each of the metabolites with pie charts to show amounts relative to
total radioactivity detected from lane, experiment run in triplicate. The major product for 25559
and C592 CDCA metabolism under CO2 is 7-oxo-3α-chenodeoxycholic acid.
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C592 oxo-bile acid derivatives inhibit 7α-dehydroxylation in vitro

Since C592 and 25559 both exhibited significant changes in bile acid metabolism based on
atmospheric gas composition, we first wanted to test if a similar effect occurred with 7adehydroxylating bacteria. We performed the same bile acid metabolism test as above using the
7α-dehydroxylating bacteria Clostridium scindens VPI 12708 (12708). There was no significant
effect of CO2 or H2 gas atmosphere on CA or CDCA 7a-dehydroxylation by 12708 (Figure
3.26). Next we tested the impact of the formation of oxo-bile acids on the 7α-dehydroxylation
of primary bile acids by 12708. We isolated [14C]-labeled CDCA metabolites (CDCA-A,
CDCA-B, CDCA-C) and introduced them into a growing culture of 12708. After 24 hours,
12708 was able to reduce CDCA-A back to CDCA and subsequently 7α-dehydroxylate a portion
of the newly formed CDCA (Figure 3.27). Over the same time course, 12708 metabolized 7oxo-3β-chenodeoxycholic acid (CDCA-B) to a product whose Rf matched iso-CDCA (3βCDCA), but was unable to subsequently 7α-dehydroxylate (Figure 3.26). C. scindens VPI 12708
is known to have 3α-HSDH and 7α-HSDH activity (148) but has never reported to have 3βHSDH activity, possibly explaining the lack of 7α-dehydroxylation of the 3β CDCA-B
metabolite. When CDCA-C was added to growing cultures of 12708, it was only partially
reduced back to a mixture of CDCA and 3-oxo-CDCA (Figure 3.27). These results suggest in
vitro, two of the three major bile acid products from C592 and 25559 metabolism of CDCA
prevent effective 7α-dehydroxylation by 12708. When C592 and 12708 were grown in a mixed
culture containing CDCA, the pattern of CDCA metabolites suggested a significant decrease in
7α-dehydroxylation when compared to the results of a 12708 pure culture (Figure 3.28). Likely
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Figure 3.26: C. scindens VPI 12708 metabolism of CA and CDCA does not change under
anaerobic CO2 or H2 atmospheric gas

Clostridium scindens VPI 12708 was grown overnight in anaerobic BHI in the presence of
25mM CA or CDCA and 1µCi CA or CDCA under varying atmospheric conditions (N2, CO2, or
H2). Cultures were extracted and run on TLC plates as described in Materials and Methods. C.
scindens VPI 12708 did not alter its metabolism of CA or CDCA under any of the varying
atmospheric gases.
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Figure 3.27: C. scindens VPI 12708 recognizes C592 CDCA metabolites but is unable to
effectively 7α-dehydroxylate

A. First spot is a CDCA TLC standard. Next two spots are C592/12708 overnight cell culture
conversions of CDCA. C592 generates three products as described above. 12708 generates one
major metabolite, lithocholic acid (LCA), indicated by the black star. B. The three CDCA
metabolites were isolated, concentrated, and added to 12708 overnight cultures at approximately
25µM final concentration. 7-oxo-3α-CDCA (red star) was reduced back to CDCA by 12708.
Some trace LCA is formed, but not as significant as 12708 + CDCA cell culture. C. 12708
reduces 7-oxo-3β-CDCA (green star) to a band that does not comigrate with CDCA. This band
has a similar Rf to 3β-CDCA (iso-CDCA), suggesting 12708 reduces this metabolite back to isoCDCA. However, 7α-dehydroxylation does not appear to occur, suggesting 12708 is unable to
7α-dehydroxylate the 3β-epimer. D. 12708 recognizes 3,7-dioxo-CDCA (yellow star) and
produces two major metabolites. One metabolite comigrates with CDCA, while the other
comigrates with 3-oxo-CDCA. There does not appear to be any metabolite formed that
comigrates with LCA.
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Figure 3.28: Coculture of C. scindens VPI 12708 and C592 inhibits 7α-dehydroxylation of
CDCA

A. C. scindens VPI 12708 whole cell conversion of CDCA. B. C592 whole cell conversion of
CDCA. C. 10mL anaerobic BHI broth under N2 was inoculated with 1% overnight culture of
both 12708 and C592 along with 25mM CDCA and 1mCi [24-14C]-CDCA. This coculture was
grown overnight at 37ºC and then extracted and run on TLC as described above. The coculture
CDCA pattern of metabolites matches neither the C592 nor 12708 patterns. A significant
amount of CDCA remains, while the other major product comigrates with 7-oxo-3α-CDCA.
This suggests that in coculture, C592 and 12708 cycle CDCA back and forth between an
oxidized and 3α-reduced C7-oxo group.
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these two gut bacteria cycle between oxidation and reduction of hydroxyl groups on the bile
acids regulating secondary bile acid formation.
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Discussion:

E. lenta is a normal inhabitant of the human intestinal microbiome. It has been studied due to its
propensity to metabolize bile acids and steroids, including the isomerization of primary and
secondary bile acids at the 3-hydroxyl group (150) and the 21-dehydroxylation of corticoids
(248). The effects of these biotransformations are significant for both the gut microbiome as a
whole and the host. E. lenta-derived glucocorticoid metabolites can inhibit renal cells ability to
modulate response to cortisol, ultimately leading to fluid retention and hypertension (251).
Isomerized secondary bile acids, such as iso-DCA, have been shown to be less toxic to other
members of the gut microbiome at physiological concentrations (150). Additionally, isomerized
secondary bile acids have been hypothesized to be less toxic to colonocytes. However, the
pattern of isomerization requires what would at the surface appear to be an energetically
unfavorable oxidation of a hydroxyl group in an anaerobic environment. Oxidized bile acids
(oxo-BA), or bile acids with a ketone hydroxyl moiety, were thought to be intermediates in the
ultimate bile acid metabolism profile. However, oxidized bile acids are known to be present in
significant amounts in serum, portal blood, fecal water, and fecal pellets (158-163, 267).
Cholecystectomized patients are reported to have increased oxo-BA in portal circulation, likely
due to more primary bile acids escaping into the large intestine and undergoing metabolism by
gut microbes (165). Oxo-BA have been shown to have differing agonistic properties than their
fully reduced counterparts for host nuclear and G-protein coupled receptors. For instance, 3oxo-LCA is the most potent bile acid VDR receptor agonist (175). However, oxo-BA receptor
activation remains to be fully tested for other known receptors that respond to bile acids.
Additionally, how the oxidation of the hydroxyl groups of bile acids by E. lenta plays into its
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general host metabolism is not known, instead the studies focused on the effects of the fully
reduced end products. Additionally, the effects of oxidation or epimerization of hydroxyl groups
on other gut microbes, specifically those that are known to metabolize bile acids, had not been
previously studied.

In the current study, a novel strain of Eggerthella lenta, C592, was characterized, with an
emphasis on the composition of its genome as well as its steroid and bile acid metabolism
profile. C592 was originally isolated from the fecal sample from Okinawa, Japan. Initially
suspected to be a 7α-dehydroxylating bacterium, C592 was shown to create both mono- and diketo bile acid metabolites from CDCA. Additionally, it was shown to completely metabolize
secondary bile acids DCA and LCA to numerous secondary metabolites. When compared to
high activity and low activity 7α-dehydroxylating bacteria, most are not able to completely
convert CA and CDCA to secondary metabolites. Conversely, C592 was shown to convert
concentrations of CDCA that can inhibit the growth of other bacteria (500µM) to secondary
metabolites. This pattern of metabolites initially suggested an irreversible conversion of primary
bile acids, such as 7α-dehydroxylation. However, MS analysis confirmed the CDCA and DCA
C592 metabolites lost two or four mass units, indicating oxidation of one or two hydroxyl
groups, respectively.

C592 was subsequently determined to have high 16S sequence similarity to the Eggerthella lenta
type strain. Various E. lenta strains had been shown previously to have 3α-HSDH, 7α-HSDH,
and 12α-HSDH activity (151, 153). However, complete oxidation of primary and secondary bile
acids by E. lenta was not noted in the literature. Additionally, the accumulation of dioxo-
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primary or secondary bile acids in E. lenta whole cell extracts, such as 3,7-dioxo-CDCA or 3,12oxo-DCA, was not reported. This study also shows that both C592 and the E. lenta type strain
have 17β-HSDH activity, capable of converting testosterone to its precursor, androstenedione.
While E. lenta has been reported to metabolize some steroids, 17β-HSDH activity has never
before been reported. Testosterone and other androgens are known to be excreted in the bile and
become substrates for metabolism by gut microbes (268). Additionally, androgens may undergo
passive diffusion across colonocytes. The effects of bacterial inactivation of androgens on host
physiology is not known, however the conservation of these genes in numerous strains of E.
lenta indicate they give some evolutionary advantage.

In this study, a full, closed genomic sequence for the novel C592 E. lenta strain was determined.
Impressively, it maintains high genomic and metabolic similarities to the Eggerthella lenta type
strain isolated from a patient in Europe in the 1930s. This strong homology over both temporal
and geographical differences emphasizes the importance of its set of genes, especially those for
bile acid metabolism, in its ability to grow in the niche environment of the human intestinal tract.
However, some differences between C592 and the type strain arose. For instance, the cgr gene
locus reported to encode the gene for digoxin reductase was not found in C592. Current testing
of C592 is underway in order to ascertain its ability to reduce digoxin in vitro. The results of
these future experiments will be important, as the clear lack of the described “cgr locus” from the
type strain should indicate C592 would not have the ability to reduce digoxin. However, if it is
able to successfully reduce digoxin, it is likely this gene cluster does not in fact encode the
enzymes responsible for catalyzing this reaction
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Additionally, a bai-like operon in E. lenta was identified in the Devlin et al. study describing the
enzymes responsible for 3α-hydroxyl epimerization of bile acids (150). Within this operon and
downstream of three SDR family enzymes is a gene that is currently being analyzed by
collaborators as the putative 21-dehydroxylase, the enzyme responsible for 21-dehydroxylation
of glucocorticoids. The gene responsible for the production of this enzyme has not been
previously reported. However, this gene is conspicuously absent from C592. In fact, both genes
flanking this putative 21-dehydroxylase are there with high similarity. This suggests that C592
may not have 21-dehydroxylase activity in vitro. Experiments to ascertain C592’s ability to
perform the 21-dehydroxylase reaction are ongoing, although preliminary results suggest it does
not have the activity (data not shown).

Whole genome sequencing of C592 allowed for better determination of the reasoning behind the
formation of these oxo-bile acid derivatives. The anaerobic environment in the colon has a very
low redox potential, therefore the oxidation of bile acid hydroxyl groups would appear to be
energetically unfavorable. However, numerous previous observations gave us direction,
including E. lenta production of acetate and succinate as its only fermentative end products (VPI
Anaerobe Laboratory Manual) and its propensity to utilize CO2 gas from its headspace during
growth (VPI Anaerobe Laboratory Manual, past laboratory observations). It was found that
C592, along with the type strain, harbor genes encoding the majority of the enzymes in the
Wood-Ljungdahl pathway. This pathway of fixing CO2 to produce acetate requires
numerousreducing equivalents, including reduced ferredoxin and NADH (93) and is an
explanation as to why C592 was preferentially oxidizing bile acids (Figure 3.29). Under inert
nitrogen gas, C592/25559 oxidation of bile acids would generate reduced pyridine nucleotides.
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Figure 3.29: Illustration of C592 whole cell redox balancing with bile acids under low H2
partial pressure

C592, under low H2 partial pressure, preferentially oxidizes bile acids. This would lead to an
increased level of reduced pyridine nucleotides, which could either be cycled through the RNF
complex to generate reduced ferredoxin or be used in other metabolic processes, such as the
Wood-Ljungdahl pathway.
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These reduced pyridine nucleotides could then be transferred to oxidized ferredoxin while
utilizing a H+ or Na+ gradient via the putative RNF complex, also located in C592 and E. lenta
type strain. Reduced ferredoxin could then be used in the Wood-Ljundahl pathway to generate
acetate. Additionally, the reduced ferredoxin could be used to generate a H+ gradient via the
putative Ech complex located in both C592 and E. lenta type strain genome. Ultimately, under
inert gas, C592 and 25559 use bile acids as electron donors for various other metabolic
pathways.

This study showed that the tendency of E. lenta strains to oxidize bile acids is sensitive to the
atmospheric gases present. When the atmospheric gas in the headspace was changed to 100%
hydrogen, oxidation of bile acids was significantly inhibited. The reasoning behind this shift
gives further insight into why C592 and 25559 oxidize bile acids. C592 and 25559 encode
numerous genes annotated to be ferredoxin oxidoreductases. This family of enzymes is able to
utilize H2 to reduce ferredoxin. Additionally, the membrane-bound Ech complex, also present in
both C592 and 25559, can perform a similar reaction while utilizing a proton gradient. The RNF
complex can utilize reduced ferredoxin to generate a proton gradient and reduced NADH.
Reduced NADH can be utilized in various metabolic pathways, including the Wood-Ljungdahl
pathway to create acetate. The proton gradient generated from the RNF complex can be used to
generate ATP via ATP synthase. Energetically, the oxidation of H2 to form reduced ferredoxin
is a more favorable reaction than the oxidation of bile acid hydroxyl groups, as H2 has a redox
potential (Eº’) of -0.421 V while NADH is -0.315 V (41). Therefore, when H2 is abundant, C592
is able to switch to the higher energy electron donor to regenerate both reduced ferredoxin and
NADH, while generating a H+ gradient for ATP generation (Figure 3.29). More
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experimentation about this putative link between bile acid metabolism and acetogenesis in E.
lenta should be performed, including the confirmation of acetate generation from CO2 utilizing
radiolabeled CO2 gas. Collaborators are currently testing the fermentative end products
produced by both C592 and 25559 under the various gas atmospheres used to screen bile acid
metabolism. Additionally, the presence or absence of bile acids will be tested to see its impacts
on the amount of fermentative end products, as we hypothesize if E. lenta has more access to
electron donors, then it will produce quantitatively more acetate.

Another important observation was the effect that oxo-bile acid production by E. lenta strains
has on other bacteria that metabolize bile acids. The ability for high-activity 7α-dehydroxylating
bacteria to produce LCA from oxo-CDCA metabolites was impaired. Additionally, co-culturing
of C592 and 12708 prevented formation of LCA, even though in pure cultures C592 grows to
only two tenths the optical density of 12708 in the same time frame (data not shown). The two
major bands from the coculture assay were CDCA and 7-oxo-CDCA, indicating both strains
cycle the bile acid hydroxyl groups between oxidation and reduction. Taken together, these
results suggest that in the human colon, under conditions of low available H2, that E. lenta strains
could prevent 7α-dehydroxylation of primary bile acids (Figure 3.29).

This has significant implications for C592 and E. lenta bile acid metabolism in vivo. The
composition of gas in the colon, specifically with regard to H2, can vary significantly. Both
methanogens and sulfidogens utilize H2 and have higher affinity to H2 than acetogens. However,
the amount of methanogens found in colonic samples can vary on individuals to be undetectable
to over 109 CFU/g stool (47). Additionally, even if hydrogen sulfide producing bacteria are
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present, sulfidogenesis requires the presence of sulfate or sulfite to occur. Some patients who
have a very high level of bacterial fermentation occurring in their colon, such as native Africans
eating a diet rich in complex carbohydrates, can have additional H2 in their colon above what is
already being utilized by methanogens and sulfidogens (14, 269). Therefore, E. lenta strains’
ability to oxidize bile acids, if solely determined by availability of H2, could be altered based on
the amount of bacterial fermentation, presence of methanogens, presence of sulfidogens, and
presence of sulfate/sulfite in the colon (Figure 3.30). This ability to metabolize primary bile
acids would then affect the ability for 7α-dehydroxylating bacteria to product more toxic
secondary bile acids.

Current metrics for measuring the “metabolic potential” of an individual’s gut microbiome relies
on OTUs, or groups of bacteria able to carry out specific metabolic reactions. However, this
method lacks the resolution to see both differences between members of the same OTUs, such as
C592 vs. other strains of E. lenta. Additionally, it cannot adequately take into account other
variables that may affect microbial metabolism in vivo more than whether or not the genes are
present, demonstrated by C592 and E. lenta bile acid oxidation reliance on a lack of available
higher-energy electron donors.

Since secondary bile acids have been shown to be toxic molecules involved in many
pathophysiological gastrointestinal disorders, E. lenta may turn out to be a very desirable
bacterium in the colon, under the right circumstances. However, not all E. lenta strains were
created equal. A strain such as C592, which does not contain the cardiac glycoside reductase
operon nor the putative 21-dehydroxylase gene, may be a better probiotic candidate.
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Figure 3.30: Illustration of C592 whole cell redox balancing with bile acids under high H2
partial pressure

C592, under high H2 partial pressure, significantly cuts back on its metabolism of bile acids.
This is likely due to the fact that H2 is able to directly reduce oxidized ferredoxin via cytoplasmic
and membrane bound ferredoxin oxidoreductases. Reduced ferredoxin could then either be
cycled through the RNF complex to generate reduced pyridine nucleotides or be used in other
metabolic processes, such as the Wood-Ljungdahl pathway. Increased concentration of
intracellular reduced pyridine nucleotides would inhibit the oxidation of bile acids.
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Additionally, it has been shown that metabolism of primary bile acids has been associated with a
resistance to antibiotic-induced C. difficile infection (209). However, the effects of oxo-bile acid
derivatives have not been studied. Future experiments are warranted to look at the possible
protective effects oxo-bile acids could have to prevent C. difficile spore germination.

The major products of C592 and E. lenta bile acid metabolism determined in this study, oxo-bile
acids, may be the explanation behind previous studies involving E. lenta. In a study of
conventionalized ex-germ free mice, Claus et al. found that both the C. scindens and E. lenta
OTUs were correlated with significant increases in hepatic triglyeride levels. The authors
hypothesized that secondary bile acids DCA and LCA, produced by gut microbes such as C.
scindens, were responsible for this increase since they are the most potent bile acid activators for
TGR-5, which can ultimately lead to GLP-1 production, pancreatic insulin release, and hepatic
triglyceride synthesis. However, E. lenta is not shown to make secondary bile acids DCA or
LCA, which was also confirmed by this study. This suggests that other bile acid derivatives
made by E. lenta, such as oxo-bile acids, have a significant role in modulating host physiology.
More studies are needed to see the effects of varying oxidation states of the various hydroxyl
groups on primary bile acids CA and CDCA to further understand this interaction.

The studies described in this report give insight into how E. lenta and novel strain C592 are able
to link bile acid metabolism to redox balancing. It is the first report of acetogenic gene clusters
in E. lenta and asserts its role as an acetogen in the gut microbiome. The formation of oxo-bile
acid derivatives is also shown to inhibit microbial 7α-dehydroxylation. More studies, like those
outlined above, are needed to understand the complex interactions between E. lenta, other gut
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microbes, and the host under varying conditions which might alter its bile acid and steroid
metabolic profile. However, it is apparent that oxo-bile acids, often overlooked as metabolic
intermediates, are important molecules both for gut microbial physiology and for host
physiology.
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Chapter 4: Clostridium scindens ATCC 35704 Δ4,6 reductase gene discovery

Introduction:

The human liver synthesizes two primary bile acids from cholesterol, cholic acid (3α, 7α, 12αtrihydroxy-5β-cholan-24-oic acid; CA) and chenodeoxycholic acid (3α, 7α-dihydroxy-5β-cholen24-oic acid; CDCA). Bile acids are conjugated to either taurine or glycine and secreted into the
gallbladder where they form a major constituent of bile. Meal induced hormonal stimulation of
the gallbladder results in secretion of bile into the small bowel where bile salts function to
solubilize lipids and lipid-soluble vitamins. When bile salts reach the terminal ileum, they are
actively transported across the epithelium and return to the liver in the portal circulation. This
process is termed the enterohepatic circulation and is 95% efficient (113). However, roughly
400-800 mg of bile salts escape into the large bowel where they encounter a population of
microbes whose functional gene capacity dwarfs that of the host. Indeed, 99% of functional
genes in the human are microbial and most of these reside in the gut microbiome (132). Of these
functional genes, there are two classes of enzymes that have the capacity to alter bile salt
structure and thereby change the composition of the bile acid pool (270).

When bile salts encounter the gut microbiome, they are rapidly deconjugated to free bile acids
and taurine or glycine by an enzyme encoded by the bile salt hydrolase (BSH) gene. BSH is
widespread among members of the gut microbiome (116). Once the free bile acid is liberated, it
becomes a substrate for bile acid 7α-dehydroxylation (BA7). BA7 is a multi-enzyme biochemical
pathway that results in the removal of the 7α-hydroxy group through a series of oxidation
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reactions (Figure 4.1). Unlike BSH, BA7 is found in only a few species within the genus
Clostridium (125). Studies in numerous Clostridia strains led to the discovery of an eight-gene
operon that was upregulated in the presence of primary unconjugated bile acids (262, 265, 271277). Work on determining the enzymes in this bile acid-induced operon (bai operon) and the
genes responsible for their production has yielded significant insight into the inner workings of
this process (Figure 4.2). Primary bile acids are transported into the bacterial cell by a protondependent bile acid transporter encoded by the baiG gene (275). Once inside the cell, the first
step of BA7 of primary bile acids is their ligation to CoA in an ATP-dependent fashion (273,
274, 276). After CoA ligation, the C3-hydroxyl group undergoes oxidation via the baiA gene
(278), which is specific for CoA conjugates. Next, a C=C bond is formed between the fourth
and fifth carbon by a NADH:flavin-dependent oxidoreductase encoded by the baiCD gene (262).
The rate-limiting, non-reversible step of the reaction occurs next, the bile acid 7a-dehydration.
The gene encoding the enzyme for the 7α-dehydratase is baiE (265), and the resulting bile acid
products are 3-dehydro-Δ4,6-deoxycholyl-CoA or 3-dehydro-Δ4,6-lithocholyl-CoA, based on the
starting metabolite (279). The 3-dehydro-Δ4,6 bile acid intermediates then undergo three
successive reductive steps leading to LCA or DCA. The genes responsible for the production of
these enzymes have yet to be determined. Secondary bile acids are then exported from the cell,
although the gene encoding the bile acid exporter has not yet been identified.

Our lab recently reported the structure and catalytic mechanism of the rate-limiting enzyme, the
bile acid 7α-dehydroxylase, encoded by the baiE gene, that converts 7α,12α-dihydroxy-5β-3dehydro-chol-4-en-24-oic acid to 12α-dihydroxy-5β-3-dehydro-chol-4,6 dien-24-oic acid (279).
The bile acid reaction product of the BaiE undergoes three reductions at C4- C5, C6-C7 and
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Figure 4.1: Schematic of 7α-dehydroxylation pathway in Clostridium scindens ATCC
35704.
This multi-step enzymatic process to remove the C7α-hydroxyl group contains an oxidative arm,
an irreversible 7α-dehydration step, and a reductive arm that ultimately forms deoxycholic acid
from cholic acid. The enzymes that constitute the reductive arm of this pathway are currently
unidentified, although a Δ4 and a Δ6 reduction are two of the three proposed reaction steps in the
pathway.
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Adapted from (125)
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finally the 3-oxo-group is converted to a 3α-hydroxy forming DCA, a major secondary bile acid
produced in the vertebrate gut. Genes in the “oxidative” arm have been identified and
characterized (113), while genes in the “reductive” arm have yet to be identified. Here, we report
the identification and initial characterization of a recombinant flavoprotein involved in the
metabolism of 3-dehydro-DCA. Our phylogenetic analysis identified this gene in other bile acid
BA7 bacteria. Mass spectrometric analysis of the product revealed a loss of four atomic mass
units (amu) suggesting the formation of two double bonds. We suggest likely end products
generated by this novel enzyme.
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Results

Previous work in our laboratory identified bile acid intermediates in the “reductive arm” of the
bile acid pathway including a 3-oxo-4 and a 3-oxo-4,6-intermediate (143). We also showed that
oxidation of 3-dehydro-CDCA (7α-hydroxy) and 3-dehydro-UDCA (7β-hydroxy) prior to bile
acid 7α-dehydroxylation is catalyzed by stereo-specific NAD-dependent flavin oxidoreductases
encoded by the baiCD and baiH genes, respectively (262). Therefore, we searched the annotated
genome of C. scindens ATCC 35704 for “flavin oxidoreductase”. Our search identified 24 genes
annotated as containing flavin-binding domains (Table 4.1). The BaiCD and BaiH proteins were
identified in the search, previously demonstrated to oxidize the C4-C5 of primary bile acids prior
to 7α-dehydration (262). One ORF in particular, EDS08212.1, was selected for further analysis.
The deduced amino acid sequence is in the HpnE squalene-associated FAD-dependent
desaturase domain family, an enzyme involved in the mammalian cholesterol biosynthesis
pathway (Figure 4.2). Taken together, this suggests that EDS08212.1 is a flavoprotein similar to
those that metabolize sterols and may be involved in bile acid metabolism.

We overexpressed EDS08212.1 as a C-terminal streptavidin-tagged recombinant protein
(rEDS08212) in E. coli BL21 (DE3) RIL. The predicted amino acid sequence is 44.5 kDa, and
we observed a single band by SDS-PAGE after streptactin affinity chromatography at 46.5±2
kDa (Figure 4.3). After binding crude E. coli extracts overexpressing rEDS08212.1 and washing
with binding buffer (see Materials and Methods), we observed a bright yellow protein that eluted
during the desthiobiotin elution step (Figure 4.3). The rEDS08212.1 was stable only for <12 hrs
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Table 4.1: Flavin reductases identified in the genome of Clostridium scindens ATCC 35704
Table&1:&Flavin&Reductases&iden3ﬁed&in&the&genome&of&Clostridium+scindens&ATCC&35704&&
Accession
Number

Annotation

Regions/folds

EDS06786.1

flavin reductase-like protein

Pyridoxine 5'-phosphate oxidase-like and flavin reductase-like proteins

EDS08212.1
EDS07700.1

squalene-associated FAD-dependent desaturase
NADH-FMN oxidoreductase RutF, flavin reductase(DIM6/NTAB) family
Multimeric flavodoxin WrbA
NAD(P)H dehydrogenase, quinone family
Uncharacterized NAD(FAD)-dependent dehydrogenases
rubredoxin
Nitro_FMN_reductase
rubredoxin_SM

EDS06682.1
EDS05114.1
EDS08567.1
EDS08382.1
EDS08369.1
EDS07342.1
EDS07048.1
EDS06690.1
EDS06281.1
EDS06280.1
EDS06153.1
EDS05767.1
EDS05762.1

flavoprotein family protein
flavin reductase-like protein
flavin reductase
flavin reductase
pyridine nucleotide-disulfide oxidoreductase
rubredoxin
Nitroreductase
rubredoxin
oxidoreductase, 2-nitropropane dioxygenase family
protein
4Fe-4S binding domain protein
Rubrerythrin
pyridine nucleotide-disulfide oxidoreductase
nitroreductase family protein
hypothetical protein
hypothetical protein
putative enoyl-[acyl-carrier-protein] reductase II
rubredoxin
Rubrerythrin
NADH oxidase
pyridine nucleotide-disulfide oxidoreductase (BaiCD)
pyridine nucleotide-disulfide oxidoreductase (BaiH)

WP_004604785.1
WP_039909174.1

flavin reductase
2,4-dienoyl-CoA reductase

EDS08305.1
EDS06663.1
EDS08737.1
EDS08749.1
EDS07050.1
EDS06718.1

Dioxygenases related to 2-nitropropane dioxygenase
NAD(P)H-flavin oxidoreductase
rubredoxin_SM
Uncharacterized NAD(FAD)-dependent dehydrogenases
NAD(P)H-flavin oxidoreductase
NADH-FMN oxidoreductase RutF, flavin reductase(DIM6/NTAB) family
Nitroimidazol reductase NimA or a related FMN-containing flavoprotein
Dioxygenases related to 2-nitropropane dioxygenase
Rubrerythrin
Rubrerythrin
OYE_like_FMN_family
ADH oxidase (NoxB-2)
noxB-1; NADH oxidase
rubredoxin
OYE_like_FMN_family
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Deduced Mr
(kDa)

Reference

24.2
45.5
21.1
28.7
19.8
70.8
23.7
20.3
79
38.4
30.1
23.4
69.5
21.7
19.7
19.6
33.2
19.8
22.2
70.1
70.1
72
23.6
72.5

[13]
[13]

Figure 4.2: Schematic representation of the reaction catalyzed by squalene-desaturase and
the oxidation of 3-dehydro-4-DCA to 3-dehydro-DCA in the 7α-dehydroxylation pathway.

A gene encoding a putative flavoprotein (EDS08212.1) in the FAD-dependent squalenedesaturase family is hypothesized to be involved in the “reductive arm” of the bile acid 7αdehydroxylating pathway.
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35dehydro5DCA!

Figure 4.3: Overexpression and purification of rEDS08212.1 from C. scindens ATCC
35704

A: Lane “M” is the protein marker, lane “1” is the soluble crude extract (30 µg), lane “2” is the
eluent following streptavidin affinity chromatography (2 µg). B: rEDS08212.1 bound to
streptavidin column after thorough washing displaying distinctive yellow pigmentation.
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after which visible precipitation was evident. Storage at -20°C in 50% glycerol did not improve
solubility.

We detected formation of a single product on TLC after incubation with rEDS08212.1 (0.5 µg)
in the presence of 3-dehydro-DCA, but not DCA, at pH 7.0 (Figure 4.4). We did not observe
formation of this product with heat-killed enzyme (70°C 1 min). This reaction occurred in the
presence or absence of pyridine nucleotides (NAD+, NADH, NADP+, NADPH), suggesting that
this reaction proceeds by bile acid-dependent flavin reduction followed by regeneration of FAD+
via chemical oxidation via molecular oxygen (data not shown).

Next, the reaction substrate (Rf =0.78) and product (Rf =0.40) were scraped from the TLC plate,
extracted from the silica gel by ethyl acetate, and dried under nitrogen gas for mass spectrometry
analysis. The substrate had a retention time of 25 minutes and a major mass ion was detected in
positive mode at 391.2878 m/z and 389.2559 m/z in negative mode, as predicted (Figure 4.5).
The product retention time was 22.5 minutes with a major mass ion in positive mode of 387.1681
m/z and 385.1739 m/z in negative mode. These data suggest that the substrate lost four atomic
mass units (amu) and may potentially be involved in the metabolism of two carbon-carbon
double bonds. This observation was repeated in three separate reactions and confirmed.

In order to investigate the most likely origin of the C. scindens ATCC 35704 EDS08212.1 gene,
we have performed a wide-scale maximum-likelihood phylogenetic analysis involving all protein
sequences from the public databases displaying a reasonable level of similarity to the protein
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Figure 4.4: Autoradiograph of thin layer chromatography separation of rEDS08212.1
reaction products from [24-14C] 3-dehydro-DCA.

A. [24-14C] DCA TLC standard, B. [24-14C] 3-dehydro-DCA TLC standard, C. [24-14C] 3dehydro-DCA + rEDS08212.1 +150µM NAD+ , D. 3-dehydro-DCA + rEDS08212.1 + 150 µM
NAD+ biological replicate, E. [24-14C] DCA standard, F. [24-14C] 3-dehydro-DCA + heat-killed
rEDS08212.1, G. [24-14C] 3-dehydro-DCA + heat-killed rEDS08212.1 + 150 µM NAD+.
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Figure 4.5: LCMS-IT-TOF analysis of rEDS08212.1 reaction products.

Substrate and product were separated from TLC, scraped and bile acids extracted from silica,
concentrated and analyzed by LCMS. A. From top-bottom, UPLC profile with major peak
identified at RT 25 minutes (substrate), Positive mode analysis of RT 25 minutes peak, Negative
mode analysis of RT 25 minutes peak. B. From top-bottom, UPLC profile with major peak
identified at RT 22.5 minutes (product), Positive mode analysis of RT 25 minutes peak, Negative
mode analysis of RT 22.5 minutes peak.
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characterized herein. Our final alignment involved 1,273 protein sequences from a diverse
assemblage of bacterial groups, as well as some eukaryotic sequences.

A previously determined sequence, from Clostridiales bacterium VE202-26 (280), is identical to
the one for C. scindens VPI 12708, at the nucleotide as well as the amino acid level. Thus, as
expected, they group in the tree with branch lengths of zero and bootstrap support of 100. The
sequence for C. scindens ATCC 35704 clusters very closely to these two other sequences, also
with the highest bootstrap support. The other Clostridium sequence nearest in the tree belongs to
C. hylemonae DSM 15053, a bacterium previously shown to harbor the bai pathway (272).

The EDS08212.1 gene and homologous genes from the strains analyzed here grouped deep
within a large group of Firmicutes bacteria (Figure 4.6) and, as seen in Figure 4.6-B, group with
a number of bacteria from the Lachnospiraceae and Ruminococcaceae families, as seen
previously in a phylogenomic analysis of 20 single-copy protein-coding genes that were present
in 99 Firmicutes genomes (217). Thus, the EDS08212.1 gene in C. scindens strains does not
seem to have been derived from a horizontal gene transfer event, since its phylogeny agrees
closely with the species phylogeny.
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Figure 4.6: Maximum likelihood phylogenic tree of EDS08212.1 from Clostridium scindens
ATCC 35704.

A. Wide-scale phylogeny (1,273 protein sequences). B. Details of the region of the tree
containing EDS08212.1. Values on nodes represent bootstrap support (only 50 or higher shown).
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Discussion:

The conversion of primary to secondary bile acids such as DCA and LCA is implicated in
diseases of the GI tract, including liver (179) and colorectal cancer (67, 281). The bile acid 7αdehydroxylation pathway has only been reported in a few species of intestinal clostridia,
including C. scindens (113, 125). The genes encoding the enzymes for the oxidative half of the
pathway have been delineated in numerous Clostridium species (113). However, the enzymes
catalyzing the final three reductive reactions have not yet been identified (Figure 4.1).

In the current study, we identified a likely candidate for the first two reductive steps following
7α-dehydration. The gene encoding EDS08212.1 in C. scindens ATCC 35704 is predicted to
encode a flavin-dependent squalene desaturase, a reaction that is analogous to the
oxidation/reduction of secondary bile acids. We cloned and overexpressed rEDS08212.1 in E.
coli and purified the enzyme to apparent electrophoretic homogeneity. The enzyme yielded a
bright yellow color, indicative of flavin-binding. The enzyme was active against 3-dehydro-DCA
but not DCA, suggesting specificity for the A-ring. We observed a loss of 4 amu from the
substrate after purification of the reaction products by TLC and then UPLC-IT-TOF-MS. This
suggests that two oxidations are occurring, strongly indicating the formation of the 3-dehydro4,6-DCA intermediate. Alternatively, the aerobic degradation of cholic acid to carbon dioxide by
soil microorganisms, particularly by Comamonas testosteroni, results in the formation of a 3dehydro-1,4-intermediate, which also requires two oxidations (282).
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Further work is underway to confirm the specific activity of EDS08212.1, although the lack of
commercial availability of substrates makes this further characterization difficult. However, we
are currently testing the utilization of 3-dehydro-Δ4,6-LCA by EDS08212.1 as a substrate for
reduction under anaerobic conditions. If EDS08212.1 is confirmed to make 3-dehydro-LCA
from this substrate, it will confirm the enzyme acts on the Δ4,6 double bonds in bile acids
formed during the 7α-dehydroxylation pathway. Additionally, EDS08212.1 is being tested for
its pyridine nucleotide specificity, as we predict that under anaerobic conditions, NADH would
be required to reduce the bound FAD/FMN.
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Chapter 5: Clostridium scindens VPI 12708 RNAseq and 17α-HSDH gene discovery

Introduction:

Bile acids are not the only steroidal compounds excreted by the liver that undergo enterohepatic
circulation. Sharing the same four cycloalkane rings as bile acids, endogenously produced
steroid hormones are conjugated to glucuronate or sulfate and then can be excreted into bile
(283). The levels of excreted steroid hormones in bile are higher in females, as estrogen
secretion into bile is a major mechanism used to modulate host serum levels (284). Once inside
the lumen of the intestines, conjugated steroid hormones are deconjugated via hydrolysis by both
host epithelial and bacterial deconjugating enzymes, such as glucuronidases and sulfatases, and
deconjugated hormones can then be reabsorbed or enter the large intestine (268). Glucuronidase
activity is found in some of the most abundant microbes in the gut microbiome, including
Bacteroides species (285). After deconjugation, most steroid hormones reenter the circulation
where they are eventually permanently excreted in urine. Studies have shown that treatment
with broad-spectrum antibiotics increased fecal secretion of steroid hormones and decreased
renal excretion, likely due to the lack of deconjugation and subsequently increased loss of steroid
hormones in the feces (286). Interestingly, dietary changes such as increased fiber or decreased
dietary fat have also been associated with increased fecal excretion and decreased levels of
circulating androgenic steroid hormones (284). Both increased fiber and a vegetarian diet low in
fat have been shown to be associated with reduced fecal bacteria β-glucuronidase activity, which
would results in a decreased reuptake of excreted steroid hormones (287, 288).
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Once deconjugated, steroid hormones that escape reabsorption in the intestines, similarly to bile
acids, become substrates for various bacterial biotransformations. In the anaerobic environment
of the large intestine, the majority of bacterial steroid conversions are hydrolytic and reductive in
nature. On C21 and C17 steroid hormones, the 4-ene-3-keto moiety can be reduced to either
3α/β and 5α/β, leading to a variety of differing metabolites (289-291). The reduction of this
moiety generally leads to less biologically active molecules (268). The majority of bacteria
shown to have this activity are within the Clostridium genus.

Other bacterial conversions target the side-chain of glucocorticoids (Figure 5.1). As discussed
previously, Eggerthella lenta has been shown to have 21-dehydroxylase activity (247, 248, 292).
This bacterium is able to convert deoxycortisone to progesterone. Other bacterial species within
the genus Clostridia have been shown to have 17,20 desmolase activity capable of performing
side-chain cleavage of glucocorticoids to form androgens. A recent study identified a gene
cluster in Clostridium scindens ATCC 35704 encoding the steroid-17,20-desmolase, which is
inducible by cortisol (217). In C. scindens, it was shown through RNAseq analysis that the
17,20-desmolase may feed the two carbons released from cortisol into the pentose-phosphate
pathway for cellular growth and maintenance (217).

The product of 17,20-desmolase metabolism of cortisol, 11β-hydroxy-androstenedione, and
endogenously produced androgens such as testosterone and its precursor androstenedione harbor
a C17-hydroxyl group that can undergo bacterial metabolism in the colon. The C17-keto group
of androstenedione and 11β-hydroxy-androstenedione can be reduced by Bacteroides fragilis to
testosterone and 11β-hydroxy-testosterone, respectively (291). Additionally, the same C17-keto
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Figure 5.1: Biotransformations of cortisol by gut microbes.
Cortisol can undergo numerous biotransformations. Numerous strains of bacteria have been
shown to 3α/β and 5α/β reduce the 4-ene-3-keto moiety of cortisol. Clostridium scindens ATCC
35704 has been shown to harbor 20α-HSDH activity on cortisol. Eggerthella lenta has been
shown to have 21-dehydroxylase activity on cortisol. Clostridium scindens ATCC 35704
encodes a 17,20 desmolase able to convert cortisol to 11β-hydroxy-androstenedione.
Clostridium scindens VPI 12708 has been shown to have 17α-HSDH activity on C17 steroid
molecules. Bacteroides fragilis and, in this work, Eggerthella lenta has been shown to have
17β-HSDH activity on C17 steroids.
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group on androstenedione can be reduced to epitestosterone by Clostridium scindens VPI 12708
(228). Unpublished results from our lab have also shown that C. scindens VPI 12708 recognizes
11β-hydroxy-androstenedione. Since both of these bacterial strains are present in the colon, it is
possible that strains would be able to epimerize the C17-hydroxyl group on these molecules,
interconverting these molecules between androgenically active (testosterone) and inactive
(epitestosterone) compounds. The physiological purpose behind these biotransformation
reactions is still unknown, but both interkingdom signaling and microbe-microbe signaling are
valid hypotheses for why the enzymatic potential to interconvert these androgenic compounds
persists in the colon.

The androgenic steroid molecules that are excreted in bile, become unconjugated and substrates
for further bacterial metabolism can be physiologically active on host tissue even at nanomolar
concentrations. This physiological activity can vary based on the presence, stereospecificity, and
reductive state of the functional groups on the steroid core (293). It is important therefore to find
the genes responsible for encoding enzymes that recognize androgens in the microbes that are
known members of the gut microbiome. Clostridium scindens VPI 12708 has been shown to
have 17α-hydroxysteroid dehydrogenase activity, but the gene responsible for its production has
never been found (de Prada 1994). Additionally, a very similar strain, Clostridium scindens
ATCC 35704 was recently shown to metabolize endogenous steroid compounds, but not have
17α-HSDH activity (217). I therefore set out to locate the gene in Clostridium scindens VPI
12708 responsible for the production of the 17α-HSDH enzyme.
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Results:

Previous work in Clostridium scindens VPI 12708 suggested that its 17α-hydroxysteroid
dehydrogenase activity was inducible by androstenedione (228). We therefore set out to confirm
that C. scindens 12708 had androstenedione-inducible 17α-HSDH activity. C. scindens VPI
12708 was grown overnight and induced with 100µM androstenedione. Overnight cultures were
then centrifuged, the pellets washed with buffer, and then incubated with radiolabeled 11βhydroxy-androstenedione (11β-OHAD). Results showed that over the course of two hours,
androstenedione-induced C. scindens VPI 12708 generated reduced 11β-OHAD (Figure 5.2).
Uninduced C. scindens VPI 12708 did not form a product from 11β-OHAD over the same time
period (Figure 5.2). This suggested that metabolism of androstenedione was an inducible trait in
this bacterium.

We also wanted to confirm that the product of androstenedione metabolism was epitestosterone,
a 17α-reduced compound. Overnight cultures of C. scindens VPI 12708 were inoculated with
100µM androstenedione and allowed to grow overnight. Cultures were then extracted with ethyl
acetate and the resulting organic layer was concentrated and run on HPLC using a reverse-phase
C18 column. The formation of a secondary product was monitored at 240nm and fractionally
collected (Figure 5.3). This isolated metabolite of androstenedione was then sent for NMR
analysis. The resulting NMR structure confirmed that C. scindens VPI 12708 produced
epitestosterone from androstenedione (Figure 5.4).
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Figure 5.2: Clostridium scindens VPI 12708 exhibits inducible 17α-HSDH activity
Clostridium scindens VPI 12708 was grown in the presence of 100µM androstenedione
(induced) or without androstenedione (uninduced) overnight and then cells pelleted, washed, and
exposed to fresh radiolabeled 11b-hydroxyl-androstenedione. Conversion was tracked overtime
with 1mL aliquots taken out and quenched with ethyl acetate. Organic extracts were run on TLC
and the formation of a secondary metabolite was visualized over time only in the induced whole
cell samples.
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Figure 5.3: Clostridium scindens VPI 12708 produces a secondary metabolite from
androstenedione that maintains the 4-ene-3-keto moiety
Clostridium scindens VPI 12708 was grown overnight in 10mL BHI in the presence of 100mM
androstenedione and then extracted with ethyl acetate. 20% of the total organic extract was run
on HPLC to separate androstenedione from its metabolite. Other than the injection peak, which
is visible on all injections and corresponds with an influx of 100% methanol, the two peaks
absorbing at 240nm correspond to the two steroids. Androstenedione, based on control data,
elutes around 30 minutes. The secondary metabolite eluted at approximately 52 minutes. This
elution also matched that of commercially obtained epitestosterone. The collected sample was
subsequently sent for NMR analysis.
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Figure 5.4: NMR analysis of the Clostridium scindens VPI 12708 androstenedione
metabolite confirms epitestosterone formation

NMR analysis confirmed epitestosterone was being formed by Clostridium scindens VPI 12708.
NMR analysis was performed on the fractionally collected C. scindens VPI 12708
androstenedione metabolite (see Figure 5.3). NMR analysis was performed as described
previously (217). Table on left denotes hydrogen positioning. Table on right compares chemical
shift, in ppm, as compared to two previous NMR spectrums of epitestosterone from literature
(294, 295). Both findings are congruent with the C. scindens VPI 12708 metabolite being
identified as epitestosterone.
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After confirming C. scindens VPI 12708 has inducible 17α-HSDH activity, we next set out to
find the gene encoding the respective enzyme. RNA-seq had been used previously to great effect
in identifying the cortisol-induced 17,20 desmolase operon in a highly similar strain of
Clostridium scindens (ATCC 35704) (217). Therefore, we set out to use the same technique for
the identifying the C. scindens VPI 12708 17α-HSDH. Additionally, RNAseq could be used
simultaneously to study the changes in the overall transcriptome when certain steroid hormones
and bile acids are present. In this aim, C. scindens VPI 12708 cultures were grown to mid-log
phase under varying inducing conditions, including cortisol, androstenedione, cholic acid, and
allocholic acid. The cells were pelleted and frozen at -80ºC and the supernatants were extracted
and run on TLC to confirm substrate metabolism (data not shown). Total RNA was then isolated
from cell pellets following methods derived from Ridlon et al., including the enrichment of
mRNA using custom designed biotinylated polynucleotides (217). rRNA depleted samples were
used to generate libraries for sequencing using NEBNext Ultra RNA Library Prep Kit for
Illumina and sequenced using the MiSeq 2 x 300 bp protocol. Reads were then populated to a
previously sequenced Clostridium scindens VPI 12708 genome (unpublished). Results indicated
that in the cholic acid-induced and allocholic acid-induced samples, the bile acid operon (baioperon) was significantly induced versus uninduced control (Table 5.1). These results
functioned as a positive internal control, showing the quality of the RNA in these samples was
high enough to determine induction of various genes against uninduced controls. Interestingly,
although cortisol, androstenedione, cholic acid, and allocholic acid all share a similar steroidal
backbone, their effects on the overall transcriptomic pattern in C. scindens VPI 12708 are
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Table 5.1: Induction of bile acid inducible operon in Clostridium scindens VPI 12708 by cholic acid (CA) and allocholic acid
(ACA)

Cholic acid-induced vs. uninduced “bai operon” Illumina MiSeq Reads
locus
Cs12708_c00003_00018
Cs12708_c00003_00019
Cs12708_c00003_00020
Cs12708_c00003_00021
Cs12708_c00003_00022
Cs12708_c00003_00024
Cs12708_c00003_00026
Cs12708_c00003_00027

Uninduced
Reads
CA-induced reads log2(fold_change) p_value
q_value
significant
8.28709
924.929
6.80233
0.0167
0.0894583 no
8.4592
1268.97
7.22892
0.0018
0.0176897 yes
0
1624.22 inf
5.00E-05
0.000844444 yes
12.077
1433.27
6.8909
0.0654
0.210908 no
12.5373
1431.1
6.83476
0.0167
0.0894583 no
8.97984
1240.13
7.10958
0.0167
0.0894583 no
12.2184
1535.93
6.97392
0.00025
0.00367742 yes
42.0197
2020.16
5.58726
0.0167
0.0894583 no

Allocholic acid-induced vs. uninduced “bai operon” Illumina MiSeq Reads
locus
Cs12708_c00003_00018
Cs12708_c00003_00019
Cs12708_c00003_00020
Cs12708_c00003_00021
Cs12708_c00003_00022
Cs12708_c00003_00024
Cs12708_c00003_00026
Cs12708_c00003_00027

Uninduced
Reads
ACA-induced reads log2(fold_change) p_value
q_value
significant
8.31544
140.121
4.07474
0.0019
0.0156222 yes
8.48946
135.107
3.99229
0.00035
0.00390943 yes
0
174.78 inf
5.00E-05
0.000700592 yes
12.1164
109.976
3.18216
0.11395
0.283439 no
12.5816
132.8
3.39987
0.001
0.00935968 yes
9.01056
89.4478
3.31136
0.00625
0.0396766 yes
12.2606
119.024
3.27915
5.00E-05
0.000700592 yes
42.1566
133.286
1.6607
0.0541
0.17104 no
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striking (Figure 5.5). Cholic acid-induced C. scindens VPI 12708 transcriptomic pattern appears
to cluster separately from allocholic, androstenedione, and cortisol induced transcriptomic
patterns (Figure 5.5). This observation is interesting, as the only difference between cholic acid
and its epimer allocholic acid is the position of the hydrogen on the fifth carbon. With hydrogen
in the α-configuration, the steroid backbone of allocholic acid more closely resembles a planar
steroid hormone than a bile acid. Therefore, it appears that because of this change, C. scindens
VPI 12708 responds to it more as a steroid hormone than a bile acid, although the bai-operon is
still induced, although to a lower level than what is seen from cholic acid induction (Figure 5.4).

From previous studies and unpublished data, we knew that the 17α-HSDH should have the
following characteristics: be annotated to be within the SDR family or alcohol polyol
dehydrogenase family; encode a polypeptide sequence around 40kDa; be induced by
androstenedione and cholic acid; should have a metal binding and pyridine nucleotide binding
site; not be found in similar strain Clostridium scindens ATCC 35704 (de Prada 1994). In
contrast to the cholic acid-induced sample, there were not very many significantly induced genes
in the androstenedione-induced sample (Table 5.2). Putative genes that matched the 17α-HSDH
criteria were chosen for further analysis (Table 5.3).

Genes that were chosen based on the RNAseq analysis were successfully cloned into expression
vectors, overexpressed in E. coli, purified, and tested for their 17α-HSDH activity. Constructs
were made with either a C- or N-terminal streptavidin tag for column purification, or no tag in
the case of whole cell extract assays, and constructs were checked for nucleotide fidelity by
sequencing. Purified enzymes, whole cell extracts, and induced whole cell transformed E. coli
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Table 5.2: Genes upregulated in Clostridium scindens VPI 12708 in response to
androstenedione induction

Locus
Cs12708_c00002
_00026:0-663
Cs12708_c00043
_00034:0-1050
Cs12708_c00073
_00017:0-1962
Cs12708_c00056
_00017:0-1014
Cs12708_c00163
_00001:0-657
Cs12708_c00001
_00068:0-1086
Cs12708_c00117
_00003:0-840
Cs12708_c00060
_00011:0-888
Cs12708_c00002
_00029:0-543
Cs12708_c00064
_00002:0-2043
Cs12708_c00022
_00007:0-1275
Cs12708_c00005
_00015:0-1062
Cs12708_c00005
_00016:0-1014
Cs12708_c00005
_00013:0-759
Cs12708_c00065
_00020:0-1551
Cs12708_c00119
_00005:0-1446
Cs12708_c00039
_00001:2-2760
Cs12708_c00060
_00013:0-657
Cs12708_c00038
_00001:0-1506

Uninduced Androstenedione
Reads
induced reads

log2 (fold
change)

p value

225.526

969.11

2.10337 5.00E-05

114.12

391.381

1.77803 5.00E-05

180.598

393.201

1.12249 5.00E-05

222.157

460.616

1.05198 5.00E-05

2456.39

4786.56

0.962446 5.00E-05

211.009

409.538

0.956696 5.00E-05

641.622

1184.81

0.884863 5.00E-05

3375.83

6031.37

0.837242 5.00E-05

12527.7

21981.3

0.811153 5.00E-05

354.865

622.498

0.810802 5.00E-05

257.052

449.644

0.806724 5.00E-05

442.204

760.787

0.782782 5.00E-05

411.663

705.56

0.777307 5.00E-05

555.471

951.575

0.776607 5.00E-05

628.777

1056.69

0.748936 5.00E-05

273.459

459.123

0.747557 5.00E-05

94.0148

157.74

0.746587 5.00E-05

603.456

1004.75

0.735521 5.00E-05

2022.81

3350.23

0.727895 5.00E-05
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q value
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607

significant
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

Cs12708_c00214
_00001:0-555
Cs12708_c00043
_00033:0-1422
Cs12708_c00002
_00028:0-537
Cs12708_c00131
_00003:0-1344
Cs12708_c00060
_00010:0-771
Cs12708_c00144
_00011:0-627
Cs12708_c00146
_00003:0-1326
Cs12708_c00007
_00064:0-2184
Cs12708_c00075
_00015:0-936
Cs12708_c00001
_00016:0-1740
Cs12708_c00103
_00014:0-2139
Cs12708_c00060
_00012:0-1533
Cs12708_c00202
_00002:0-1311
Cs12708_c00149
_00007:0-1335
Cs12708_c00195
_00007:0-828
Cs12708_c00076
_00015:0-1035
Cs12708_c00023
_00037:0-657
Cs12708_c00013
_00036:0-1314
Cs12708_c00059
_00020:0-375
Cs12708_c00114
_00009:0-768
Cs12708_c00194
_00002:0-489

1403.85

2300.25

0.712406 5.00E-05

242.143

383.461

0.663222 5.00E-05

5594.94

8752.84

0.645628 5.00E-05

405.984

628.224

0.629855 5.00E-05

2460.73

3740.22

0.604038 5.00E-05

1277.69

1914.51

0.583437 5.00E-05

766.735

1145.99

0.57979 5.00E-05

1370.67

2031.96

0.567989 5.00E-05

717.297

1050.21

0.550039 5.00E-05

886.114

1295.91

0.548396 5.00E-05

1801.65

2626.09

0.543598 5.00E-05

583.929

850.414

0.542371 5.00E-05

661.761

963.585

0.542102 5.00E-05

444.439

643.149

0.533168 5.00E-05

658.498

936.879

0.508683 5.00E-05

5197.37

7209.73

0.472162 5.00E-05

4351.25

5896.36

0.438396 5.00E-05

642.023

860.493

0.422539 5.00E-05

32471.2

43056.3

0.407062 5.00E-05

32.2213

422.962

3.71444

0.0001

233.608

598.168

1.35646

0.00015

199

0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0011
0607
0.0019
8908
0.0027
9567

yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

Cs12708_c00064
_00017:0-1359
Cs12708_c00008
_00038:0-396
Cs12708_c00058
_00001:0-492
Cs12708_c00166
_00003:0-786
Cs12708_c00151
_00009:0-924
Cs12708_c00022
_00038:0-501
Cs12708_c00081
_00005:0-624
Cs12708_c00005
_00027:0-1767

44.4706

112.038

1.33307

0.00015

1091.75

1948.95

0.836058

0.0002

271.411

517.127

0.93004

0.0031

124.227

229.998

0.888637

0.00405

101.621

182.081

0.841384

0.00405

199.674

412.743

1.0476

0.00465

83.9893

208.062

1.30874

0.00495

26.5059

55.6576

1.07027

0.005
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0.0027
9567
0.0035
594
0.0320
424
0.0389
689
0.0389
689
0.0435
042
0.0457
682
0.0460
506

yes
yes
yes
yes
yes
yes
yes
yes

Figure 5.5: Overall transcriptomic heatmap of Clostridium scindens VPI 12708 induced
with numerous bile acid and steroid molecules

C. scindens VPI 12708 was grown in the presence of 50µM cortisol, androstenedione, allocholic
acid, or cholic acid. mRNA was isolated, purified, and then sequenced for each sample.
RNAseq results were used to generate heat maps of induction using a distance metric of 1(abs(pearson correlation)). Results show that the C. scindens VPI 12708 transcriptomic pattern
in response to cortisol, androstenedione, and allocholic acid cluster together and separately from
the cholic acid induced transcriptomic pattern.
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Table 5.3: Putative 17α-HSDH genes from Clostridium scindens VPI 12708 screened for activity
Locus

Annotation
Size
based on blastp
results
Glycerol
39.1
dehydrogenase kDa

Presence
in 35704
strain
No

Metal
binding
site
Yes

NAD(P)
Induction by Induction by
binding site androstene- cholic acid
dione
Yes
Yes
Yes

17αHSDH
activity
No

Cs12708
_00005_
00084

“Old yellow
enzyme”,
NADH flavin
oxidoreductase

70.5
kDa

No

Not
annotated

Yes

Yes

No

No

Cs12708
_00124_
00009

Short chain
dehydrogenase
/reductase
(SDR)

31.3
kDa

No

Not
annotated

Yes

Yes

No

No

Cs12708
_00114_
00009

Short chain
dehydrogenase
/reductase
(SDR)

27.6
kDa

No

Not
annotated

Yes

Yes

No

No

Cs12708
_00064_
00018
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Other information
of interest
Part of operon,
including
membranespanning protein,
that is upregulated
by androstenedione
and cholic acid
Alignment with
previously
characterized 12708
baiCD (262) shows
conservation of
catalytically
necessary cysteine
residues
Has bacterial 3αHSDH conserved
domain (via NCBI
protein blast,
ascension =
cd05328)

cultures were tested for 17α-HSDH activity. Assays were performed both aerobically and
anaerobically (under N2 stream). Reduction of androstenedione or oxidation of epitestosterone
was measured spectrophotometrically for the change in NAD+/NADH oxidation state or via
organic extraction and HPLC separation of products. Under all these experimental conditions,
none of the tested enzymes exhibited 17α-HSDH activity. At this point, there were no more
candidate genes left from the RNAseq analysis.
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Discussion:

Gaining a better understanding of our gut microbiome’s ability to metabolize numerous
endogenous and exogenous molecules to secondary molecules of varying physiological
relevance is an important area of study. Bacterial bile acid and steroid metabolites have been
shown on numerous occasions to have important physiological effects on the host. Finding the
genes responsible for the production of genes that encode steroid/bile acid metabolizing enzymes
is important in order to get a better understanding of why microbes utilize these substrates in
vivo. Of equal importance, as the era of “personalized medicine” approaches, it is becoming
more important to be able to predict metabolic potential of an individual’s gut microbiome as it
may pertain to other pathophysiological disorders. In this aim, it is important to have more a
more robust understanding of specific enzymes in the “sterolbiome”, as it makes predictive
annotation and therefore the prediction of an individual’s gut microbiome’s “metabolic
potential” more accurate. Therefore, we set out to find the gene in Clostridium scindens VPI
12708 responsible for the synthesis of a 17α-HSDH enzyme able to interconvert
androstenedione and epitestosterone. In concert with other bacteria known to have 17β-activity
such as B. fragilis (291), this would allow the gut microbiota to interconvert active testosterone
to anti-antrogenic epitestosterone, and vice versa.

We were able to confirm that C. scindens VPI 12708 has inducible 17α-HSDH activity, able to
convert androstenedione to epitestosterone in vitro. We performed RNAseq analysis on
differentially induced C. scindens VPI 12708 samples and showed interesting differences in
whole transcriptomic changes under these varying conditions. After finding candidate genes, we
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tested them for their 17α-HSDH activity using numerous experimental conditions. Ultimately
the gene responsible for the production of the C. scindens VPI 12708 17α-HSDH was not found.

There are numerous potential explanations for this outcome. One explanation is that the C.
scindens VPI 12708 genomic data used as reference for the RNAseq data was not a closed
genome. Therefore, if the gene for the 17α-HSDH was not sequenced in the genomic
sequencing, it would not have been identified through RNAseq analysis. Alternatively, it is
possible that any of the putative 17α-HSDH purified enzymes lost activity at some stage in their
production or purification. However, we took every precaution to prevent this including using
various expression vectors, confirming fidelity of the inserts, confirming production of protein,
testing whole cell extracts and transformed cell cultures for activity, testing enzymes activity
aerobically and anaerobically using two separate metrics for screening, and testing both the
oxidation of epitestosterone and reduction of androstenedione.

It is possible that in producing these Clostridial proteins in a different genus (Escherichia) that
an additional component, such as differing molecular chaperones, are necessary for the proper
maturation of the 17α-HSDH. A way of getting around this difficulty would be to knock out
genes of interest directly in C. scindens. Unfortunately, a mechanism for directly knocking out
genes in Clostridium scindens has not been developed, however not for a lack of effort. Most
recently, work on developing a Crispr-Cas9 knockout system in Clostridium scindens is
underway in a collaborating lab. Such a system in Clostridium scindens would be a huge
accomplishment and widely utilized. The production of secondary bile acids by Clostridium
scindens have been differentially implicated to be associated with CRC (67, 281) as well as with
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protection against post-antibiotic Clostridium difficile infection (209). If one was able to knock
out the bai-operon responsible for producing secondary bile acids in Clostridium scindens, the
contributions of secondary bile acids to these disease processes could be more accurately
determined.

Until either more cost-effective means of screening transcriptomic data for prokaryotes or a
genetic knockout system for Clostridium scindens is developed, the gene encoding 17α-HSDH
will continue to elude us. A future direction may be to screen other fecal isolates for 17α-HSDH
activity on androstenedione and then comparing the genomic data to more accurately search for a
putative gene. This experiment would be interesting, as the prevalence of microbial 17α-HSDH
activity in human fecal samples is unknown.

The work on identifying the 17α-HSDH gene in C. scindens VPI 12708 did provide some
interesting results. It showed how differently C. scindens VPI 12708 recognizes steroid
compounds with the same steroidal backbone. Additionally, based on the clustering of heat
maps of the four treatment groups, C. scindens VPI 12708 appears to recognize cholic acid
differently from allocholic acid, androstenedione, and cortisol (Figure 5.4). Since allocholic acid
is a 5α-epimer of cholic acid, these results suggest that the planar orientation of the A ring on the
steroid backbone on these molecules is an important regulator of its molecular function. To
make better use of this data, I recommend the resequencing of C. scindens VPI 12708 genome
using more up to date annotation techniques. That way, the transcriptomic data from the
RNAseq analysis we performed can give more insight into how these steroid molecules impact
the overall cell metabolism. Additionally, it could test one of the possible reasons for the
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inability to identify the 17α-HSDH gene. Ultimately, this work gives interesting preliminary
data for future studies, as well as a list of genes not to screen for 17α-HSDH activity in
subsequent studies.
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Chapter 6: Summary and Perspectives

The human gut microbiome is a diverse ecosystem of microbial organisms that inhabit our
gastrointestinal tract. The concentration of living cells, approximately 1011/g feces, is of the
highest density found in nature. The study of the human gut microbiome has undergone a
renaissance in the past decade with the advent of next-generation sequencing techniques (2).
High-throughput analysis of the constituents of the gut microbiome has given significant insights
into human health and changed how we study the general makeup of the gut microbiome.
Changes to certain characteristics of the gut microbiome, such as the quantities of specific
bacterial species or changes in the presence and levels of microbial-derived metabolites, have
been associated with a wide range of pathophysiological conditions. Obesity (226, 256, 296),
cardiovascular disease (297), hypertension (242, 252), inflammatory bowel disease (66, 84),
colorectal cancer (67, 281), liver cancer (179), cirrhosis (298, 299), and post-antibiotic C.
difficile infection (209) have all been associated with changes to the gut microbiome or the
various metabolites it produces. There are, however, limitations to the conclusions we can draw
from 16S, COG, and KEGG DNA and transcriptomic analysis. 16S screens of fecal bacteria do
not delineate differences that may exist within different strains of the same species. The
reference genomes that guide the predictive annotation for shotgun sequencing, such as COG and
KEGG, account for only a third of all genomic data that is obtained (227).

This problem is evident when looking at specific aspects of gut microbial metabolism such as the
“sterolbiome”, or the prokaryotic genes that encode enzymes metabolizing bile acids within the
gut microbiome. Numerous bacterial strains within the Firmicutes and Actinobacteria phyla, two
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of the three most prevalent phyla present in the GI tract, encode enzymes responsible for
biotransformations of both bile acids and other steroid molecules. A small subset of bacteria
within the Clostridium genus have been shown to have genes encoding enzymes in a multi-step
7α-dehydroxylation pathway, making them capable of turning endogenously produced primary
bile acids CA and CDCA into secondary bile acids DCA and LCA, respectively (113).
Production of secondary bile acids have been reported to be qualitatively the most common
bioconversion of bile acids in the colon, as the majority of primary bile acids that escape
enterohepatic circulation end up 7α-dehydroxylated in the large intestine (133). The genes
encoding enzymes in the oxidative arm of the 7α-dehydroxylation pathway have been
characterized in numerous Clostridium species (113). However, the genes encoding the enzymes
for the three successive reductive steps have not been identified. In the current study, evidence is
presented that the Clostridium scindens ATCC 35704 gene EDS08212.1 encodes a Δ4,6
reductase that catalyzes the two reductive steps immediately following 7α-dehydration. This
gene is closely related to genes found in other 7α-dehydroxylating strains. It is unique in its
ability to catalyze two reductive reactions on both the A and B ring of bile acids (both the C4=C5
and C6=C7 bonds). Ultimately this work helps to further characterize a very important
biochemical pathway within the “sterolbiome” and will ultimately serve to help us better
understand the entirety of the 7α-dehydroxylation pathway.

While 7α-dehydroxylation of primary bile acids is the most studied bacterial bile acid metabolic
pathway, other biotransformations do occur. One such set of reactions is the oxidation and
epimerization of bile acid hydroxyl groups. Oxidation of the α-hydroxyl groups on the 3rd, 7th,
and 12th carbon of bile acids leads to the formation of an oxo-moiety. Microbial oxidation of
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bile acids occurs regularly in the large intestine, as previous analysis of fecal samples and portal
circulation show the accumulation of oxo-bile acids to varying degrees (158-163, 165, 267)

Once epimerized, these oxo-bile acids can undergo further biotransformations. They can be
reduced back to an α-configuration by bacterial or host hepatic α−HSDHs. Alternatively, they
can be epimerized to the β-configuration. Numerous gut-associated microbes have been shown
to harbor bile acid C3- and C7-hydroxyl-β-HSDHs (146, 150, 157). Epimerized bile acids have
been shown to be less toxic to other gut microbes that inhabit the large intestine (150). As such,
if an individual harbors gut microbes that can epimerize bile acids, the makeup of their gut
microbiome may be different from an individual who does not, although that has not been
experimentally proven. Additionally, epimerized bile acids pose a problem for bacteria that
otherwise utilize primary bile acids. These 7α-dehydroxylating bacteria were not induced to 7αdehydroxylate primary bile acids by ursodeoxycholic acid, although they are capable of 7βdehydroxylation if induced by 7α-bile acids (261). Additionally, urosdeoxycholic acid has been
shown to inhibit the germination and vegetative growth of Clostridium difficile spores and be
protective against recurrent infection (216). It is clear that the epimerization of bile acids forms
less toxic secondary metabolites. However, the role of oxo-bile acids, the “intermediate”
molecule in this process, is less well characterized.

In the current study, we show evidence that 7α-dehydroxylation can be inhibited by the
formation of oxo-bile acid derivatives. Clostridium scindens VPI 12708 (12708) was unable to
effectively 7α-dehydroxylate the three CDCA metabolites produced by E. lenta C592. Two of
the metabolites (7-oxo-3α-hydroxy-CDCA and 3,7-dioxo-CDCA) were partially reduced back to
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CDCA, although 7α-dehydroxylation did not occur to the same extent as fully reduced CDCA.
Additionally, the 7-oxo-3β-hydroxy-CDCA metabolite was reduced by C. scindens VPI 12708
back to isoCDCA, but was not 7α-dehydroxylated. Taken together, this shows that C. scindens
VPI 12708 does not recognize isoCDCA as a substrate for 7α-dehydroxylation, possibly due to
the absence of a 3β-HSDH. Additionally, the oxidation of hydroxyl groups appears to inhibit the
7α-dehydroxylation of primary bile acids, even if C. scindens is able to reduce the oxo-bile acid
metabolites back to the original primary bile acid. One potential explanation for these findings is
that oxo-bile acids do not induce the “bai” operon, similar to ursodeoxycholic acid (261).
Therefore, in the C. scindens VPI 12708 oxo-bile acid metabolism analysis, the oxo-bile acids
are reduced but 7α-dehydroxylated products do not form because they require induction of the
bai operon. Further experimentation should be done to test C. scindens “bai” gene expression via
qPCR when induced with the various oxo-bile acid derivatives made by C592.

In coculture experiments, E. lenta C592 and C. scindens 12708 appear to cycle CDCA back and
forth between 7α-CDCA and 7-oxo-CDCA, but LCA does not appear to accumulate. This
experiment gives insight into what might happen if both C. scindens 12708 and E. lenta C592
were in the large intestine under low H2 partial pressure and suggests a mechanism by which
secondary bile acid formation may be inhibited in vivo by another member of the gut
microbiome (Figure 6.1). Future experimentation on this point is warranted. In vivo experiments
of humanized mice (mice designed to have a humanized gut microbiome), could be designed to
include supplementation with E. lenta strains to see if secondary bile acid formation is inhibited.
Additionally, the effect of diet, such as the supplementation of complex carbohydrates that could
lead to an excess of H2 gas in the colon and thus inhibit E. lenta bile acid metabolism, could be
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Figure 6.1: Model of Eggerthella lenta C592 bile acid metabolism in vivo.
In the lumen of the large intestine, both Clostridium scindens and Eggerthella lenta would be
competing for the same pool of primary bile acids. C. scindens preferentially 7α-dehydroxylates
primary bile acids to secondary bile acids. At the same time, E. lenta would be competing for
the same primary bile acids to use as electron donors. These oxidized bile acids would be
reduced by C. scindens back to primary bile acids, leading to a cycle of oxidation-reduction
between the two strains. This cycle would inhibit the build up of secondary bile acids in the
colon. However, the ability for E. lenta to oxidize bile acids would be dependent on the
availability of H2 gas. The availability of H2 gas in the lumen of the colon is dependent on two
factors; the rate of production via anaerobic fermentation and the rate of utilization by H2
utilizers. Other gut microbial H2 utilizers, sulfidogens and methanogens, have higher affinity to
H2 than acetogens. Therefore if sulfidogens or methanogens were present and their preferred
substrates for reduction were available, the amount of H2 for utilization by E. lenta would be
low. With a paucity of available H2, E. lenta would use bile acids as electron donors, leading to
the formation of oxo-bile acids. Alternatively, if H2 production outpaces the H2 utilization or if
methanogenesis and sulfidogenesis are not occurring, E. lenta would switch to utilizing H2 as an
electron donor and cease to oxidize bile acids. This would allow C. scindens to properly 7αdehydroxylate primary bile acids, leading to an accumulation of secondary bile acids.
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tested in this model. Within this framework, other strains could be added as well, such as
hydrogen sulfide gas producing bacteria (both with and without sulfate substrates) or
methanogens, to see if their presence with E. lenta impacts the formation of secondary bile acids.
Given the in vitro data generated in this work, it would be expected that E. lenta might inhibit
7α-dehydroxylation by C. scindens strains and that excess H2 formation could counteract this
inhibition. However, given recent studies showing that secondary bile acids are directly linked
to resistance against post-antibiotic CDI, the question arises as to whether limiting the formation
of secondary bile acids should be viewed as a therapeutic target.

Recent literature has suggested that C. scindens, specifically the formation of secondary bile
acids, is protective against post-AB CDI in both human patients and animal models (209).
However, little data is available showing a mechanism linking secondary bile acids to the
inhibition of either C. difficile spore germination or vegetative growth. Perhaps the most
promising link is the study identifying the C. difficile germination receptor CspC is specifically
activated by 12α-hydroxyl bile acids (214). Work presented in this study shows that the
12α−hydroxyl group on DCA is oxidized during E. lenta C592 DCA metabolism. Future
experimentation should look to the effects that 12-oxo-DCA has on both C. difficile growth and
spore germination, as well as its ability to be recognized by the CspC receptor.

The effects these oxo-bile acid metabolites have are not limited to other members of the gut
microbiome. Host tissues are significantly affected by numerous bacterial metabolites,
particularly bile acids. Oxo-bile acid derivatives have been shown to have varying effects,
although they have not been thoroughly tested as well as their fully reduced counterparts. 7-oxo-
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CDCA, coincidentally a major product of E. lenta C592 CDCA metabolism, has been shown
previously to be a competitive inhibitor for hepatic 11β−HSDH1 (198, 199). This inhibition
prevents effective reduction of inactive cortisone to cortisol. The extent to which this inhibition
affects overall host physiology has not been tested. Additionally, bile acids are known to
activate host G-protein coupled and nuclear receptors to varying extents based on the regio and
stereo positioning of the functional groups attached to their steroid cores and side chains. 3-oxoLCA, the most likely product of E. lenta C592 LCA metabolism, has been shown to be the most
potent vitamin D receptor agonist (175). Additionally, 7-oxo-CDCA and 3,7-oxo-CDCA have
both been shown to be less potent agonists for FXR than their α-reduced counterparts, but more
potent than β-reduced epimers (167). Oxo-bile acids, therefore, already have an established role
in host physiology unique from their α- and β-reduced sister molecules. However, the full
spectrum of primary and secondary oxo-bile acid derivatives has not been tested for agonist
properties on various bile acid-sensitive receptors. Of particular interest would be to determine
oxo-bile acids’ ability to activate TGR-5, as this is implicated in significantly altering host
metabolism. Previous literature has suggested C. scindens is associated with increased hepatic
triglyceride levels (258), which is a downstream effect of secondary bile acid activation of TGR5 (173). Secondary bile acids DCA and LCA are the most potent activators of TGR-5 (170). E.
lenta was also shown to be associated with increased hepatic triglyceride levels (258), but they
do not perform 7α-dehydroxylation. Therefore, this suggests that oxo-bile acid derivatives made
by E. lenta are performing similar activities to secondary bile acids, potentially through the
activation of TGR-5.
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Epimerized bile acids, such as ursodeoxycholic acid, have been shown to be less toxic to
colonocytes (254, 255). The toxicity of oxo-bile acid derivatives has not been studied, but would
likely be different from fully reduced bile acids. Previous studies have shown that varying the
configuration of hydroxyl groups on bile acids directly affects their hydrophobicity (254), which
is a major contributor to bile acid toxicity. However, the hydrophobicity of oxo-bile acid
derivatives has not been assessed.

The formation of oxo-bile acids by E. lenta strains could have many effects, both to other gut
microbes and to various host tissues. The extent of these effects have yet to be fully elucidated,
likely owing to the fact that oxo-bile acids have been seen as intermediates in the epimerization
of bile acids. However recent published studies, as well as the work presented here, suggest that
oxo-bile acids could be key actors in modulating host and gut microbial physiology. Evidence
has been presented that E. lenta strains share many qualities with acetogens, and how bile acid
oxidation play into their whole cell redox balancing and energy production. Additionally, our
studies show that atmospheric gases play a key role in determining the extent of E. lenta bile acid
metabolism. Both the E. lenta strains and oxo-bile acids warrant further exploration as possible
therapeutic agents. However, this comes with a warning, since recent studies have suggested an
important role of secondary bile acids in the prevention of CDI. Therefore, it is important to
acquire a better understanding of the mechanism by which secondary bile acids prevent CDI
before suggesting for their diminution in patients. Ultimately, this work makes a case for E.
lenta strains to be considered acetogens, for the formation of oxo-bile acids as a means to
prevent 7α-dehydroxylation, and serves as a baseline to direct future study of oxo-bile acid
formation in vivo.
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